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Non-alcoholic fatty liver disease (NAFLD) is fast becoming a global health concern. It 
is closely associated with obesity, diabetes and the metabolic syndrome, has a global 
pooled prevalence of 25% and is the leading cause of chronic liver disease in Europe 
and the United States. 
People of Indian ethnicity are at increased risk of diabetes and metabolic 
complications at a lower body mass index (BMI) than Caucasians. This predisposition 
for NAFLD is further compounded by Westernisation of Asian culture resulting in 
increased intake of sugar-rich, energy-dense foods and decreased levels of physical 
activity.  
Despite this well documented propensity to metabolic disease (including NAFLD), 
there is a lack of knowledge about the true disease prevalence in India. The studies 
that have been published are biased towards urban, tertiary centres, where access 
to healthcare and appropriate diagnostic tools is more readily available. In addition 
to this, there is conflicting data about the role of changing lifestyle habits on NAFLD 
risk – particularly in relation to diet. Reduced brown adipose tissue (BAT) activity has 
also been linked to obesity and diabetes, however there have been no prospective 
studies done to examine whether reduced BAT activity could also contribute to the 
increased NAFLD risk within this ethnic group. 
Aims 
The aim of this thesis is therefore to fill the above gaps in knowledge, to estimate 
accurately the NAFLD prevalence within a large Indian population, to identify the 
impact of different NAFLD risk factors within this population and compare NAFLD risk 
profile of native Indians with their UK migrant counterparts. It will also investigate 
the impact of BAT activity on NAFLD risk and understand the ethnic differences in 
BAT activity.  
Results 
Through population-level sampling of a large Southern Indian district, NAFLD 
prevalence (as diagnosed by ultrasound) was shown to be 49.8%. 
Risk factors for NAFLD within India were the same as those seen worldwide, namely 
male gender (adjusted OR 2.29 1.86-2.83, p<0.001), obesity (adjusted OR 2.81 2.015-
3.68, p<0.001) – in particular central obesity – and components of the metabolic 
syndrome (diabetes adjusted OR 1.76 1.40-2.21, p<0.001). Dietary fat intake was also 
independently associated with NAFLD within India (adjusted OR 1.02 1.00-1.03, 
p=0.019). These risk factors appear unchanged by migration to the UK. Although 
there were no significant differences in dietary habits following UK migration, there 




carbohydrate within the UK-migrant Indian cohort. This may result in changes to 
NAFLD phenotype over time. 
BAT activity was lower in native Indians (ΔTrel 0.36°C) compared to UK Caucasians 
(ΔTrel 0.50°C, p=0.010) and UK South Asian migrants (ΔTrel 0.57°C, p<0.001). This 
difference was however due to environment, as there was no difference in BAT 
activity between control groups of different ethnicity living in the same country. BAT 
activity does not directly influence risk of NAFLD (adjusted OR 0.47 0.07-3.20, 
p=0.444). Any differences in BAT activity were related to increasing BMI, which is 
itself a risk factor for NAFLD. 
Conclusion 
The prevalence of NAFLD in India is significantly higher than current national and 
global estimates. There is a commonality of risk between India and the rest of the 
world – namely obesity, diabetes and a diet high in fat. Within India, increased 
consumption of saturated fat in the form of edible oils and meat appears to impact 
NAFLD risk additionally. Whilst BAT activity is lower in Indians, it is not a direct cause 
for the increased NAFLD risk in this ethnic group. This work highlights the need for 
NAFLD screening for people of Indian ethnicity, both in India and in migrant 
populations. Further research needs to focus on education and interventional 
strategies to reduce prevalence of obesity and diabetes, which may be achieved 
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Table 5-2 Measures of BAT activity for each cohort 
baseTscv = baseline temperature of the supraclavicular ROI in the 
minute prior to cooling, baseTrel = baseline relative temperature 
(baseTscv-baseTref), peakTscv = maximal temperature of the 
supraclavicular ROI during cooling, peakTrel = maximal relative 
temperature, ΔTscv = peakTscv – baseTscv), ΔTrel = Change in relative 
temperature (peak relative temperature – base relative temperature 
(Tscv-Tref) 
Table 5-3 Brown adipose tissue activity in control groups 
ΔTrel = Change in relative temperature within supraclavicular region 
of interest 
Table 5-4 Measures of brown adipose tissue activity in NAFLD and Control 
groups 
baseTscv = baseline temperature of the supraclavicular ROI in the 
minute prior to cooling, baseTrel = baseline relative temperature 
(baseTscv-baseTref), peakTscv = maximal temperature of the 
supraclavicular ROI during cooling, peakTrel = maximal relative 
temperature, ΔTscv = peakTscv – baseTscv), ΔTrel = Change in relative 
temperature (peak relative temperature – base relative temperature 
(Tscv-Tref) 
Table 5-5 Iteration 0 (R2=0.00, log likelihood=-87.19) 
Table 5-6 Iteration 1, addition of BAT activity to the model (R2=0.02, log 
likelihood=-85.69, p=0.083) 
  Abbreviations: BAT = brown adipose tissue 
ΔTrel = change in relative temperature within the supraclavicular 
region of interest 
Table 5-7 Iteration 2, addition of age to the model (R2=0.04, log likelihood=-
83.51, p=0.037) 
  Abbreviations: BAT = brown adipose tissue 
ΔTrel = change in relative temperature within the supraclavicular 
region of  
Table 5-8 Iteration 3, addition of BMI to the model (R2=0.21, log likelihood=-
69.21, p<0.001) 




ΔTrel = change in relative temperature within the supraclavicular 
region of interest 
Table 5-9 Iteration 4, addition of diabetes to the model (R2=0.22, log 
likelihood=-68.38, p=0.197) 
  Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular 
region of interest, diabetes = formal diagnosis or fasting 
glucose>7.0mg/dl 
Table 5-10 Comparator model examining the interaction effect of ethnicity on 
BAT activity (R2=0.23, log likelihood=-67.00, p=0.252) 
  Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular 
region of interest, diabetes = formal diagnosis or fasting 
glucose>7.0mg/dl 
Table 5-11 Comparator model examining the interaction effect of ethnicity on 
BMI (R2=0.24, log likelihood=-66.62, p=0.172) 
  Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular 
region of interest, diabetes = formal diagnosis or fasting 
glucose>7.0mg/dl 
Table 5-12 Comparator model examining the interaction effect of ethnicity on 
presence of diabetes (R2=0.28, log likelihood=-63.19) 
  Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular 
region of interest, diabetes = formal diagnosis or fasting 
glucose>7.0mg/dl 
Table 5-13 Adjusted logistic regression for diabetes risk  
  Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular 
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CHAPTER 1: Introduction  
 
Non-alcoholic fatty liver disease (NAFLD) is a condition defined by fat deposition 
within the liver (>5% of hepatocytes), in the absence of an alternative cause of liver 
disease or excess alcohol intake (greater than 20g/day women, greater than 30g/day 
men). It is a disease that is closely associated with obesity, diabetes and the 
metabolic syndrome[1]. Non-alcoholic steatohepatitis (NASH) is a subtype of NAFLD 
that may result in progressive inflammation and fibrosis within the liver, culminating 
in cirrhosis, hepatocellular carcinoma (HCC) and necessity for transplantation. NAFLD 
has an estimated global prevalence of 25%[1] and is the leading cause of chronic 
liver disease in the Europe and the United States of America (USA)[2]. NAFLD is 
associated with increased morbidity and mortality. Those with NAFLD have a higher 
10-year mortality than controls, and NAFLD itself is a risk factor for incident 
metabolic disease[3].   
People of Indian ethnicity are at increased risk of diabetes and metabolic 
complications at a lower body mass index (BMI) than Caucasians[4, 5]. This has 
been compounded by Westernisation of Asia-Pacific culture[6], resulting in higher 
rates of NAFLD in this ethnic group[7, 8].  
The purpose of this thesis is to add to this evidence base, to estimate accurately the 
NAFLD prevalence across a large Indian district and to confirm which factors 
influence disease risk, to investigate whether decreased brown adipose tissue (BAT) 
activity contributes to the adverse metabolic phenotype seen in this group, and to 
understand the impact of culture and environment on the NAFLD risk profile of 













1.2 Non-alcoholic fatty liver disease (NAFLD) 
 
1.2.1 Introduction 
NAFLD is defined by the presence of fat within >5% of hepatocytes within the liver, in 
the absence of an alternative cause of liver disease or excess alcohol consumption 
(less than 20g/day women, less than 30g/day men)[9, 10]. NAFLD represents a 
spectrum of disease from simple steatosis (fat accumulation within hepatocytes) to 
NASH (liver cell injury and death), which is a sub-type which is more likely to lead to 
increasing stages of fibrosis to cirrhosis[11]  resulting in increased risk of HCC[12] 
and liver transplantation requirement[13]. NAFLD is widely considered the hepatic 
manifestation of the metabolic syndrome, a constellation of metabolic abnormalities 
including glucose intolerance, obesity (particularly central obesity), dyslipidaemia 
and hypertension[14]. These metabolic complications often coincide and have been 
shown to increase risk of cardiovascular disease and mortality overall[15]. Thus, with 
the global pandemic of obesity and the metabolic syndrome in both developed and 
developing countries, comes a dramatic rise in prevalence of NAFLD[16, 17]. 
1.2.2 Prevalence and disease burden 
The prevalence of NAFLD is increasing at a similar rate to obesity[18]. NAFLD has a 
current estimated global prevalence of 25%[1], whilst prevalence of NASH is 3-5%[2, 
19]. It is important however to highlight the difference in NAFLD prevalence across 
the world. For example, prevalence of NAFLD has been shown to be significantly 
higher in South America, than North America[20], despite having lower rates of 
obesity[2]. This is likely to be due to a combination of lifestyle and genetic factors. 
Data on the burden of NAFLD within Asia is evolving. Urbanisation of developing 
countries has resulted in increased sedentary lifestyle and over-nutrition, resulting in 
increased rates of metabolic disease[21]. Prevalence of NAFLD in China has doubled 
over the last 20 years[22]. Here in the UK, rates of NAFLD also appear to be slightly 
higher than global estimates, ranging from 26.4%-32% depending on the diagnostic 
criteria used[23-25] - which is unsurprising given that 25% of the UK population is 
obese[26]. Global rates of NAFLD appear to be increasing in line with rates of obesity 
and diabetes, with data modelling suggesting increasing cases of advanced liver 
disease and liver-related mortality over the coming decade[27]. 
A diagnosis of NAFLD is associated with an increase in both morbidity and mortality. 
Population-based data on NAFLD has shown that ten-year mortality is higher in those 
with NAFLD compared with controls (10.2% vs. 7.6%), and that NAFLD itself is a risk 
factor for incident metabolic disease[3]. In those with NAFLD, an increasing number 
of metabolic complications is associated with increasing mortality, and as such, 
development of NAFLD in those with obesity and diabetes predisposes to further 
metabolic disease and further increases risk of death. This is almost a self-fulfilling 




type 2 diabetes[1]. Presence of diabetes in those with NAFLD is of particular concern, 
as it is associated with increased risk of fibrosis and thus progression of disease[28]. 
Whilst the most common cause of mortality in those with NAFLD is cardiovascular 
disease[29], NAFLD itself only independently increases risk of cardiovascular disease 
in those without the metabolic syndrome i.e. incident metabolic complications 
annuls impact of NAFLD on cardiovascular disease[3]. 
Alongside the significant clinical burden of NAFLD, there is also huge socioeconomic 
burden. Data from a large national administrative claims database has shown that 
the long-term annual cost to a patient with NAFLD in the USA is $3,789 (IQR $1,176-
10,539), compared to a patient with metabolic syndrome alone $2,298 (IQR $681-
6,580)[30]. The global economic burden of NAFLD has been estimated through 
Markov modelling, with the USA having 39 million cases of NAFLD costing their 
economy $62 billion, whilst in Europe, 30 million people are estimated to have 
NAFLD costing their economy $19 billion[31].  
In addition to significant economic burden, there is also emerging data on the 
burden of NAFLD to patients themselves. One study showed that 27.2% of patients 
with NAFLD report symptoms of depression, a rate that is four times higher than in 
the general population[32]. Another study showed that 20% of patients with NAFLD 
reported their health as “fair or poor”, compared to 10% of healthy controls[33]. 
Interestingly, loss of 5% of body weight in those with NAFLD appears to improve not 
only disease-related outcomes, but also measures of health-related quality of 
life[34].   
Given the rapidly growing global burden of NAFLD and NASH, further research is 
needed to identify those at risk, the reasons for their increased risk and to enable 
future interventional studies to focus on those factors that influence risk the most. 
1.2.3 Diagnosis 
The gold standard for diagnosis of NAFLD is through histological assessment of liver 
tissue via liver biopsy. Disease activity and stage are in general assessed using the 
Kleiner classification (Table 1-1)[11]. Due to its invasive nature and inherent 
sampling error[35], liver biopsy is not a suitable diagnostic tool for a disease with 
such high prevalence. Imaging modalities such as ultrasound and magnetic 
resonance imaging (MRI) techniques are now more widely used[36], although these 
modalities are also limited by their sensitivity/specificity (ultrasound has a sensitivity 









Histological Feature Score Category Definition 
 
Steatosis 












1 1-2 foci per x20 field 
2 2-4 foci per x20 field 
3 >4 foci per x20 field 
Total NAS score = 0-8 






1a Zone 3 mild perisinusoidal 
1b Zone 3 moderate 
perisinusoidal 
1c Periportal/portal 
2 Zone 3 + periportal/portal 
3 Bridging 
4 Cirrhosis 
Fibrosis grade = 0-4 
Table 1-1. NAFLD activity score (NAS)[11] 
 
In addition to identifying presence of NAFLD, it is also important to stage disease 
accurately. This is because numerous natural history studies have demonstrated that 
severity of liver fibrosis most accurately predicts liver-related outcomes in people 
with NAFLD[38, 39]. 70% of patients with NASH develop fibrosis progression[1], and 
studies show that HCC may develop in 1.1% of those with NASH cirrhosis over a 10 
year period[40]. This demonstrates the importance of risk stratifying those 
diagnosed with NAFLD, identifying those at risk of significant fibrosis and those with 
advanced liver disease. This can be done utilising a number of non-invasive tools 
developed over the last decade. These include blood-based biomarkers such as the 
NAFLD fibrosis score, FIB-4, ELF and Fibrotest®, as well as imaging tools such as TE 
and magnetic resonance elastography[28, 41, 42]. 
1.2.4 NAFLD risk factors 
Given the high prevalence of disease and the metabolic/cardiovascular implications 
of the diagnosis, screening for NAFLD could be considered important both clinically 
and economically. However, high upfront costs of screening, low yield for significant, 
advanced disease and lack of effective treatments mean that it is not currently 
appropriate to screen for NAFLD within the general population[9]. Attempts to 




made in those at risk of NAFLD, such as those with diabetes or the metabolic 
syndrome, as its presence is important in prognostic terms for both liver-related and 
cardiovascular outcomes[43].  
Age and sex 
NAFLD prevalence is known to increase with age[2]. Studies have also demonstrated 
that there is an increased risk of advanced fibrosis and HCC in NAFLD with advancing 
age[44]. These findings may however be in part due to the increased prevalence of 
metabolic disease in older age. Data relating to NAFLD risk in relation to gender is 
conflicting. Some studies suggest a female preponderance to NAFLD[45, 46], whilst 
others report higher rates in men[47, 48]. Neither age nor gender form part of 
current risk stratification models in the UK[9, 43]. 
Metabolic risk factors 
NAFLD is strongly linked to obesity, diabetes and the metabolic syndrome[1, 49]. The 
physiological links between obesity, insulin resistance and NAFLD have been studied 
in detail – a process outlined by Shulman et al in 2014. Essentially, intake of dietary 
lipid that exceeds the storage capacity of adipose tissue leads to spill-over and 
ectopic lipid deposition in skeletal muscle and liver. Lipid deposition within the 
muscle leads to local insulin resistance, which further drives lipid accumulation in the 
liver. When carbohydrate is ingested, skeletal muscle usually acts as a “sink”, utilising 
the energy from the glucose. However, intramyocellular lipid disrupts uptake of 
glucose, which is diverted to the liver where it is metabolised to free fatty acids. The 
liver, therefore, accumulates fat from both spill-over from adipose tissue, and de 
novo lipogenesis from glucose diversion from insulin resistant muscle [50]. 
In addition to this process, adipocytokines (TNF α, IL-6, IL-8, Resistin, Leptin and 
Adiponectin) also play a role in regulation of hepatic and peripheral glucose and lipid 
metabolism. The balance between these adipocytokines may be important in the 
pathogenesis of NAFLD [51]. One theory is that visceral adiposity causes release of 
adipocytokines, which are transported to the liver via the portal vein [52]. 
Evidence shows that increased visceral adipose tissue is a risk factor for hepatic 
steatosis and increased severity of disease [53, 54], whereas subcutaneous fat 
distribution and peripheral adiposity is negatively associated with liver fat [55] – a 
distribution more commonly seen in African American populations, who have the 
lowest rates of NAFLD. Visceral adiposity is also directly associated with liver 
inflammation and fibrosis [56]. 
Therefore, central obesity, impaired glucose tolerance or type 2 diabetes, 
hypertension and dyslipidaemia all form part of the NAFLD risk profile, and current 
guidelines recommend assessing for presence and severity of NAFLD if any of these 
are present[9, 57]. 
Lifestyle risk factors 
The rising prevalence of NAFLD may be linked to global changes in lifestyle, where 




activity are associated with contemporaneous epidemics of obesity, diabetes and the 
metabolic syndrome. Diet in particular has been strongly linked to the development 
of obesity and subsequent insulin resistance[58], as well as directly resulting in fat 
deposition, altered lipid metabolism and oxidative stress within the liver[50, 59, 60].  
Animal models have shown that a high fat diet induces steatosis of the liver as well 
causing steatohepatitis and fibrosis through oxidative damage[61, 62]. The same was 
shown in humans through a dietary intervention crossover study, where obese 
women followed diets composed of 16% (low fat) and 56% (high fat) of total energy 
intake as fat. Liver fat as measured by magnetic resonance spectroscopy (MRS) 
decreased 20% on the low fat diet, and increased 35% on the high fat diet in the 
absence of change in body composition[63]. 
Type of food consumed also has an impact on insulin sensitivity and glucose 
handling. It is suggested that foods of high glycaemic index are associated with 
insulin resistance[64], in particular consumption of fructose-rich soft drinks lead to 
increased hepatic synthesis of triglycerides[65].  
Physical activity also has an effect on the pathophysiology of NAFLD even in the 
absence of change in weight, through improvement of insulin sensitivity and glucose 
homeostasis with higher physical activity levels. Evidence shows that exercise 
training causes upregulation of insulin receptors in muscle tissue leading to 
increased delivery of glucose and insulin to the muscle[66]. Through strength 
training, increased muscle mass further increases insulin sensitivity by increasing 
glucose storage capacity[67]. Physical activity also has a positive impact on lipid 
metabolism, improving whole-body lipid oxidation and decreasing hepatic free fatty 
acid uptake[68]. 
In the absence of pharmacological treatments, interventions targeted at diet and 
exercise have long been the hallmark of NAFLD management, with evidence showing 
that weight reduction and increased physical activity can lead to reduced steatosis 
and degree of inflammation and fibrosis[69-71]. Less is known however about the 
impact of lifestyle on the development of NAFLD. This section presents detailed 
evidence on the impact of lifestyle on presence of NAFLD. 
Diet 
Multiple case-control and cross-sectional studies have been undertaken to identify 
differences in diet between people with NAFLD and those without. Some studies 
analysed the differences in macronutrients, whilst others look at dietary patterns to 
enable assessment of overall effects of diet through quantification of the cumulative 








Patient groups Study type Results 






Dietary intake of NASH higher in 
saturated fat and cholesterol, lower 
in polyunsaturated fats (PUFA). 
Toshimitsu et 






Higher consumption of simple 
carbohydrates and lower 
consumption of protein in NASH 









Diet with higher proportion of 
carbohydrate increased odds of 
histological inflammation 






Negative correlation between 
total/saturated fat intake and 
measures oxidative stress. Converse 
for carbohydrate and PUFA 







Improved histological markers of 
NAFLD severity with PUFA therapy 
Abdelmalek et 




Daily fructose consumption 
associated with higher fibrosis grade 
Zelber-Sagi et 





Higher consumption of soft drinks 
and meat associated with increased 








Carbohydrate consumption lower in 
cases, fat intake higher (including 
omega-3)  




Cohort study “Western” diet associated with 
increased risk of NAFLD compared to 
“Healthy” diet 






“Animal food” dietary pattern 
associated with greatest odds of 
NAFLD, “Grains-vegetables” pattern 
the lowest 







“Traditional” dietary pattern 
associated with greatest odds of 
NAFLD, “Simple” pattern the lowest 




Musso et al compared 25 patients with NASH to 25 matched controls using a seven-
day dietary record and postprandial lipid metabolism testing[59]. They found that 
there was no difference in total energy, carbohydrate, protein or fat intake between 
cases and controls, but that people with NASH consumed more cholesterol, 
saturated fat, and less polyunsaturated fat and dietary fibre (likely due to reduced 
intake of fruit and vegetables). Those with NASH had increased postprandial 
triglyceride levels. This work suggested that whilst total calories and macronutrient 
intake were the same between groups, it is the quality of fat intake that differs, 
which may lead to altered lipid metabolism.  
A similar study was conducted by Toshimitsu et al, who compared three days of 
dietary intake between 28 patients with NASH and 18 with simple steatosis[72]. 
There was no difference in total calorie or fat intake between groups, but it 
appeared that those with NASH had a higher carbohydrate intake and lower protein 
intake. However, these findings were only seen within specific age groups, and, as 
such, are limited by small sample size. 
Dietary composition may also influence severity of NAFLD. Solga et al analysed the 
diet of 74 morbidly obese women undergoing bariatric surgery, of whom 90% had 
NAFLD[73]. Food intake was analysed in conjunction with liver histology from 
intraoperative biopsy. They showed that a higher carbohydrate intake (>54% of total 
calories) was associated with increased odds of inflammation, whilst the converse 
was true of higher fat intake (as proportion of diet consumed as fat increases, 
proportion of carbohydrate decreases). The study however was underpowered to 
detect differences between those with/without inflammation, and did not give detail 
about the differences in specific lipid subtypes. The same result was not seen by 
Machado et al, who examined differences in blood markers of oxidative stress 
between NAFLD cases and controls in relation to dietary intake[74]. They 
demonstrated a pro-oxidant effect with increased total and saturated fat intake and 
the reverse with increased carbohydrate, fibre and polyunsaturated fat intake when 
adjusted for total energy consumption. This link between increased poly-unsaturated 
fatty acid intake and improvement of NASH was further demonstrated by Li et al[75].  
Other studies have demonstrated links between specific nutrients and NAFLD. The 
consumption of sugar-sweetened beverages has been linked to development of 
obesity, diabetes and may result in fat deposition within the liver[65]. A sugar-rich 
diet is also associated with higher fibrosis grade in those with NASH[76].  Evidence 
also suggest that fructose in particular is linked to NAFLD, where hepatic metabolism 
of fructose increases lipogenesis (NAFLD) and formation of reactive oxygen species 
resulting in increased risk inflammation (NASH)[82, 83]. Omega-3 consumption has 
been linked to NAFLD too, although observational studies are conflicting as to 
whether patients with NAFLD consume more [78] or less [77] in their diet. 
Interventional studies do however appear to support a protective role of Omega-3 




In addition to studies examining macro and micronutrient dietary composition and 
presence of NAFLD, more recent studies have focussed on dietary patterns and 
disease. This is of particular relevance when there is such difficulty in achieving and 
maintaining sustained weight loss long-term in patients with NAFLD, and where a 
change in diet composition without reducing calorie intake may be a more realistic 
alternative. One study showed that following a “Western” diet (high in processed 
food, red meat, refined cereals and confectionary) resulted in increased risk of 
NAFLD over three years (OR 1.59, p<0.005) when compared to a “healthy” diet (high 
in wholegrain cereals, fruit, vegetables and fish)[79]. Other studies have examined 
the effect of a Mediterranean diet on NAFLD[86, 87]. The Mediterranean diet is 
traditionally low in saturated fat and cholesterol, and high in monounsaturated fatty 
acids with a balanced PUFA omega-6 to omega-3 ratio. The protective effect of this 
balanced fatty acid consumption on NAFLD further strengthens the findings outlined 
in the previous paragraph. Large studies in Asia have looked at the impact of a 
“Traditional diet” compared to a Western diet, or a diet composed of more grains, 
fruit and vegetables[80, 81]. These studies appear to show that “Simple diets” 
composed principally of vegetables and grains infer the least risk of NAFLD, but are 
conflicting in which diet patterns confer the most risk, mainly due to differences in 
local dietary habits. 
Exercise 
Numerous studies have looked at the impact of physical activity in relation to NAFLD, 
in terms of amount or type of exercise, or in relation to amount of time spent 
inactive. Perseghin et al showed that compared to controls, people with NAFLD did 
less exercise overall[88], and Zelber-Sagi et al showed that people with NAFLD 
engage in less leisure-time physical activity - although only differences in resistance 
training remained significant when adjusted for insulin resistance, diet and BMI[89]. 
Kistler et al examined the role of exercise in relation to severity of disease, and 
showed that in patients with biopsy-proven NAFLD, meeting the recommendations 
for vigorous activity (75 minutes per week) was the only way to reduce the risk of 
NASH and significant fibrosis[90]. Church et al demonstrated an inverse association 
between cardiorespiratory fitness in general and NAFLD prevalence, regardless of 
BMI[91]. In addition to studies demonstrating the link between exercise and NAFLD, 
a British group looked at the link between sedentary time and presence of NAFLD 
and found that, compared to matched controls, those with NAFLD took fewer steps 
per day, had a lower overall energy expenditure and spent more time inactive[92]. 
The largest and most detailed longitudinal study of the effect of exercise on 
development of NAFLD was undertaken in South Korea, utilising data from regular 
health check-ups of over 126,000 staff members from a large corporation over an 
average period of five years[93]. They demonstrated that any amount of regular 
exercise improved the hazard ratio (HR) for NAFLD development, independent of 
BMI (HR 0.86, p<0.001) and that NAFLD risk decreased with increasing amount of 




any amount of regular exercise increased the chance of NAFLD resolution (HR 1.4, 
p<0.001).  
Brown adipose tissue activity 
As a result of changing lifestyle habits and increasing rates of metabolic syndrome 
and NAFLD, much work has been done to try to identify the intricate mechanisms 
that trigger these metabolic diseases. With this, there has been a resurgence of 
interest in BAT, its relationship with obesity, and its ability to increase energy 
expenditure on activation[94, 95].  
BAT was first documented in 1551 by the naturalist Conrad Gesner, who described 
tissue found in the interscapular region of the marmot as “neither fat nor flesh – but 
something in between”[96]. Having initially been identified solely by its colour (due 
to its granular, mitochondria-rich cytoplasm), BAT was only conclusively 
demonstrated as being from a separate cell lineage to white adipose tissue (WAT) in 
the early 2000’s – where it was shown that bone morphogenic proteins were 
involved in the differentiation of adipocytes into white or brown adipose tissue [97]. 
BAT is unique, in that it contains uncoupling protein 1 (UCP1) on the inner surface of 
its mitochondrial membrane, which, when activated, allows rapid dissipation of 
energy by the free flow of electrons, producing heat [94] and playing a pivotal role in 
thermoregulation, particularly in infancy. Historically, BAT was thought to disappear 
with age, however the persistence into adulthood of BAT in small depots, at sites 
similar to those found in infants, was noted by the pathologist Heaton in the 1970s 
[98]. The largest BAT depots are found surrounding the vasculature of the neck [99], 
where they are thought to play a role in thermoregulation of the blood to and from 
the brain [100]. It is the activity of these depots, noticed on positron emission 
tomography/computed tomography (PET-CT) imaging of adults [95, 101], which 
promoted the resurgence of interest into BAT activity early in the millennium. 
BAT activity is controlled by the action of norepinephrine (from the sympathetic 
nervous system) on β3-adrenoreceptors[102], and is inhibited by vagal nerve 
stimulation [103] (from the parasympathetic nervous system). Norepinephrine has a 
number of actions on BAT to increase its activity: promoting proliferation of 
preadipocytes, differentiation of mature adipocytes[104], directly upregulating the 
expression of genes coding for UCP1 [105], increasing mitochondrial mass [106] and 
preventing apoptosis [107]. The activation of BAT through this pathway can be acute 
(i.e. in response to abrupt cold exposure or a meal [108]) or can be a result of 
enhanced BAT recruitment (through prolonged, mild cooling), which can increase 
thermogenic capacity over a period of time.  
One theory proposed within the literature is that activation of BAT may be one way 
to control whole-body energy expenditure as well as amount of body fat. Mice who 
overexpress UCP1 are notably leaner than wild-type mice and further activation of 
BAT (using cold or beta-agonists) results in a reduction in body fat and BAT 
hyperplasia [109]. In mice, UCP1 ablation induces obesity even on a controlled diet, 




augmenting diet-induced obesity [110]. Further work utilised mouse-models to 
examine the link between BAT activity and NAFLD. Giles et al demonstrated that 
thermoneutral housing (22-24°C) augmented proinflammatory immune responses 
and exacerbated high fat diet-induced NAFLD in mice – implying lack of thermogenic 
energy expenditure from BAT [111]. In addition, Poekes et al [112] showed that 
foz/foz mice (prone to obesity, insulin resistance and progressing fibrosing NASH) 
have severely impaired thermogenic adaptability to diet or cold exposure associated 
with decreased sympathetic tone in BAT. Intermittent cold exposure however did 
restore BAT function, improve glucose tolerance and reduce fat mass and liver 
steatosis. This study concluded that failure of BAT adaptation might play an 
important role in development of hepatic steatosis.  
Early work looking at BAT activity in adult humans was done through retrospective 
review of large numbers PET-CT scans performed for clinical purposes. These 
demonstrated that BAT activity is inversely proportional to body weight[113] and is 
linked to insulin sensitivity[114] and plasma lipid profile[115]. This promoted further 
detailed, prospective studies looking at the impact of BAT activity on the metabolic 
profile of humans. Chondronikola et al. examined the role of cold-activated BAT on 
glucose homeostasis in healthy men and showed that, when activated, BAT 
increased whole-body glucose disposal and insulin sensitivity[116]. The same was 
not seen in those participants without active BAT on PET-CT (deemed “BAT-
negative”). It was therefore hypothesised that activation of BAT could similarly 
improve glucose homeostasis in people with diabetes. Hanssen et al. looked at the 
impact of cold acclimation in men with type 2 diabetes, where participants were 
exposed to temperatures of 14-15°C for 6 hours a day for 10 days. They 
demonstrated that through activation of BAT, peripheral insulin sensitivity was 
improved by 43%[117], exceeding the improvements seen in long-term exercise 
training[118] – even in the presence of low levels of BAT activity overall. The same 
group examined the impact of 10-day cold acclimation in healthy obese men. In 
those men who were “BAT-positive” on PET-CT, cold acclimation did increase BAT 
activity[119]. There were however no changes in energy expenditure or plasma 
biochemistry. A further study compared BAT activity via PET-CT between lean and 
obese healthy men[120]. Following activation through cooling and infusion of insulin, 
glucose uptake of BAT and overall insulin sensitivity was higher in lean compared to 
obese (in whom rates of “BAT-positivity” were low). 
Although there are a number of studies that have examined BAT activity in obese 
and diabetic patients, there is a paucity of data on BAT activity in relation to 
presence of NAFLD. Yilmaz et al. retrospectively analysed clinical PET-CT scans of 
1832 individuals, of which only 2% were “BAT-positive” within a thermoneutral, non-
activated state. When compared with matched “BAT-negative” individuals, the odds 
of having NAFLD was significantly higher in the “BAT-negative” group (odds ratio – 
OR 3.12, 1.03-9.88, p<0.05)[121]. More recently, Zhang et al examined the 
prevalence and predictors of active BAT within a retrospective cohort of over 31,000 




surveillance. Again, the rate of detection of BAT from these clinical scans was only 
1.3%, but there was evidence that BAT was more likely to be detected in those who 
had no fatty liver (p<0.001)[122]. 
Whilst mechanistically it has been shown that BAT activity is linked to obesity, 
diabetes and the metabolic syndrome, and that through activation of BAT, insulin 
resistance and lipid profiles can be improved, translation of this into human studies 
is more difficult. Although rates of “BAT positivity” using PET-CT seem to be low in 
those with an adverse metabolic phenotype, cold-activation of BAT appears to 
improve metabolic parameters[117]. This suggests that it is the tool used to measure 
BAT activity that may be a limiting factor. In addition to glucose, lipid is also utilised 
by BAT as a substrate. Less is known about the rates of lipid hydrolysis within the 
BAT active state, particularly within a phenotype that have a lipid surplus. Therefore, 
it may be that glucose uptake via PET-CT is not the most appropriate modality for 
quantifying BAT activity. The methods of assessing BAT activity in clinical studies is 
described further in Chapter 5. 
Genetic risk factors 
In addition to environmental factors, genetic factors also play an important role in 
the pathogenesis of NAFLD. Numerous studies have been done looking into genetic 
variants that may predispose a person to NAFLD. These can be broadly split into 
candidate-gene studies and genome-wide association studies (GWAS). Candidate 
gene studies look at the frequency of a specific genetic variant in relation to 
prevalence of disease (one that has been previously implicated in that process), 
whereas a GWAS investigates the whole (or large proportion of) genome to identify 
variants that are more common in people with a certain disease. To date, there have 
been 10 GWASs that have identified various genetic variants that confer risk of 
NAFLD [123-132] including PNPLA3[133], PPAR[134], APOC3[135], GCKR[136] and 
TM6SF2[131]. The role of genetics on NAFLD risk falls outside the remit of this body 
of work, and as such are not described in detail here. 
1.2.5 NAFLD and ethnicity 
Several studies have demonstrated differences in prevalence and severity of NAFLD 
between ethnic groups. The majority of the large, population-based studies of 
NAFLD prevalence were conducted in America, with data collected from participants 
of the main ethnic groups in the USA, namely Caucasians, Hispanics and African-
Americans[55, 137, 138].  These studies showed that Hispanics are at greatest risk of 
NAFLD compared to Caucasians, with African-Americans having the lowest rates of 
disease prevalence and severity, despite having higher rates of obesity and diabetes. 
It was hypothesised therefore that ethnic variation in body composition – body fat 
distribution in particular – might influence NAFLD risk. African-Americans were 
shown to have less visceral fat and more lower-extremity fat than the other 
ethnicities[55]. When controlled for visceral fat, the differences in liver fat were 
abolished between groups, indicating a close association between liver fat and 




NAFLD risk factors between different ethnic groups, but are limited by sample size 
and NAFLD diagnostic tools used[139, 140]. The findings of a large number of studies 
examining the NAFLD prevalence in different countries was summarised by Younossi 
et al. in their meta-analysis[1]. They demonstrated that the highest prevalence of 
NAFLD was seen in South America (30.45%, 22.74-39.44) and the Middle East 
(31.79%, 13.48-58.23), whilst the lowest prevalence was in Africa (13.48%, 5.69-
28.36). These data suggest the interaction of genetic and environment factors may 
influence the prevalence of NAFLD. 
 
1.3 NAFLD and Indian ethnicity 
 
People of Indian ethnicity are at increased risk of diabetes and metabolic 
complications at a lower body mass index (BMI) than Caucasians[4, 5]. This has 
been compounded by Westernisation of Asia-Pacific culture[6], resulting in higher 
rates of NAFLD in this ethnic group[7, 8]. The causes of the increased risk of NAFLD 
amongst Indians have been studied widely throughout the literature, a summary of 
which is presented below. 
1.3.1 Indian NAFLD prevalence 
As outlined in section 1.1.2, the prevalence of NAFLD is rising on a global scale, with 
a recent meta-analysis showing a pooled global prevalence of 25.24% [1]. The issue 
with this generalisation is that it is mainly based on large population-based studies 
from the USA, which include relatively small numbers of people of Indian ethnicity. 
In addition, the sub-meta-analysis of Asian NAFLD prevalence within this study 
(27.37%) was calculated from studies undertaken in East Asian populations such as 
Japan and China, and is therefore not representative of the Asian population as a 
whole.  
The documented prevalence of NAFLD also varies depending on the diagnostic tool 
used. In low-middle income countries (like India), it is difficult to perform large 
population-based studies, with those that are published being biased towards urban, 
tertiary centres where ultrasound and biopsy are more readily available[7, 141]. This 
is likely to give an overestimate of disease prevalence in India due to the significant 
variation in degrees of urbanisation and socioeconomic class.  
Studies published on the prevalence of NAFLD in India are often small in sample size 
and heterogeneous in their diagnostic modality, with very few utilising biopsy. 
Documented prevalence ranges from 8.7% in rural West Bengal [142], where the 
majority of people are manual workers and are economically poor, to 87% in an 
urban tertiary diabetes centre [143]. Other large population-based studies include 
the Chennai Urban Population study, which included a random sample of 541 
participants (from the total population cohort of 26,000) demonstrating prevalence 




of two suburban railway colonies (n=1168) reported NAFLD prevalence as 16.6% 
[144]. Table 1-3 shows the variation in documented prevalence according to setting, 











Sample size Population 
Mohan et al. 
[7] 
Urban Ultrasound 32 541 Subset of Chennai Urban Population Study 
Das et al. 
[142] 
Rural Ultrasound 
(USS) and CT 
8.7 
(9.9 via USS) 





Ultrasound 87 204 Tertiary diabetes centre 
 
Amarapurkar 
et al. [144] 
Urban 
Suburban 
Ultrasound 16.6 1168 Railway colonies 
 
Chan et al. 
[145] 
Urban Ultrasound 33 73 Medical students 
 









Biopsy 65.7 134 Morbidly obese patients undergoing bariatric surgery 
Majumdar et 
al. [8] 
Rural Ultrasound 30.7 176 Random selection from 8/28 villages 
Anurag et al. 
[141] 
Rural Ultrasound 28.1 302 Subjects attending a tertiary centre from villages 










Sample size Population 




Ultrasound  49 100 Consecutive patients with diabetes  




Ultrasound 57.2 124 Consecutive patients with diabetes 




Biopsy 31 200 Patients undergoing cholecystectomy 




Ultrasound 54.3 971 Voluntary blood donors 
 




Ultrasound 22.6 1003 Consecutive patients attending routine health check-up 
Bajaj et al. 
[153] 
Urban Ultrasound 32.2 121 Consecutive healthy individuals 




This emerging data shows that NAFLD is no longer a disease confined to the Western 
world. The World Health Organisation (WHO) Global Burden of Disease study shows 
that hypertension and raised fasting blood glucose are the leading cause of non-
communicable disease in India, unlike other low-middle income countries where 
childhood malnutrition and unsafe water predominate [154]. This rapid rise in non-
communicable disease is predicted to impede poverty reduction initiatives in low-
income countries by increasing household costs associated with healthcare. It is for 
this reason that we need to identify and address causes of the increased prevalence 
of the metabolic syndrome and its sequelae in this population. 
1.3.2 Indian NAFLD Risk factors 
Anthropometry 
The links between obesity and NAFLD in general have been outlined in section 1.1.4. 
Whilst the average BMI has plateaued in high-income countries, dietary globalisation 
has led to accelerated rates of obesity across Asia, which is likely to be a contributing 
factor to the increased prevalence of NAFLD within these populations[155, 156]. This 
is a particular concern as evidence shows that South Asians are at higher risk of 
obesity-related morbidity and mortality compared to other ethnic groups[157] and 
at lower BMI [7]  - the so-called Asian paradox. This resulted in the reclassification of 
BMI cut-offs for Asian populations in the year 2000 [4]. Data shows that for every 
increase in BMI of 1kg/m2, Asians have an increased risk of diabetes/hypertension of 
15% compared to 11% in Caucasians and 8% in Black ethnic groups [158].  
Within the literature, it has often been suggested that Asian populations have high 
rates of “lean NAFLD”. However, a review of these studies suggest it is failure to 
utilise the Asia-specific cut-offs for BMI that give increased prevalence of disease in 
those considered “normal” weight[159]. Published data examining differences in 
prevalence of lean NAFLD suggest that rates are higher in Asia (19%)[18, 160] than in 
the USA (7%)[161].  
Other studies looking at risk factors for biopsy-proven NAFLD in Indian populations 
specifically show varying levels of obesity (12-69%) [162-164] but are significantly 
limited by their small sample sizes. The two large Indian population-based cross-
sectional studies of NAFLD within the literature also give varying rates of obesity, 
which is likely to be related to differences in degree of urbanisation and 
socioeconomic class. The Chennai Urban Population study showed that patients with 
NAFLD had an obesity prevalence of 36.5-76.9% which was linked to the grade of 
steatosis [7],  whereas the rural population-based study from West Bengal showed 
an obesity prevalence of 25% in patients with NAFLD when only 7% of this 
population as a whole was classified as overweight when using Asia-specific BMI cut-
offs[142]. The implications of lean NAFLD are yet unknown. Some studies suggest 
that those with lean NAFLD have lower rates of other metabolic components[161], 
whilst others suggest that those with lean NAFLD share a common metabolic and 




less metabolic complications, cumulative survival was worse in lean NAFLD than non-
lean NAFLD[166]. 
Nevertheless, the disproportionate effect of weight gain on risk of NAFLD in the 
Indian population also contributes to the theory that the distribution of fat rather 
than overall obesity has a greater influence on NAFLD risk. Indians are documented 
as having more visceral adipose tissue and have a higher tendency to central 
adiposity compared to Caucasians [167, 168], and that waist-hip ratio correlates with 
risk of metabolic complications within this ethnic group[169].  
Increased visceral fat is also related to increased frequency of insulin resistance, 
which is thought to be a precursor for NAFLD. This may be part of the “missing link” 
between tendency to central adiposity and increased NAFLD risk in Indians. This has 
been demonstrated in a number of studies, including one that examined the 
relationship between insulin sensitivity and visceral fat between age, gender, BMI 
and diet-matched healthy volunteers who were Caucasian and Indian [167]. Indians 
had significantly lower glucose disposal rates compared to Caucasians and had 
significantly greater total abdominal and visceral fat (despite being matched for 
BMI). There were no differences in waist hip ratio (WHR), suggesting that this 
method may not be sensitive enough to detect important differences in body 
composition. In both groups, insulin-mediated glucose disposal (insulin sensitivity) 
was inversely correlated with all fat compartments, suggesting that, for any increase 
in abdominal fat, there is a proportional change in insulin sensitivity. This work 
corroborated the findings of Banerji et al, who also found that healthy non-obese 
Indian men were more insulin resistant with high percentage body fat relative to BMI 
and muscle mass than matched Caucasian men [170]. Although not significant in 
these papers, WHR has been shown to correlate with diabetes within an Indian 
population, with a UK group finding that increased abdominal adiposity in Indians 
resulted in a 4 fold increased risk of diabetes as compared to Caucasians [169].  
All the above literature suggests that Indians have more central adipose tissue, 
which in itself correlates to high levels of insulin resistance and therefore NAFLD.  
Insulin resistance 
Increasing prevalence of diabetes is not limited to Western populations, with India 
showing a dramatic rise in estimated diabetes prevalence from 2011 to 2030 (mean 
annual increment of diabetes diagnoses UK=31,000, India=2,102,000) [5]. Rates of 
diabetes and the metabolic syndrome in India vary according to degree of 
urbanisation and affluence with the odds ratio for impaired glucose tolerance (IGT) 
and diabetes increasing with increasing income [171]. Interestingly, this is not the 
case for developed countries, where higher socioeconomic status results in lower 
prevalence of the metabolic syndrome – which is likely to be due to better education 
and health awareness [172]. Data from the Chennai Urban Population Study shows 
that prevalence of NAFLD is higher in those with diabetes (54.5%), than those with 




Multiple studies have shown that even healthy, non-obese Indians are more insulin 
resistant than other ethnicities[167, 170, 173]. Peterson et al. demonstrated that the 
prevalence of insulin resistance in healthy, young, lean Indian men is 3-4 times 
greater than other ethnicities and that they had higher levels of hepatic triglyceride 
and blood levels of the adipocytokines IL-6 and leptin, even when matched for BMI, 
dietary intake and activity levels[173]. 
The increased prevalence of insulin resistance in Indians has been confirmed in 
cohorts of patients with NAFLD. The NAFLD cohort from the population-based study 
in West Bengal had higher rates of insulin resistance (measured using the 
homeostatic model assessment of insulin resistance - HOMA-IR, mean 2.24 vs 1.44) 
despite being largely non-obese, suggesting that the strength of the physiological 
link between IR and NAFLD transcends anthropometric phenotypes [142]. A 
retrospective review of 71 cases of biopsy-proven NAFLD showed that 60% were 
insulin resistant[162] (although this was not an independent risk factor for NAFLD) 
whilst another cohort study of 51 biopsy-proven NAFLD showed 80% were insulin 
resistant [163]. Both studies were small, retrospective and had significant selection 
bias, meaning these results could be a significant over-estimate. 
This wealth of evidence demonstrates that Indian populations are more insulin 
resistant, even at a normal BMI, which may be related to their tendency to visceral 
adiposity. 
Lifestyle factors 
Changes in dietary composition and exercise habits over the last century are thought 
to be contributing to the rising burden of obesity and diabetes. This trend in 
changing lifestyle habits is not consistent between socioeconomic classes across the 
globe. In developed countries, higher socioeconomic status is often associated with 
healthier lifestyle habits, whereas in developing countries, higher income usually 
equates to a more sedentary job and poorer dietary habits[172]. Within an urban 
population in India, those within the middle-income group (as opposed to low-
income) were shown to consume more total calories, fat and sugar [171]. 
Evidence shows that the adverse cardiovascular risk profile related to the metabolic 
syndrome is associated with a diet high in carbohydrate, low in unsaturated fat and 
with low levels of physical activity [174], which unfortunately describes the typical 
Indian diet. Sudha et al. describes the Indian diet as “predominately vegetarian, rich 
in complex carbohydrate and high in visible fat”, and with increasing urbanisation 
and affluence, the use of fat is increasing across the country [175]. As outlined in 
section 1.1.4, a diet rich in carbohydrate in persons with excess adipose tissue 
increases hepatic fat deposition and insulin resistance. This means that within the 
Indian population, which is already more insulin resistant (even when young, lean 
and healthy), their high carbohydrate diet is likely to increase risk of NAFLD further.  
There are similar findings in Indian studies. One case control study conducted of 




including 98 NAFLD cases (diagnosed via ultrasound) and 102 controls, confirmed 
that the total calorie intake, percent carbohydrate and fat intake was significantly 
higher in cases than controls [176]. There was no difference in physical activity levels 
between groups. A larger case-control study done through a gastroenterology clinic 
in Orissa, India compared 464 consecutive patients diagnosed with NAFLD to 181 
age-matched controls (who underwent ultrasonography for other reasons) [177]. 
NAFLD patients were more likely to consume a non-vegetarian diet (35.3% vs 22.9% 
p=0.002). Frequent consumption of fried food was seen more in the NAFLD group 
(34.9% vs 9.2% p<0.0001) as was drinking tea, which often contains large amounts of 
sugar (54.9% vs 39.1% p<0.001). Through logistic regression, only consumption of 
non-vegetarian diet and fried food was associated with NAFLD. This study was 
interesting in that encompassed patients from both urban and rural communities. 
9.7% of the NAFLD group were manual labourers, with 45.9% having a sedentary job 
(57% cases middle class, 59% controls lower class). This again highlights the differing 
lifestyle habits in relation to socioeconomic class and their impact on NAFLD risk. 
Despite low levels of obesity overall within this study, they found that those with 
NAFLD were richer, less active and had a higher BMI (even when within the “normal” 
range) indicating that income and lifestyle play a large role in development of 
NAFLD, potentially through the increased rates of obesity in those of higher 
socioeconomic class (Table 1-4).  
 
 NAFLD adjusted OR 
(95% CI) 
P value 
Family income   
      <$1.00/day 1.0  
      $1.00-$2.00/day 1.8 (1.0-3.2) 0.05 
      >$2/day 2.4 (1.2-5.0) 0.01 
BMI   
      <18.5kg/m2 1.0  
      18.5-24.9kg/m2 2.0 (1.1-3.8) 0.03 
      >25kg/m2 4.3 (1.6-11.5) <0.001 
Table 1-4. Multiple logistic regression for risk factors for NAFLD in a rural Indian 
population [142]  
There have only been two studies looking at whether differences in BAT activity 
account for differences in rate of metabolic disease between Indians and Caucasians. 
In 2011, a Dutch group used PET-CT to examine the BAT activity of 20 healthy, lean 
men (10 European Caucasian, 10 South Asians) and found that there were no 
differences between the groups [178]. A similar study was conducted in 2013 with 
similar results; Bakker et al showed that, although BAT activity measured as 




Caucasians and South Asians, the total BAT volume and daily energy expenditure was 
reduced in the South Asian group[179]. However, both these studies were 
conducted using healthy, lean participants, and may not give a true representative of 
the impact of BAT activity in those with components of the metabolic syndrome. 
It is this paucity of data on the differences in BAT activity between South Asians and 
Caucasians and the possible link between reduced BAT activity and NAFLD that has 
prompted the work of Chapter 5.  
Genetics 
As outlined in section 1.1.4, through genome-wide association studies, a number of 
genetic variants have been linked to NAFLD risk. These studies include a wide variety 
of ethnicities, including some South Asian populations (mainly Japan), but to date, no 
GWAS has been done looking at genetic susceptibility for NAFLD in Indian groups. 
There have been however, a number of candidate-gene studies looking at some of 
the most well documented single-nucleotide polymorphisms (SNPs) and their link to 







Study Variant Sample size Diagnostic modality Result P value 
Zain  et al. [180] PNPLA3  
  
Case 144  
Control 198  
Histology  OR 2.34  
(1.69-3.24)  
<0.0001 
Kanth et al. [181] PNPLA3  Case 156  
Control 150  
Ultrasound  OR 12.66  
(5.45-29.38)  
0.001 
Bhatt et al. [182] PPAR  Case 162  
Control 173  
Ultrasound  OR 1.64  
(1.09-2.45)  
0.05 
Peterson et al. 
[183] 
APOC3  n = 95  H-MRS  Variant: Mean HTG 7.5 ±10.3%  
WT: Mean  HTG 1.5±1.3%  
<0.001 
Puppala et al.  
[184] 
APOC3  Case 150  
Control 150  
Ultrasound  OR 1.706  
(1.22-2.37)  
0.001 
Kanth et al. [181] APOC3  Case 156  
Control 150  
Ultrasound  OR 1.83   
(1.02-3.28)  
0.12 
Tan et al. [185] GCKR  Case 144  
Control 198  
Histology  OR 2.64  0.012 
Kanth et al. [181] GCKR  Case 156  
Control 150  
Ultrasound  OR 1.22   
(0.69-2.15)  
0.62 
Bale  et al. [186] TM6SF2  South  
 
North-East   
Case 93   
Control 138  
Case 163  
Control 109  
Ultrasound  OR 2.7   
(1.37-5.3)  





Kanth et al. [181] FDFT  Case 156  
Control 150  
Ultrasound  OR 0.69  
(0.36-1.36)  
0.40 




Due to the limitations in sample size, and lack of whole-genome examination, these 
studies merely confirm association of specific single-nucleotide polymorphisms with 
NAFLD within Indian populations. This highlights the need for large, robust, deeply 
phenotyped population-based studies of NAFLD in India to enable better 
understanding of the links between genetic, phenotypic and lifestyle habits of this 




The evidence presented in this chapter highlights the need for further research to 
estimate accurately the prevalence of NAFLD in India, to confirm which factors 
influence disease risk, and to understand the impact of culture and environment on 
NAFLD risk profile within people of Indian origin. This thesis will therefore address 
the following hypotheses, using the subsequent aims and objectives. 
 
1.5 Hypotheses, aims and objectives 
 
 The NAFLD prevalence in India is higher than global pooled estimates 
 NAFLD risk factors in India are similar to those described globally – namely 
obesity, insulin resistance and components of the metabolic syndrome 
 Dietary composition influences NAFLD risk within India – with increased 
consumption of fat and carbohydrate increasing NAFLD risk 
 Migration of South Asians to the UK results in alteration of NAFLD risk profile 
through dietary acculturation 
 Indians have lower brown adipose tissue activity than Caucasians 
 Reduced brown adipose tissue activity increases NAFLD risk 
 
AIM 1: To estimate accurately the population prevalence of NAFLD in a large Indian 
district  
Objective A)  Clean and analyse data from the Trivandrum population-based study 
forming a nested NAFLD case-control study 
Objective B)  Calculate NAFLD prevalence within Trivandrum from the nested 
NAFLD cohort 




Objective C)  Perform case-control analysis of NAFLD risk factors within the 
Trivandrum NAFLD cohort, identifying which factors are 
independently associated with NAFLD risk 
Objective D) Analyse transient elastography data from the Trivandrum NAFLD 
cohort to identify which factors influence severity of disease  
Objective E)  Clean and analyse dietary data from the Trivandrum NAFLD cohort, 
creating a database which outlines the average macronutrient intake 
as grams per day and percentage of total calorie intake 
Objective F)  Summarise the dietary intake of the Trivandrum NAFLD cohort with 
regard to the 12 basic food groups 
Objective E)  Summarise the physical activity of the Trivandrum NAFLD cohort as 
metabolic equivalent hours per week 
Objective F)  Perform case-control analysis of NAFLD risk with regard to dietary 
intake and physical activity within the Trivandrum NAFLD cohort, 
identifying which lifestyle factors are independently associated with 
NAFLD risk 
AIM 3: To compare NAFLD risk profile of native Indians with their UK migrant 
counterparts  
Objective G)  Design and create a multi-ethnic study comprised of native Indian, 
UK-migrant South Asian and UK-Caucasian participants with and 
without NAFLD, collecting data regarding NAFLD risk profile  
Objective H)  Compare NAFLD phenotype between native Indian, UK-migrant Indian 
and UK-Caucasian cohorts 
Objective I)  Perform case-control analysis of NAFLD risk across the multi-ethnic 
study 
Objective J)  Analyse the impact of ethnicity on NAFLD risk within the multi-ethnic 
study 
AIM 4: To investigate the ethnic differences in BAT activity and its impact on NAFLD 
risk  
Objective K)  Assess BAT activity across the multi-ethnic study 
Objective L)  Compare BAT activity between native Indian, UK-migrant Indian and 
UK-Caucasian cohorts 
Objective M)  Perform case-control analysis of NAFLD risk with regard to BAT 
activity across the multi-ethnic study 
Objective N)  Analyse the impact of ethnicity on BAT activity and NAFLD risk within 















As outlined in Chapter 1, NAFLD has long been considered a disease of the Western 
world. However, Westernisation of Asian culture has led to more sedentary 
behaviour and increased consumption of energy-dense foods [187] resulting in a 
dramatic rise in rates of obesity, diabetes and NAFLD in South Asia [18]. This is 
reflected in the fact that hypertension and raised fasting blood glucose are now the 
leading cause of non-communicable disease in India [154]. 
Within India, there is dramatic variation in NAFLD prevalence across different 
geographic, cultural and socioeconomic regions, making it hard to estimate the true 
population prevalence accurately. Evidence suggests that NAFLD prevalence in India 
is anywhere between 9-32% depending on the population of interest, study setting 
and method of NAFLD diagnosis utilised (section 1.2.1, Table 1-3). To date there have 
been no large, cross-regional population-based studies to assess NAFLD prevalence 
in India. Studies of this size are difficult to conduct, particularly within this lower-
middle income country, which has a large rural contingent and where access to 
healthcare or research opportunities is limited. Studies of this nature may not even 
be appropriate, considering the apparent variation in disease prevalence.  
In addition to the limitations of available studies in relation to sample size and 
availability of diagnostic tools, the documented variation in NAFLD prevalence across 
India is likely to be due to differences in risk profile across different regions. This may 
include: i) cultural differences in diet including access to energy-dense, high fat 
snacks ii) geographic setting - whether rural or urban domicile - which may be an 
indicator of socioeconomic group iii) level of physical activity in relation to work or 
iv) genetic predisposition based on ethnic background. For this reason, it is 
important not only to identify disease, but also to identify those factors that most 
influence risk of disease within a population. Thus, population-based studies should 
include collection of data on the different variables attributed to NAFLD risk in order 
to focus future studies and interventions. Furthermore, given the difficulties 
identifying population prevalence within India as a whole and likely variance in 
regional risk profiles, focussed interventions targeted at areas of higher rates of 
disease prevalence and in those with specific at-risk profiles may be more 
appropriate. 
2.2 Hypotheses, aims and objectives 
This chapter will address the following hypotheses using the subsequent aims and 
objectives: 




 NAFLD risk factors in India are similar to those described globally – namely 
obesity, insulin resistance and components of the metabolic syndrome 
AIM 1: To estimate accurately the population prevalence of NAFLD in a large Indian 
district  
Objective A)  Clean and analyse data from the Trivandrum population-based study 
forming a nested NAFLD case-control study 
Objective B)  Calculate NAFLD prevalence within Trivandrum from the nested 
NAFLD cohort 
AIM 2: To identify the impact of different NAFLD risk factors within this population  
Objective C)  Perform case-control analysis of NAFLD risk factors within the 
Trivandrum NAFLD cohort, identifying which factors are 
independently associated with NAFLD risk 
Objective D)  Analyse transient elastography data from the Trivandrum NAFLD 
cohort to identify which factors influence severity of disease 
2.3 Methods 
 
2.3.1 Study design 
The Trivandrum NAFLD cohort was originally designed and set up in 2013 to examine 
the interaction between genetics and lifestyles factors that result in increased risk of 
NAFLD within this population. The cohort also gives an accurate estimation of 
population prevalence of NAFLD and enables analysis of impact of different variables 
on NAFLD risk. The development of this cohort also facilitates further disease-
specific studies, including interventional studies, and has the capability of generating 
longitudinal follow-up data. 
Trivandrum (Thiruvanathapuram) is the southern-most district in the state of Kerala, 
located on the south-west coast of India . At the time of the Indian census in 2011, it 
had a population of 3.3 million divided into urban and rural domiciles (urban 54%, 
rural 46%) [188]. The Trivandrum NAFLD cohort was created between February 2013 
and July 2016 through population-based sampling of all inhabitants over the age of 







As described, Trivandrum has both urban and rural districts. The rural districts are 
divided into 12 blocks, which are themselves formed of 78 panchayats (originally 
denoting a village council). Panchayats are then subdivided further into wards 
(originally denoting a local authority area – usually indicating a neighbourhood). The 
urban districts are divided into wards only.  
The enrolment of study participants was through un-weighted multi-stage cluster 
sampling. Using random number tables, 3 out of 12 rural blocks were selected (made 
up of 22 panchayats), 4 rural panchayats were selected out of 22 (made up of 71 
wards), and finally 40 out of 71 wards were selected. Using the same technique, 7 






Figure 2-1. Trivandrum NAFLD cohort sampling framework 
Using the Trivandrum electoral roll from 2011, households within these wards were 
grouped into clusters of seven. Using random number tables, 112 of 2,420 rural 
clusters and 128 of 2,631 urban clusters were identified for sampling. Each 
household within the chosen clusters was sampled and, through house-to-house 
survey by local social workers, all eligible inhabitants were invited to enrol. For some 
households, this meant repeated visits to ensure all those who were eligible (anyone 
over the age of 25 years) were given the opportunity to participate. Originally, the 
aim was to recruit around 1000 cases of NAFLD, enabling a genome-wide association 
study with 80% power to detect an odds ratio of 1.6 for genetic variants with a mean 
allele frequency (MAF) of at least 20% (OR 1.8 for MAF of 10%, OR 1.5 for MAF of 
35%) with a genome-wide significance of p<1x10^-6, in line with previous NAFLD 
GWAS[189, 190]. Based on an estimated NAFLD prevalence of 31.8% from a previous 
pilot study [191], this meant recruiting a total cohort of 3,125 participants. Due to 
time constraints, cohort recruitment at household-level was ceased at 2,222 
participants (Figure 2-2), which, based on estimated prevalence, would result in 711 






Figure 2-2. Trivandrum NAFLD cohort recruitment diagram 
 
2.3.2 Ethical approval 
Ethical approval for the study was granted by the Sree Gokulam Medical College and 
Research Foundation, Venjaramoodu, Trivandrum ethics committee. This study and 
all relevant documentation received approval from the University of Nottingham 
Faculty of Medicine and Health Sciences Research Ethics Committee (REC: 
26/299/05/2017, 14/06/17) and the Nottingham University Hospitals NHS Trust 
Research and Development department. As participants were not NHS patients, no 
NHS ethics was required or obtained. 
3.3.3 Consent 
All participants provided written informed consent at the time of recruitment, having 
had the opportunity to discuss the study in full with those taking consent 
(particularly those that were illiterate) and to receive written information about the 
study. Participants had the opportunity to ask questions prior to signing consent and 
before any data was collected.  
2.3.4 Data collection 
Clinical data 
Potential participants were approached and consented to the cohort through house-
to-house survey by social workers within their wards. Initial clinical data were 
collected at the time of consent within the participant’s home. For clarity, variables 
were grouped into categories and data were collected using the following 
definitions: 
Demographics  
 Date of birth (for age)  
 Gender 




 Level of education: 
i. Illiterate 
ii. Just literate 
iii. Primary school 
iv. Secondary school 
v. College (but not graduate) 
vi. Graduate or professionalᵻ  
vii. Postgraduateᵻ 
viii. Unknown 
 Work status 
i. Student 
ii. Not currently working for pay 
iii. Working full time 
iv. Unable to work due to disability 
v. Retired 
 Religion 





ᵻ Entry into higher education (graduate or above) was used as an indicator of higher 
socioeconomic position. The use of education as a socioeconomic indicator 
originates from Weberian theory[192]. It captures knowledge-related assets of a 
person and is a strong determinant of future employment and income[193].  
Anthropometry 
 Height: measured using a wall-mounted vertical rule, standing height was 
measured to the nearest centimetre (cm), standing without shoes. 
 Weight: measured using mechanical standing-scales to the nearest kilogram 
(kg) without outdoor clothes or shoes. 
 Waist circumference: measured using a non-expandable tape measure 
midway between the lower rib margin and iliac crest during exhalation. The 
average of two readings were taken to the nearest cm. Central obesity was 
defined as ≥80cm in women and ≥90cm in men (as per Indian consensus 
statement and International Diabetes Federation (IDF) ethnic-specific 
metabolic syndrome definition)[194]. 
Medical history 
Participants were asked if they had a history of the following conditions, and if so, 









e) Ischaemic heart disease (IHD) – history of chest pain or myocardial infarct 
f) Cerebrovascular disease (CVD) – history of cerebrovascular accident 
g) Peripheral vascular disease (PVD) 
h) Hyperlipidaemia 
i) Diabetes 
j) Thyroid dysfunction 
k) Peptic ulcer disease 
l) Cancer 
Lifestyle 
 Tobacco smoking (including pack/years) 
i. Current smoker 
ii. Past smoker 
iii. Never smoked 
 Tobacco chewing 
i. Current chewer 
ii. Past chewer 
iii. Never chewed 
 Alcohol intake (alcohol excess defined as >21units per week) 
i. Never 
ii. Drank alcohol in last year 
iii. Average units per week 
Pathological data 
To collect pathological data, study camps were held within the area local to the 
selected wards and those who had been recruited were invited to attend.  
Participants who attended the study camps had fasting bloods taken for the 
following: 
a) Liver function tests 
- Alanine transferase (ALT) 
- Aspartate aminotransferase (AST) 




- Triglycerides (TG) 




- High density lipoproteins (HDL) 
- Very-low density lipoproteins (VLDL) 
d) Metabolic parameters 
- Fasting glucose 
- Fasting insulin 
Participants also underwent abdominal ultrasonography to assess presence and 
grade of fatty infiltration (Grade 1: Liver echogenicity is increased. Grade 2: 
Echogenic liver obscures the echogenic walls of portal vein branches. Grade 3: 
Echogenic liver obscures the diaphragmatic outline) [36]. A qualified radiographer 
using a portable ultrasound machine undertook ultrasound at the study camps. Due 
to logistical constraints, a specific ultrasonographer was not used at each site, and 
the ultrasound scans were not crosschecked. 
Those who had evidence of NAFLD (of any grade) subsequently underwent TE using 
FibroScan® (Echosens, Paris, France) as a surrogate marker to stage degree of 
fibrosis. Based on a paper by Das et al, which analysed liver stiffness measurements 
compared to histology within an Indian population, a reading of ≤8.4kPa is 
considered low risk of fibrosis, 8.5-11.6kPa intermediate risk and ≥11.7kPa high risk 
(NAFLD fibrosis stage >2, AUROC 0.965)[195]. Whilst this study utilised a sample 
from a population-based study within India, its sample size was reasonably small 
(n=625), reducing confidence in the results. It is however the only study examining 
the accuracy of TE in an Indian population and its cut-offs were therefore considered 
the most appropriate for this study, rather than using data from Caucasian 
populations. FibroScans® were undertaken by an operator who had been formally 
trained by Echosens. The operator obtained ten valid liver measurements and the 
median liver stiffness was calculated. The IQR was calculated and the TE reading was 
considered valid if the IQR was less than 30% of the median stiffness[196].   
2.3.5 Data management 
All study staff and investigators endeavoured to protect the rights of the study 
participants to privacy and informed consent, and adhered to the Data Protection 
Act, 1998.  
Detailed identifiable data were collected for each participant including name 
(including father’s name – which is taken as surname), address and date of birth. 
Clinical data were collected during the household visit using paper case report forms 
(CRF) and pathological data were collected from laboratory or imaging reports. Data 
from these forms were then transcribed onto an electronic Access database 
(Microsoft®, Redmond, USA). The minimum required information for the purposes of 
the study were recorded on the CRF and held securely, in a locked room, or locked 
cupboard. Access to the information was limited to the study staff, investigators and 
relevant regulatory authorities. Electronic data including the study database were 




2.3.6 Data cleaning 
Data from the original Access database were converted into STATA format (version 
15, Statacorp, Texas, USA). Data were examined for duplicates, using name, fathers 
name, gender and postcode. Any true duplicates were deleted. Each participant was 
then allocated a new unique identifier number for purposes of data analysis and any 
identifiable data was removed from the database.  
The distribution of continuous variables was examined for normality and outliers. 
Those outlier results that were considered implausible were deleted and treated as 
missing, but plausible data were allowed to remain and its use decided upon 
dependant on the individual research question.   
2.3.7 Data analysis 
Due to the large sample size and the use of random sampling, central limit theorem 
suggests that continuous data are presumed to be normally-distributed[197] and as 
such were presented as mean (SD). For variables with clear non-normality of data 
when plotted via histogram [198] (e.g. ALT and age), data were presented as median 
(IQR). Categorical data were presented as number (%).  
Univariate analysis was undertaken using unpaired Students t-test of equal variance 
(normal continuous), Mann-Whitney U test (non-normal continuous) and Chi 
squared test (categorical) to compare the following: i) cohort characteristics to 
population data ii) numbers of cases and controls (population prevalence) iii) 
characteristics of the cohort with/without NAFLD iv) characteristics of urban and 
rural districts and v) characteristics of those with/without fibrosis who had NAFLD. 
The analyses were not adjusted to account for missing data points, as these 
numbered less than ten for any given data set.  
Univariate logistic regression was used to determine the odds for NAFLD in relation 
to each variable. This was then used to calculate unadjusted odds ratios (OR), 
presented with a 95% confidence interval (CI) and p value.  BMI and waist 
circumference were presented as both continuous and categorical variables, (as per 
BMI cut-offs and categorised as presence or absence of central obesity), and 
components of the metabolic syndrome were presented individually. Forward, 
stepwise logistic regression was then performed with significance set to p<0.05 to 
identify which variables independently influenced NAFLD risk. All variables that 
increased NAFLD risk on univariate analysis were included in the model, with BMI 
and central obesity as categorical variables. Baseline categories for ordinal variables 
were as presented e.g. male sex, normal BMI and fibrosis risk (in those with NAFLD). 
2.4 Results 
Of the original 2222 population sample, 2161 participants attended the camps – 
demonstrating a high attendance rate and only 3% dropout. Three participants did 
not have an ultrasound so were excluded, leaving the total number of study sample 
participants as 2158. Analysis of the demographic/anthropometric data of those who 




40.6% p<0.001) and a higher proportion of people within the rural setting (73.4% vs 
46.3% p<0.001) did not attend. This was likely to be due to difficulty in getting to the 
rural camps, which covered a larger geographical area than the urban camps, and 
that men were often limited by their need to work. 
Demographic characteristics of the study sample (n=2158) are presented in Table 2-1 
to enable comparison with data from the Trivandrum population census of 2011.  
There was a higher proportion of women in the study sample compared to the 
population census. The proportion of rural and urban population sampled was the 
same as the population census, demonstrating adequate sampling within the study. 














Age (years, mean, SD) N/A 47.22 (11.56)              




1,581,678 (47.9)        
1,719,749 (52.1) 
 








1,529,831 (46.3)        
1,771,597 (53.7) 
 




Education (n, %) 
- Illiterate 
- Just literate 
- Primary school 
- Secondary school 
- High school 






































Work status (n, %) 
- Student 
- Not working  
- Working full time 
















2,194,057 (66.5)        
630,573 (19.1)           
452,915 (13.7)           
 
1765 (81.79)             
226 (10.47)                























The purpose of the creation of the Trivandrum NAFLD cohort was to enable accurate 
estimation of NAFLD prevalence within this population. Through population-level 
sampling, the most representative cohort possible was created. Through ultrasound 
assessment of liver echogenicity, the prevalence of an echo-bright liver within this 
population was 49.8%.  
To enable analysis of variables that may influence risk of NAFLD within this cohort, it 
was necessary to ensure that those with NAFLD had not been identified in error due 
to the presence of an alternative cause of an echogenic liver. For this reason, those 
participants who had a documented cause of liver disease (e.g. viral hepatitis) or 
who were at risk of alcohol-related fatty liver (anyone who consumed >21 units of 
alcohol per week) were excluded leaving a final cohort of n=2089 (NAFLD n=1040, 
Control n=1049, NAFLD prevalence 49.8%)(Figure 2-3).  
 
Figure 2-3. NAFLD prevalence of study sample (49.81%) and creation of NAFLD 
cohort (n=2,089, NAFLD prevalence 49.78%).  
 
2.4.1 Clinical data 
Table 2-2 outlines the anthropometric, medical history and social data of the NAFLD 
cohort, with statistical testing to demonstrate whether any differences between 










Demography    
Age (years, mean SD) 48.34 (10.74) 45.98 (12.31) <0.001 























Higher education (n, %) 200 (19.2) 166 (15.8) 0.04 
Anthropometry    
Height (cm, mean SD) 159.34 (10.23) 158.12 (8.48) <0.001 
Weight (kg, mean SD) 68.35 (11.79) 60.77 (11.20) <0.001 
BMI (kg/m2, mean SD) 26.90 (4.16) 24.30 (4.08) <0.001 
BMI category (n, %) 
- Underweight 
(<18.5kg/m2) 
- Normal weight 
(18.5-22.9kg/m2) 



































Waist circumference  
(cm, mean SD) 

















Past Medical History    
































Thyroid disease (n, %) 63 (6.06) 62 (5.92) 0.89 
















Peptic ulcer disease (n, %) 4 (0.39) 10 (0.96) 0.11 
Cancer (n, %) 3 (0.29) 2 (0.19) 0.65 
Social history    
































Alcohol (n, %) 
- Never 










Table 2-2. Baseline anthropometric, medical history and social data of the NAFLD 
cohort  
Abbreviations: BMI, body mass index; IHD, ischaemic heart disease; CVD, 
cerebrovascular disease; PVD, peripheral vascular disease.  
Higher education = graduate or above; diabetes = history of diabetes &/or fasting 
glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-density 
lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or lipid 
lowering therapy; hypertension = history of hypertension, antihypertensives, systolic 





Overall, females outnumbered males and constituted 1277 of the total 2089 
participants (61.1%). 55.2% of the urban population had NAFLD compared to 43.4% 
of the rural population. Those with NAFLD were taller, heavier and had a higher BMI 
than the control group, although the proportion of participants who were 
categorised as overweight was the same between NAFLD and control groups. Waist 
circumference was also larger in the NAFLD group. There were higher rates of all 
components of the metabolic syndrome within the NAFLD group. Despite this, rates 
of IHD, CVD and PVD are the same. Rates of thyroid disease, lung disease, peptic 
ulcer disease and cancer were the same between groups, as were rates of smoking. 
The proportion of participants who had never drunk alcohol was higher in the 
control group with rates of alcohol intake over the last year being lower.  
On analysis of the impact of these variables on NAFLD risk, living within an urban 
domicile was associated with increased risk of NAFLD with an unadjusted OR of 1.60 
(1.35-1.91). An increase in BMI was associated with increased odds of NAFLD 
(unadjusted OR 1.79 if overweight; OR 3.25 if obese) and, for every unit increase in 
BMI, the odds of having NAFLD appeared to increase by 17% (unadjusted OR 1.17, 
1.15-1.20).  
Presence of diabetes (unadjusted OR 2.27, 1.85-2.79), dyslipidaemia (unadjusted OR 
1.99, 1.66-2.79) and hypertension (unadjusted OR 1.61, 1.34-1.93) were also 
associated with increased odds of disease. A waist circumference above that 
outlined in the Asian-specific IDF definition for metabolic syndrome appeared to 
increase odds of NAFLD (unadjusted OR 2.47, 1.98-3.10), and for every cm increase 
in waist circumference, the odds of NAFLD appeared to increase by 7% (unadjusted 
OR 1.07, 1.07-1.09). Following multivariate logistic regression adjusting for all 
variables as potential confounders, living within an urban domicile and presence of 
hypertension were no longer associated with an increased risk of NAFLD. These data 





 Unadjusted OR 
(95% CI, p value) 
Adjusted OR 
(95% CI, p value) 
Age (years) 1.02      (1.01, 1.03 p<0.001) 1.01 (1.00, 1.02 p=0.029) 
Male sex 1.75      (1.46, 2.09 p<0.001) 2.29 (1.86, 2.83 p<0.001) 
Urban domicile 1.60      (1.35, 1.91 p<0.001) 1.18 (0.98, 1.44 p=0.084) 





   23-24.9kg/m2 
- Obese 
>25kg/m2 
1.17      (1.15, 1.20 p<0.001) 
0.12      (0.04, 0.34 p<0.001) 
 
1.79      (1.36, 2.34 p<0.001) 
 
3.25      (2.58, 4.10 p<0.001) 
 
0.18 (0.06, 0.52 p=0.001) 
 
1.55 (1.15, 2.08 p=0.004) 
 
2.81 (2.15, 3.68 p<0.001) 
Waist circumference (cm)  
- Central obesity 
1.07     (1.07, 1.09 p<0.001) 
2.47     (1.98, 3.10 p<0.001) 
 
1.60 (1.19, 2.15 p=0.002) 
Diabetes 2.27     (1.85, 2.79 p<0.001) 1.76 (1.40, 2.21 p<0.001) 
Dyslipidaemia 1.99     (1.66, 2.39 p<0.001) 1.70 (1.39, 2.06 p<0.001) 
Hypertension 1.61     (1.34, 1.93 p<0.001) 1.14 (0.93, 1.41 p=0.204) 
Table 2-3. Unadjusted and adjusted odds ratios for NAFLD risk factors within the 
cohort 
 
Abbreviations: BMI, body mass index 
Higher education = graduate or above; central obesity = ≥80cm in women and ≥90cm 
in men; diabetes = history of diabetes &/or fasting glucose>126mg/dl; dyslipidaemia 
= triglycerides>150mg/dl &/or high-density lipoproteins<50mg/dl female, high-
density lipoproteins<40mg/dl male &/or lipid lowering therapy; hypertension = 
history of hypertension, antihypertensives, systolic blood pressure >130, diastolic 
blood pressure >85. 
 
To understand the interaction between urban-living and other risk factors for NAFLD, 
the rates of obesity, diabetes and levels of higher education for each domicile are 












BMI >25kg/m2  
(n, %) 
1098 (53.58) 696 (61.65) 402 (41.88) <0.001 
Diabetes 
(n, %) 
550 (26.84) 326 (28.88) 224 (23.33) 0.004 
Higher education 
(n, %) 
366 (17.52) 237 (20.99) 129 (13.44) <0.001 
Table 2-4. NAFLD risk factors as per domicile 
Abbreviations: BMI, body mass index 
Diabetes = Diagnosis of diabetes &/or fasting glucose >126mg/dl; higher education = 
graduate or above. P value between urban and rural groups. 
Within the urban domicile, there were higher rates of obesity (61.7% vs 41.9%), 
higher rates of diabetes (28.9% vs 23.3%) and higher rates of people with higher 
education/of higher socioeconomic class (21% vs 13.4%).  
2.4.2 Pathological data 










Liver function tests    
ALT  
(U/l median IQR) 
31 (25) 19 (12) <0001 
AST  
(U/l median IQR) 
29 (15) 25 (10) <0.001 
GGT  
(U/l median IQR) 
25.7 (18.4) 17.25 (9.8) <0.001 
Platelets    
Platelets  
(10^9/l mean SD) 
249 (70) 247 (66) 0.68 
Lipids    
Cholesterol mg/dlmean (SD) 219.19 (44.05) 212.26 (44.34) 1.00 
Triglycerides mg/dl 
median (IQR) 
133 (85) 94.5 (59) <0.001 
HDL mg/dl 
median (IQR) 
46 (14) 49 (15) <0.001 
LDL mg/dl 
mean (SD) 
141.02 (37.50) 138.46 (38.24) 0.94 
LDL-C mg/dl 
mean (SD) 
140.71 (39.04) 140.03 (38.87) 0.69 
VLDL mg/dl  
median (IQR) 
27 (16) 19 (12) <0.001 
Metabolic parameters    
Glucose mg/dl 
median (IQR) 
107 (39) 98 (11) <0.001 
Insulin mU/l 
median (IQR) 
7.8 (7.7) 4.8 (4.8) <0.001 
HOMA-IR  
median (IQR) 
2.14 (2.14) 1.17 (1.2) <0.001 
Table 2-5. Pathological data for NAFLD cohort  
Abbreviations:  ALT = alanine transferase, AST = aspartate aminotransferase, GGT = 
Gamma-glutamyl transpeptidase, HDL = high-density lipoproteins, LDL = low-density 
lipoproteins, LDL-C = low-density lipoprotein cholesterol, VLDL = very low-density 
lipoproteins, HOMA-IR = homeostatic model assessment of insulin resistance 
HOMA-IR ((fasting insulin*fasting glucose)/405) calculated for those not on 




All liver function tests were higher in the NAFLD group compared to controls. 
Platelet counts were similar between groups. Triglyceride levels were higher in the 
NAFLD group with corresponding lower levels of HDL. Both fasting glucose and 
fasting insulin levels were higher in the NAFLD group. In those without diabetes, 
levels of insulin resistance were higher in the NAFLD group as demonstrated by the 
increased HOMA-IR. 
Originally, only participants with NAFLD were to be assessed for degree of fibrosis 
using FibroScan®. Due to cultural influences, a number of control group members 
were also scanned. The results of these data are presented in Table 2-6. 
  
















Table 2-6. Transient elastography results for the NAFLD cohort 
Of those with NAFLD who underwent TE, 161 (15.5%) had evidence of potentially 
significant liver disease (>8.4kPa), of which 47 (4.5% of those with NAFLD) had 
evidence of advanced chronic liver disease (≥11.4kPa). Interestingly, 4.1% of controls 
also had raised TE with 1.5% potentially having advanced chronic liver disease in the 
absence of NAFLD. This data should however be interpreted with caution, as there 
may be a degree of selection bias toward those who thought, or were perceived to 
be at higher risk of liver disease for whatever reason.  
Subsequent analysis of TE data validity revealed that 8.0% of FibroScan® readings 
had an IQR <30% of the median reading. This number dropped to 3.25% when an IQR 
cut-off of <40% was used. 
Further analysis was undertaken to identify which of the contributory risk factors 
identified in Table 2-3 were associated with presence of fibrosis (TE>8.4kPa) in those 






 NAFLD with TE result 
n=704 







48.4 (10.6) 50.4 (10.3) 0.04 
Male sex 
n (%) 
221 (40.7) 86 (53.4) 0.004 
BMI (kg/m2) 
Mean (SD) 
26.6 (3.9) 28.5 (4.8) <0.001 
Central obesity 
n (%) 
464 (85.5) 148 (91.9) 0.032 
Diabetes 
n (%) 
174 (32.0) 75 (46.6) <0.001 
Dyslipidaemia 
n (%) 
385 (70.9) 117 (72.7) 0.66 
Table 2-7. Comparison of NAFLD patients with and without significant fibrosis 
Abbreviations: BMI = body mass index 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-
density lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or 
lipid lowering therapy 
Patients with evidence of fibrosis were older, had a higher BMI, were more likely to 
have central obesity, be male and diabetic. Those variables that appeared to 
influence risk of fibrosis within this group were combined within a logistic regression 
model to give adjusted odds ratios (Table 2-8). 
 Adjusted OR 
(95% confidence interval) 
P value 
Age (years) 1.02 (0.99, 1.04) 0.075 
BMI (kg/m2) 1.13 (1.08, 1.18) <0.001 
Central obesity 1.75 (0.89, 3.44) 0.103 
Male sex  2.60 (1.75, 3.86) <0.001 
Diabetes 1.80 (1.22, 2.64) <0.001 
Table 2-8. Adjusted odds ratios for presence of fibrosis 
Abbreviations: BMI = body mass index 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 




Table 2-8 shows that increasing age was not independently associated with 
increased NAFLD risk (adjusted OR 1.02 0.99-1.04), neither was presence of central 
obesity (adjusted OR 1.75 0.89-3.44). Male sex was associated with the highest risk 
of fibrosis (adjusted OR 2.60 1.75-3.86 p<0.001), followed by presence of diabetes 





2.5.1 Principal findings 
The principal finding of this body of work was that the prevalence of NAFLD within 
this cohort was 49.8%, which through population level sampling (Table 2-1) is likely 
to be representative of the population as a whole. Univariate analysis demonstrated 
an increased odds of NAFLD in those of increased age, male sex, with higher 
education living in the urban domicile, of higher BMI and with components of the 
metabolic syndrome. Through adjusted multivariate analysis, male sex, increased 
measures of body composition (BMI and waist circumference) and presence of 
diabetes or hyperlipidaemia appeared to be independent risk factors for NAFLD. 
Those living within the urban domicile were more likely to have higher education, 
have a higher BMI, and have diabetes but interestingly did not have increased rates 
of NAFLD as is seen within the literature (Table 1-3). Of those with NAFLD, odds of 
fibrosis were higher in those of increased age, male sex, increased BMI and with 
diabetes, although increased age was no longer a significant contributing factor 
when data was analysed through adjusted logistic regression. 
These findings demonstrate a commonality of risk factors with NAFLD studies from 
India and across the world, with the most significant risk being conferred by male sex 
(adjusted OR 2.29, 1.86-2.83, p<0.001) and presence of obesity (adjusted OR 2.81, 
2.15-3.68, p<0.001). 
Prevalence 
As described, the NAFLD prevalence, as measured by ultrasound within this 
population, was 49.8%. This is significantly higher than both the global pooled NAFLD 
prevalence of 25%[1] (p<0.001) and estimates from other population-based studies 
in India, which range from 9-32%[7, 142, 144].  
To the author’s knowledge, this is the largest study of NAFLD prevalence within 
India. The size of this study and robust population-level sampling framework mean 
this estimate is likely to be accurate within this adult population. In addition to these 
strengths, this study also sampled both urban and rural domiciles at a population 
level when compared to the Indian census of 2011 (Table 2-1). Whilst other large 
studies in India also utilised population-based sampling through electoral rolls[142], 




either rural or urban regions respectively and, as such, show significant variation in 
reported NAFLD prevalence. As expected, the NAFLD prevalence from this study was 
higher than those conducted in rural regions (prevalence 8.7%-30.7%) and lower 
than studies conducted in urban tertiary units (prevalence 49-87%) (Table 1-2). Of 
note, all of these large population-based studies also sample adults only – although 
cut-offs vary from 18 years[142, 144] to 20 years[7] – meaning this study may have 
overestimated prevalence due to a marginally older group (age >25 years).  
The NAFLD prevalence reported in this work is based on the use of ultrasound as a 
diagnostic tool, and whilst this is not the gold standard, its use within this study does 
however make it comparable to the other large population-based studies in India[7, 
142, 144].  
Body composition 
Obesity has long been established as a risk factor for NAFLD. These pathological 
processes have been outlined in detail within the literature, and demonstrated 
clinically through observational studies that show that NAFLD prevalence is up to 
90% in obese adult populations[199]. This finding is highlighted within this cohort, 
with 64.9% of those with NAFLD being obese (BMI>25kgm2) compared to 40.3% of 
the control group. This gave an adjusted odds ratio of 2.81 (2.15-3.68, p<0.001). 
Rates of obesity were higher within the urban domicile compared to rural domicile 
(61.7% vs 49.5%), which could be thought to increase NAFLD risk within these areas. 
Through multivariate analysis however, urban living was no longer associated with 
increased NAFLD risk, as there were similar rates of obesity in those with NAFLD in 
both urban and rural regions (62.8% vs 58.5%).   
Interestingly, rates of obesity within this study population were much higher than 
those quoted by the WHO Non-Communicable Disease Collaboration. 52.6% of the 
Trivandrum NAFLD cohort (both NAFLD and controls) were obese compared to the 
Indian national estimate of 3.9%[200] - although national data incorporates all ages, 
compared to this pre-selected cohort of adults. Data from the National Family Health 
Report in India also show that rates of obesity vary according to domicile, with more 
adults being obese in urban areas (27-31%) compared to rural areas (14-15%)[201], a 
difference which was not apparent within this cohort (see paragraph above). Kerala 
is specifically quoted as one of the regions with highest obesity rates (29-32%), 
although this is still lower than the rates seen within this cohort.  
Although obesity rates were higher within this population compared to national 
averages, rates were similar to those quoted by other population-based studies in 
India. Mohan et al. (urban) quoted rates of obesity as 34.4% and reported an 
unadjusted NAFLD odds ratio of 2.0[7]. Amarapukar et al. (also urban) had an obesity 
prevalence of 32%[144]. Das et al. showed significantly lower rates of obesity within 
their rural population, with only 0.9% of people being obese[142]. However, the 
odds ratio for NAFLD in relation to obesity in their cohort was significantly higher (OR 




Similarly, increasing waist circumference (unadjusted OR 1.07, 1.07-1.09, p<0.001) 
and central adiposity (adjusted OR 1.60, 1.19-2.15, p=0.002) were also associated 
with NAFLD risk within this cohort. This finding is in line with data from the literature 
which suggests that tendency to central adiposity in Indians may increase insulin 
resistance and predisposition to NAFLD[169]. 
Data from this cohort, along with that from the other large works published in the 
literature, further highlight the impact of the Asian-paradox – where people of Asian 
origin are at increased risk of metabolic and cardiac complications in relation to 
smaller increases in BMI. In addition, these data add to the increasing body of 
evidence that rates of obesity and NAFLD may be higher in urban regions, which 
could be related to income and socioeconomic position. 
Demographics  
Within this cohort, when history of higher education was used as a surrogate for 
socioeconomic position[192], those that lived within the urban domicile were of 
higher socioeconomic status and as such were likely to have higher income[193]. 
When analysed in isolation, living in an urban environment was associated with 
increased risk of NAFLD, but the significance of this was lost when adjusted for 
confounders through stepwise logistic regression, and the association may instead 
be related to an increased BMI in those living within the urban domicile.  
Evidence from other large population-based studies suggest that rates of obesity, 
diabetes and NAFLD are closely linked to socioeconomic status. It has already been 
noted that within the rural district sampled by Das et al. rates of obesity were low, 
but that small changes in BMI equated to large increases in NAFLD risk[142]. The 
same was demonstrated for socioeconomic position, which was measured using 
household income (<$2 per day was considered economically poor). This work 
showed that earning more than $2 per day resulted in a more than two-fold increase 
in risk of NAFLD (adjusted OR 2.4, 1.2-5.0, p=0.01). Amarapukar et al. surveyed the 
slum settlements along the Mumbai railway lines[144]. Whilst economically poor, 
these areas are urban, and rates of obesity, diabetes and NAFLD were higher than 
the rural-poor. This is likely to be due to the availability of high energy-dense foods 
and the less active working environments. Kerala, as a state, has a higher per capita 
income (88,527 Rupees) than the average for India as a whole (74,380 Rupees), 
which may also influence rates of obesity and its metabolic consequences in this 
region. 
Insulin resistance 
Presence of diabetes was significantly associated with NAFLD risk within this cohort 
(adjusted OR 1.76 1.40-2.21, p<0.001), with rates being higher in the urban domicile 
compared to rural. The physiological link between obesity, insulin resistance and 





Of note, are the high rates of diabetes within this cohort (26.8% overall), which may 
be in some part linked to the higher rates of obesity as outlined above. 31.1% of 
NAFLD patients and 18.6% of the control group had diabetes – which is significantly 
higher than those documented in the IDF atlas (8.3%-9.9%)[5]. Again, rates of 
diabetes in relation to domicile and socioeconomic position reflect those found in 
the other large Indian studies of NAFLD – with Mohan’s urban cohort having rates of 
24.4% using the same criteria[7]. Within this cohort, the diabetes rates may be due 
to the cohort being formed of participants over the age of 25 years, an age group 
where prevalence of type 2 diabetes is expected to be substantially higher. In 
addition, collection of fasting blood glucose levels at enrolment identified those who 
met the IDF criteria for diabetes without previous diagnosis. Alternatively, it may be 
postulated that it is these high rates of diabetes that predispose this cohort to such 
high rates of NAFLD. 
Pathological findings 
Given the close link between NAFLD and the metabolic syndrome, it is unsurprising 
that the lipid components of the metabolic syndrome were higher in the NAFLD 
group compared to the control group, along with levels of fasting glucose, insulin 
and HOMA-IR. Liver enzymes were also higher in the NAFLD group. Liver enzymes 
have long been utilised as a biomarker for NAFLD, with data suggesting that as many 
as 88.4% of people with a persistently elevated ALT have NAFLD[202]. This result was 
therefore expected. Although raised ALT is linked to NAFLD, analysis of the impact of 
increased ALT on NAFLD risk within this cohort is not useful, as there is also 
significant evidence that NAFLD can exist in the context of a normal ALT[203-205]. 
The increased GGT may reflect the increased numbers of participants drinking 
alcohol within the NAFLD group. Platelets would be expected to drop in NAFLD only 
with advanced cirrhosis and portal hypertension and as such were not useful when 
examining their relationship to NAFLD risk.  
Rates of significant liver disease as assessed by TE were 15.5% in the NAFLD group 
with 4.5% having evidence of advanced chronic liver disease. These rates are roughly 
comparable to UK data (Chalmers et al. 19.1% significant, 4.3% advanced[206]), but 
there is a paucity of Indian data with which to compare. Das et al. used FibroScan® in 
their initial cohort but only assessed patients with “significant NAFLD”, as defined by 
presence of steatosis with an accompanying ALT rise[142], contrary to the fact that 
significant liver fibrosis exists in the context of a normal ALT[203, 204]. Two years 
later, the same group did some work looking at median liver stiffness within a small 
NAFLD cohort and a selection of healthy controls, but without a detailed breakdown 
of this work it is impossible to compare with this cohort[195]. Many other Indian 
studies have looked at degree of fibrosis in NAFLD using biopsy, but these are biased 
toward urban, tertiary centres and as such are likely to overestimate prevalence of 




2.5.2 Strengths and weaknesses of the study 
To the author’s knowledge, this is the largest population-based study of NAFLD 
®prevalence in an Indian population in the literature. The biggest strength of this 
work is the random, population-level sampling framework that was utilised. The 
spread across the different demographics of the district gives an accurate estimate 
of the population prevalence of NAFLD in Trivandrum, filling an important gap in the 
knowledge base. The cohort has also been deeply phenotyped, which enables 
accurate analysis of a wide range of factors and their impact on NAFLD risk. This 
population is relatively static, enabling future longitudinal and interventional studies.   
The main limitation of this work from a clinical perspective was the use of ultrasound 
as the diagnostic tool for NAFLD. Ultrasound has been shown to have a poor yield in 
the diagnosis of microvesicular fat within the liver, with an overall sensitivity of 43% 
and specificity of 73%[37]. This means that the NAFLD prevalence estimated may 
even be an underestimate. Whilst liver biopsy has been used to define NAFLD and is 
hence generally considered the gold standard for NAFLD diagnosis, its invasive 
nature and inherent risk of sampling error makes it unsuitable for population-based 
studies. Alternative diagnostic modalities, including MRS, have now be proven to 
give accurate estimates of NAFLD[138], but its cost and availability meant its use was 
not possible for this study.  
In addition to this, 8% of TE readings were not entirely reliable given their wide IQR. 
Evidence suggests that most discordance between TE reading and true fibrosis stage 
(as measured via histology) are attributable to an underestimation of degree of 
fibrosis[207]. Therefore, the amount of significant liver disease within this cohort is 
likely to be an underestimate, rather than an overestimate. 
Finally, although representative of a large Indian population, the data collected from 
this cohort are not necessarily representative of Indian as a whole, whose diverse 
population includes thousands of distinct and unique cultures.  
2.5.3 Study implications and future work 
The finding that NAFLD prevalence within this cohort is significantly higher than both 
national and global estimates is an important one. Obesity plays a significant role in 
the NAFLD risk profile of this study population, as well as in those of other studies 
across India. As such, those limited resources available should focus on obesity 
prevention strategies and NAFLD screening in those areas that have the highest rates 
of obesity, which have been shown to include the southern states and Kerala[201]. 
FibroScan®, with controlled attenuated parameter scoring (as a measure of hepatic 
steatosis), may be a useful screening tool to use on a population-level. Its portable 
nature and ability to give instant results may prove invaluable for the identification 
and stratification of disease in the future. The validity of this tool would need to be 
confirmed in an Indian population. 
Whilst examining the impact of demographic, anthropometric and pathological 




and genetics factors within this population and their influence on NAFLD risk. The 
following chapter will examine the impact of diet and physical activity on NAFLD 
within this cohort, and future work will include a genome-wide association study 




NAFLD prevalence in this South Indian population was 49.8%, which is higher than 
other national and global estimates. This is likely to be due to high rates of diabetes 
and obesity within the population (higher than rates documented in academic 
literature and government reports), both of which are shown to be significant risk 
factors for NAFLD within this group. This confirms both hypotheses outlined at the 
beginning of this chapter. 
To obtain a better understanding of the NAFLD risk profile and potential reasons for 
this higher disease prevalence, it is necessary to understand the impact of lifestyle 
factors on NAFLD risk. The following chapter will analyse food frequency and physical 








3.1.1. Lifestyle and NAFLD 
Changes in dietary composition and exercise habits over the last century may be 
contributing to the rising burden of obesity and diabetes. Evidence shows that the 
adverse cardiovascular risk profile connected to the metabolic syndrome is 
associated with a diet high in carbohydrate, low in unsaturated fat and with low 
levels of physical activity[174]. As outlined in Chapter 1, a diet rich in carbohydrate in 
persons with excess adipose tissue increases hepatic fat deposition and insulin 
resistance and therefore has been shown to also increase risk of NAFLD[72]. Further 
studies have demonstrated the link between dietary habits and NAFLD (Table 1-2). 
For example, Musso et al found that the diet of patients with NASH was higher in 
saturated fat and cholesterol [59]. Zelber-Sagi et al. confirmed these findings in their 
study of nutrition and the risk of NAFLD in an Israeli group [77]. They found that a 
diet with a higher intake of meat and soft drinks was associated with NAFLD, 
independent of total calorie intake. Although, a meta-analysis of Fructose 
consumption and risk of NAFLD concluded that the association seemed to be 
confounded by total calorie intake [208]).  
Decreasing levels of physical activity and increasing sedentary behaviour have also 
been shown to increase risk of NAFLD, even when adjusted for insulin resistance, 
diet and BMI[89, 91]. In one study, it was found that engaging in resistance exercise 
was inversely associated with NAFLD even after adjusting for insulin resistance, 
nutritional factors and BMI. However, the statistical significance of this disappeared 
when waist circumference was added to the model, suggesting this association may 
be mediated by reduced rate of abdominal obesity [89]. More recent prospective 
studies that examined changing lifestyle habits over 20 years have shown that the 
excess NAFLD risk conferred by obesity is attenuated by increased physical activity; 
at any BMI, increased physical activity reduced risk of liver-related mortality[209]. 
3.1.2 Indian lifestyle and NAFLD 
Whilst there is a wealth of evolving data on the effects of diet and exercise in 
relation to NAFLD in general, little is known about the specific impact of lifestyle on 
NAFLD risk in people of Indian origin. This is of particular relevance given the 
increased rates of disease in this population compared to other ethnic groups, as 
presented in Chapters 1 and 2. Presented here are the only available data related to 
lifestyle and NAFLD within Indian populations from the two dedicated studies 
published in the literature. 
Sathiaraj et al examined risk factors between NAFLD cases and controls from 200 




(urban)[176]. Interestingly, within this apparently healthy cohort, the NAFLD 
prevalence was 49%, similar to the Trivandrum NAFLD cohort (Chapter 2.). They 
looked at differences in nutritional intake between cases and controls and showed 
that total calorie, percent carbohydrate and percent fat were higher in the NAFLD 
group, with only percent fat remaining an independent risk factor for NAFLD on 
logistic regression. The average total calorie intake was 8100±1205kJ for NAFLD and 
6890±1255kJ for controls respectively, which is likely to represent a degree of under-
reporting, as current recommended calorie intake is 10,500kJ per day for an average 
male[210]. They also collected data on physical activity including amount and type of 
exercise undertaken, although the precise method of this data collection was not 
clear. Only 46% of the study population were involved in physical activity and there 
were no differences in amount or type between groups. 
Singh et al published the only other study that included lifestyle data in relation to 
NAFLD within an Indian population[177]. They examined NAFLD risk factors 
comparing 464 subsequent patients diagnosed with NAFLD to 181 controls. This 
included assessment of dietary intake which was split into particular dietary habits 
(e.g. vegetarian diet vs. non-vegetarian diet, rice-predominant vs. grain-
predominant), intake of particular food groups including fruits, fast food and aerated 
drinks, and methods of cooking, including consumption of fried food and level of 
spice. They found that there were no differences in rice/grain predominance 
between groups, but that those with NAFLD were more likely to consume fried or 
spicy food or follow a non-vegetarian diet – the only factor that remained a risk 
factor after adjustment for confounders. Again, low levels of physical activity were 
reported, with only 33% of NAFLD and 32% of controls undertaking any regular 
exercise, with no difference between groups. 
 
3.2 Hypotheses, aims and objectives 
 
This chapter will address the following hypothesis using the subsequent aims and 
objectives: 
 Dietary composition influences NAFLD risk within India – with increased 
consumption of fat and carbohydrate increasing NAFLD risk 
AIM 2: To identify the impact of different NAFLD risk factors within this population  
Objective E)  Clean and analyse dietary data from the Trivandrum NAFLD cohort, 
creating a database which outlines the average macronutrient intake 
as grams per day and percentage of total calorie intake 
Objective F)  Summarise the dietary intake of the Trivandrum NAFLD cohort with 




Objective G)  Summarise the physical activity of the Trivandrum NAFLD cohort as 
metabolic equivalent hours per week 
Objective H) Perform case-control analysis of NAFLD risk with regard to dietary 
intake and physical activity within the Trivandrum NAFLD cohort, 





3.3.1 Study design 
The Trivandrum NAFLD cohort is outlined in detail in the previous chapter. Briefly, 
the cohort was created in 2013 through un-weighted, multi-stage, randomised 
cluster sampling of all inhabitants of the Trivandrum district over the age of 25 years, 
totalling 2222 participants. Those who did not undergo a liver ultrasound or who had 
an alternative cause than NAFLD for an echo-bright liver were excluded.  This 
resulted in a nested NAFLD cohort of 2089 participants: n=1,040 NAFLD; n=1,049 
controls (disease prevalence 49.8%). 
3.3.2 Ethical approval  
Ethical approval for the study was granted by the Sree Gokulam Medical College and 
Research Foundation, Venjaramoodu, Trivandrum ethics committee. This study and 
all relevant documentation received approval from the University of Nottingham 
Faculty of Medicine and Health Sciences Research Ethics Committee (REC: 
26/299/05/2017, 14/06/17) and the Nottingham University Hospitals NHS Trust 
Research and Development department. As participants were not NHS patients, NHS 
ethical approval was not needed and was thus not sought. 
3.3.3 Consent 
All participants provided written informed consent at the time of recruitment, having 
had the opportunity to discuss the study in full with those taking consent 
(particularly if the participant was illiterate) and to receive written information about 
the study. Participants had the opportunity to ask questions prior to signing consent 
and before any data was collected.  
3.3.4 Data collection 
The lifestyle data that form the basis of this chapter were collected during the 
development of the Trivandrum NAFLD cohort in 2013. Participants were 
approached and consented to the cohort through house-to-house survey by social 
workers within their wards. These data were entered onto paper CRFs and were then 
transcribed onto an electronic access database (Microsoft®, Redmond, USA) using 
their unique identifier number as outlined in Chapter 2 (2.3.5). This meant that 
lifestyle data were collected prior to identifying whether individuals were NAFLD or 




Dietary data collection 
Dietary data were collected using a region-specific FFQ which was created locally 
through collection of detailed recipes of frequently consumed foods/drinks and has 
been validated against repeated food diaries[211]. The FFQ was completed through 
direct questioning from a social worker. It consists of a list of 389 items (see 
Appendix 1), some of which are complex recipes. Participants recorded how often 






Each item had a standard portion size attached to it and participants were also asked 
to report the size of the portion eaten, as well as the frequency as above. 
Dietary data analyses 
The nutrient composition of each item was calculated by entering the weight and 
volume of one portion of its raw ingredients into a nutrition programme (Dietsoft®, 
Noida, India) which utilises the Nutritive Value of Indian Foods database[212].  
To estimate the dietary and macronutrient intake of each individual (carbohydrate, 
protein, fat), the reported frequency of each item was multiplied by the reported 
portion size and its respective nutrient composition. From this, the mean daily 
macronutrient intakes (grams per day, g/day) were calculated. 
Example:  
a) Participant “A” consumed dosai (item 22) once a week, with a portion size of 
3 (3x60g).  
Portion size per day is calculated = portion size x frequency per day 
          0.42 = 3 x 0.14 
b) One portion of dosai contains:  
Fat 0.72g  
Carbohydrate 25.70g 
Protein 4.10g  
Energy 125.70kcal  
 
c) For participant “A”, their consumption of dosai (item 22) contributed; 1.72g 
per day of protein (4.10x0.42), 0.30g per day of fat (0.72x0.42) and 10.79g of 
carbohydrate (25.70x0.14) 
 
d) The same calculations were done for all 389 items, and were combined to 




Macronutrient data were also presented as proportion (%) of total kilocalories (kcal) 
eaten as each macronutrient. This percentage kcal intake for each macronutrient 
was calculated through energy adjustment i.e. 1g fat = 9kcal, 1g protein = 4kcal, 1g 
carbohydrate = 4kcal. This enabled detailed analysis of the dietary composition in 
line with government recommendations – utilising percentage macronutrient intake 
rather than grams per day, which requires adjustment for body weight[210].  
Example continued: 
e) The average total calorie intake per day  (across all 389 FFQ items) of 
participant “A” is 1941.42kcal made up of: 
Fat 54.58g/day x 9      =     491.22kcal/day     = 25.30% of total kcal 
Carbohydrate 315.53g/day x 4  =     1262.12kcal/day  = 65.01% of total kcal 
Protein 47.02g/day x 4     =     188.08kcal/day     = 9.69% of total kcal 
In addition to dietary data being presented in terms of macronutrient intake (g/day 
and %total calories), data were also presented in terms of the basic food groups, 
which include: 




5. Nuts and oil seeds 
6. Condiments and spices 
7. Meat, fish and poultry 
8. Cereals and millets 
9. Fats and edible oils 
10.  Pulses and legumes 
11.  Beverages 
12.  Bakery and snacks 
Each item/recipe was broken down into its constituent ingredients, which were 
allocated to one of the above food groups. This enabled calculation of average 
consumption in grams per day of each food group using the same calculation 
outlined in the example above. 
Physical activity data collection 
Physical activity data were collected using a modified global physical activity 
questionnaire (GPAQ – Appendix 2). The GPAQ was completed through direct 
questioning from a social worker. It consists of three main domains: occupational, 
non-occupational and transportation physical activity. For the occupational and non-
occupational domains, participants were asked what proportion (giving the number 
of whole hours) were spent doing little (sedentary), moderate or vigorous activity for 
every 8 hours in a day (8am-4pm). For the transportation domain, they were asked 




Physical activity data analyses 
These data were used to calculate the average MET for each participant across the 
three domains using the following calculation: sedentary 1 MET; moderate exercise 4 
METs; vigorous exercise 8 METs; self-transportation 4 METS to give total MET hours 
per week per person (METhr/week). These data were presented as hours per week, 
as the GPAQ was designed to collect data as proportion of 8 hours within a day, 
across an average week.  
3.3.5 Data cleaning 
As described in Chapter 2 (2.3.5) data were converted into STATA format (version 
15, Statacorp, Texas, USA) utilising individual unique identifiers to link this lifestyle 
data to clinical data for analysis. Data were examined for outliers and those data that 
were implausible were deleted and treated as missing. Repeated reporting of items 
(frequency and portion size of each item should only be included once) by an 
individual participant were deleted, leaving the highest frequency response. Those 
participants that reported consumption of less than ten different items from the FFQ 
were excluded. 
3.3.6 Data analysis 
Baseline data from the cohort were presented as follows: Categorical data were 
presented as numbers (percentage) and continuous data were presented as mean 
(SD). The reported variables within this work would usually be Normally distributed 
within the populations sampled and central limit theorem suggests that when testing 
for differences between groups (NAFLD cases and controls), these differences are 
also expected to be Normally distributed[198]. In addition, it can be assumed that 
the data had homogeneity of variance and that data points were independent and 
were derived from an equal-interval scale. For these reasons, all continuous data 
were considered parametric. Comparison was made between the lifestyle cohort 
(n=2,047) and the NAFLD cohort (n=2,089) to ensure the residual sample (due to 
missing lifestyle data) were representative of the cohort overall.  
When comparing continuous data between two groups (i.e. between lifestyle cohort 
and NAFLD cohort and between NAFLD and control groups), unpaired, two-tailed 
Students t test of equal variance was used for continuous data, and Chi squared and 
two-sample test of proportion test for categorical data. Statistical significance was 
set at p<0.05.  
Unadjusted odds ratios were calculated through univariate logistic regression 
(including 95% confidence interval and p value) to identify which lifestyle variables 
were associated with NAFLD risk.  
To understand the confounding effect of different variables on NAFLD risk, an 
adjusted logistic regression model was created. An initial model was created through 
the forward, stepwise addition of variables. This included variables identified a priori 
from the previous Chapter (e.g. gender, BMI, central obesity, diabetes and 




NAFLD and control groups (e.g. proportion of macronutrient intake as fat, saturated 
fat and fibre intake (g/day) and METhr/week). For each sequential variable added, 
likelihood testing was applied to compare explanatory power(Pseudo-R2) of the 
subsequent iteration to its previous iteration. The p value for the likelihood test 
demonstrated whether the subsequent iteration resulted in a significant change in 
likelihood ratio from the previous iteration (i.e. the variable should be kept in). Those 




3.4.1 Baseline characteristics 
Clinical data 
Dietary and physical activity data were available for 2,047 (lifestyle cohort) of the 
original NAFLD cohort (n=2,089) representing 2% data-loss (27 participants gave <10 
responses, 15 participants FFQ data were missing). When comparing the 
characteristics of this lifestyle sub-cohort to the original NAFLD cohort, there were 
no differences in age (p=0.956), gender (p=0.839), domicile (p=0.992), 
socioeconomic class (p=0.957) or body composition (BMI p=0.881).  
These data were therefore representative of the cohort overall. The full baseline 










Age (years, mean SD) 48.31 (10.77) 46.03 (12.37) 


















Higher education (n, %) 199 (19.49) 162 (15.79) 
BMI (kg/m2, mean SD) 26.85 (4.13) 24.30 (4.07) 
BMI category (n, %) 
- Underweight (<18kg/m2) 
- Normal (18.5-22.9kg/m2) 
- Overweight (23-24.9kg/m2) 











Central obesity (n, %) 553 (54.16) 410 (39.96) 
Metabolic syndrome (n, %) 
- Diabetes 
- Hypertension  









Table 3-1. Lifestyle cohort baseline characteristics 
Abbreviations: BMI = body mass index 
Higher education = graduate or above; central obesity = ≥80cm in women and ≥90cm 
in men; metabolic syndrome = central obesity and more than one of: triglycerides 
≥1.7, HDL ≤1.07, lipid lowering therapy, fasting glucose ≤5.6, diabetes, hypertension; 
diabetes = history of diabetes &/or fasting glucose>126mg/dl; dyslipidaemia = 
triglycerides>150mg/dl &/or high-density lipoproteins<50mg/dl female, high-density 
lipoproteins<40mg/dl male &/or lipid lowering therapy; hypertension = history of 
hypertension, antihypertensives, systolic blood pressure >130, diastolic blood 
pressure >85. 
As presented in Chapter 2, those with NAFLD were older, were more likely to be 
male, from an urban domicile and of higher socioeconomic class. Again, NAFLD cases 






The average portion per day of each item (as listed in the FFQ) across the whole 
cohort is presented in Appendix 1. The 10 items that were consumed most 
commonly are presented in Table 3-2 and included tea, coffee, rice, dosai (rice batter 
“pancake”), iddli (fermented rice and black lentil cake) and dried fried fish (often 
mackerel with chilli and turmeric). 
FFQ item Average portion per 
day 
Boiled rice 4.6 
Tea with milk and sugar 2.6 
Tea with milk 2.3 
Raw rice 2.0 
Tea with sugar 1.8 
Dried fried fish 1.6 
Black tea 1.5 
Black coffee 1.4 
Dosai 0.9 
Iddli 0.9 
Table 3-2. Ten most commonly consumed FFQ items across the lifestyle cohort 
Abbreviations: FFQ = food frequency questionnaire 
The average daily intake (g/day) of each of the 12 food groups across the cohort is 
outlined in Figure 3-1. This demonstrates that a large proportion of diet in 
Trivandrum was consumed as cereals and millets (including rice), which concurs with 











To enable comparison of the intake of the 12 food groups presented in Figure 3-1 
between NAFLD cases and controls, their average daily consumption (g/day) are 
presented in Table 3-3. 
 







Milk and milk products  
 
121.23 (81.34) 112.43 (75.34) 0.284 
Fruits  
 
128.92 (82.41) 141.58 (89.16) 0.081 
Vegetables 
 
165.23 (94.82) 182.65 (91.78) 0.056 
Sugars 
 
119.23 (73.65) 109.89 (72.21) 0.344 
Nuts and seeds 
 
75.23 (41.23) 73.23 (43.82) 0.645 
Condiments and spices 
 
79.43 (48.14) 81.23 (46.76) 0.387 
Meat, fish and poultry 
 
222.23 (97.37) 162.23 (82.86) 0.022 
Cereals and millets 
 
480.43 (196.64) 210.23 (98.34) 0.003 
Fats and edible oils 
 
167.27 (78.32) 63.23 (31.98) 0.001 
Pulses and legumes 
 
121.23 (87.56) 90.23 (90.23) 0.082 
Beverages 
 
89.23 (41.91) 70.23 (37.81) 0.324 
Bakery and snacks 
 
134.78 (91.89) 108.23 (48.76) 0.062 
Table 3-3. Average food group intake (g/day) in NAFLD and control groups (rice 
included within “cereals and millets”) 
Those with NAFLD consumed on average more animal protein, more cereals and 
millets and more fats and edible oils than controls. Fruit was the only food group 
that NAFLD cases appeared to consume less of than controls, although not 




The average dietary intake of each macronutrient as grams per day, proportion of 
total energy intake (kcal/day) and proportion fibre consumed as insoluble fibre is 































- Saturated fat  
- Monounsaturated fat 
- Polyunsaturated fat 
- Cholesterol 




















- Soluble (g/day) 
- Insoluble (g/day) 













Table 3-4. Average daily macronutrient intake in NAFLD and control groups 
There was no difference in total calorie intake between groups. There was also no 
difference in intake of protein. However, those with NAFLD did consumed more fat 
per day (both in terms of grams per day and percentage of total calorie intake). 
Through further, more detailed analysis of the components of dietary fat, it appears 
that this difference is largely accounted for by an increased intake of saturated fat 
within the NAFLD group. Those with NAFLD ate more fibre of both soluble and 
insoluble components with no difference in proportion of fibre sub-types consumed. 
There was no difference in total carbohydrate intake per day, but those with NAFLD 
appeared to eat a smaller proportion of calories as carbohydrate, with the increased 
proportion of calories consumed as fat.  
The physical activity data is compared between NAFLD and control groups in Table 3-









































Table 3-5. Average physical activity in NAFLD and control groups 
Abbreviations: MET = Metabolic Equivalent 
Interestingly, those with NAFLD appeared to do more physical activity than controls, 
with an increased amount of strenuous exercise and less sedentary time.  
3.4.2 Univariate analysis 
In Chapter 2, multivariate analysis was performed to identify the baseline 
characteristics that independently influenced NAFLD risk within this cohort (section 
2.4.1, Table 2-3). This showed that male sex, BMI, central obesity, diabetes and 
hyperlipidaemia were independently associated with increased NAFLD risk. In 
addition, the data presented above (Table 3-5, Table 3-6) identified lifestyle factors 
that appeared to influence NAFLD risk, including percentage of intake as fat and 
carbohydrate, saturated fat and fibre intake (g/day), amount of sedentary and 
strenuous activity (METhr/week) and total METhr/week. As such, all of these 
variables were be analysed in isolation for their impact on NAFLD risk, through 
univariate analysis (Table 3-6). This enabled identification of those variables that 





 Unadjusted OR 
(95% confidence interval) 
P value 
Male gender 1.75 (1.46, 2.09) 
 
<0.001 
BMI (kg/m2) 1.17 (1.14, 1.20) 
 
<0.001 
Central obesity 1.78 (1.49, 2.12) 
 
<0.001 
Diabetes 2.27 (1.85, 2.78) 
 
<0.001 
Dyslipidaemia 1.99 (1.66, 2.38) 
 
<0.001 
Fat intake (% total kcal) 1.02 (1.01, 1.03) 
 
0.001 
Saturated fat intake (g/day) 
 
1.01 (1.00, 1.01) 0.009 
Carbohydrate intake (% total kcal) 
 
0.98 (0.97, 0.99) 0.003 
Fibre intake (g/day) 1.01 (1.00, 1.01) 
 
0.017 
MET hr/week (total) 1.01 (1.00, 1.01) 
 
0.028 
Strenuous (MET hr/wk) 
 
1.01 (1.00, 1.01) 0.021 
Sedentary (MET hr/wk) 
 
0.96 (0.92, 0.99) 0.024 
Table 3-6. Unadjusted NAFLD odds ratios within the lifestyle cohort 
Abbreviations: BMI = Body mass index, MET = Metabolic equivalent 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-
density lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or 
lipid lowering therapy 
Considering lifestyle factors, a 1% increase in proportion of total calorie intake as fat 
is associated with an increased NAFLD risk of 2%. The reverse is seen with proportion 
of carbohydrate intake; the proportion of carbohydrate decreases as fat intake 
increases. For this reason, both variables cannot be included in a multivariate model 
due to collinearity, so fat intake (% of total) was selected. In addition, a 1g/day 




An increase of 1 MET hour per week is associated with an increased NAFLD risk of 
1%, which appears to be related to increased strenuous activity and decreased 
sedentary time in those with NAFLD within the cohort. Again, collinearity of 
increased time undertaking strenuous activity and decreased time being sedentary 
means that total METhr/week alone was included in the multivariate model. 
3.4.3 Logistic regression 
In order to understand the confounding effect of both demographic and lifestyle 
variables on NAFLD risk, an adjusted logistic regression model was created. This 
included the clinical variables as outlined above, as well as fat intake (% of total), 
saturated fat intake (g/day), fibre intake (g/day) and total METhr/week. 
The development of the final model is outlined through the tables below showing 
the sequential addition of variables and the resultant likelihood ratios, R2 values and 
a p value. This p value demonstrates whether the subsequent iteration results in a 
significant change in likelihood ratio from the previous iteration: 
 
 Adjusted OR (95% CI) 
n=2045 
Constant 1.00 (0.91, 1.09) 
Table 3-7. Iteration 0 (R2=0.00, log likelihood=-1417.48) 
 
 Adjusted OR (95% CI) 
n=2045 
Male sex 1.75 (1.46, 2.09) 
Table 3-8. Iteration 1, addition of male sex to the model (R2=0.01, log likelihood=-
1398.72, p<0001) 
 
 Adjusted OR (95% CI) 
n=2045 
Male sex  2.20 (1.82, 2.67) 
BMI (kg/m2) 1.19 (1.16, 1.22) 
Table 3-9. Iteration 2, addition of BMI to the model (R2=0.09, log likelihood=-
1287.64, p<0.001) 





 Adjusted OR (95% CI) 
n=2045 
Male sex 3.09 (2.41, 3.95) 
BMI (kg/m2) 1.15 (1.12, 1.18) 
Central obesity 1.88 (1.43, 2.46) 
Table 3-10. Iteration 3, addition of central obesity to the model (R2=0.10, log 
likelihood=-1277.10, p<0.001) 
Abbreviations: BMI = Body mass index 
Central obesity = ≥80cm in women and ≥90cm in men 
 
 Adjusted OR (95% CI) 
n=2045 
Male sex 2.88 (2.25, 3.71) 
BMI (kg/m2) 1.26 (1.11, 1.43) 
Central obesity 1.75 (1.33, 2.31) 
Diabetes 1.98 (0.68, 5.65) 
Table 3-11. Iteration 4, addition of diabetes to the model (R2=0.11, log likelihood=-
1257.32, p<0.001) 
Abbreviations: BMI = Body mass index 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl 
 
 Adjusted OR (95% CI) 
n=2045 
Male sex 2.92 (2.27, 3.76) 
BMI (kg/m2) 1.14 (1.11, 1.18) 
Central obesity 1.73 (1.31, 2.28) 
Diabetes 1.91 (1.54, 2.38) 
Dyslipidaemia 1.69 (1.39, 2.06) 
Table 3-12. Iteration 5, addition of dyslipidaemia to the model (R2=0.12, log 
likelihood=-1243.48, p<0.001) 
Abbreviations: BMI = Body mass index 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-
density lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or 





 Adjusted OR (95% CI) 
n=2045 
Male sex 2.92 (2.27, 3.77) 
BMI (kg/m2) 1.14 (1.11, 1.18) 
Central obesity 1.72 (1.30, 2.27) 
Diabetes 1.90 (1.53, 2.36) 
Dyslipidaemia 1.69 (1.38, 2.05) 
Fat intake (% calories) 1.02 (1.00, 1.03) 
Table 3-13. Iteration 6, addition of fat intake to the model (R2=0.12, log likelihood=-
1241.01, p<0.001) 
Abbreviations: BMI = Body mass index 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-
density lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or 
lipid lowering therapy 
 
 Adjusted OR (95% CI) 
n=2045 
Male sex 2.98 (2.31, 3.84) 
BMI (kg/m2) 1.15 (1.11, 1.18) 
Central obesity 1.72 (1.30, 2.27) 
Diabetes 1.87 (1.50, 2.33) 
Dyslipidaemia 1.70 (1.39, 2.07) 
Fat intake (% calories) 1.02 (1.01, 1.04) 
Saturated fat intake (g/day) 1.00 (0.99, 1.00) 
Table 3-14. Iteration 7, addition of saturated fat intake to the model (R2=0.13, log 
likelihood=-1239.94, p=0.144) 
Abbreviations: BMI = Body mass index 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-
density lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or 





 Adjusted OR (95% CI) 
n=2045 
Male sex 2.96 (2.30, 3.83) 
BMI (kg/m2) 1.15 (1.11, 1.18) 
Central obesity 1.72 (1.30, 2.27) 
Diabetes 1.89 (1.52, 2.35) 
Dyslipidaemia 1.69 (1.39, 2.06) 
Fat intake (% calories) 1.02 (1.00, 1.03) 
Fibre intake (g/day) 1.00 (0.99, 1.00) 
Table 3-15. Iteration 8, removal of saturated fat intake and addition of fibre intake to 
the model (R2=0.12, log likelihood=-1240.58, p<0.001) 
Abbreviations: BMI = Body mass index 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-
density lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or 
lipid lowering therapy 
 
 Adjusted OR (95% CI) 
n=2045 
P value 
Male sex 2.93 (2.27, 3.78) <0.001 
BMI (kg/m2) 1.14 (1.11, 1.18) <0.001 
Central obesity 1.74 (1.32, 2.30) <0.001 
Diabetes 1.89 (1.52, 2.35) <0.001 
Dyslipidaemia 1.70 (1.39, 2.06) <0.001 
Fat intake (% calories) 1.02 (1.00, 1.03) 0.019 
Fibre intake (g/day) 1.00 (0.99, 1.00) 0.479 
MET hours/week 1.01 (1.00, 1.01 0.157 
Table 3-16. Iteration 9, addition of MET hr/week to the model (R2=0.13, log 
likelihood=-1239.48, p<0.001) 
Abbreviations: BMI = Body mass index, MET = Metabolic equivalent 
Central obesity = ≥80cm in women and ≥90cm in men; diabetes = history of diabetes 
&/or fasting glucose>126mg/dl; dyslipidaemia = triglycerides>150mg/dl &/or high-
density lipoproteins<50mg/dl female, high-density lipoproteins<40mg/dl male &/or 
lipid lowering therapy 
This final model demonstrated that increased proportion of macronutrient intake as 




within this cohort. In addition to those risk factors identified a priori (Chapter 2), a 
1% increase in proportion of dietary calories consumed as fat (e.g. 25kcal/2.8g of fat 
per day from an average intake of 2,500kcal for a man) appeared to increase NAFLD 
risk by 2%. Although addition of fibre intake and METhr/week improved the fit of the 
model (and were therefore included), they were not independently associated with 




3.5.1 Principal findings 
Within this large, population based cohort in Trivandrum, India, rice was the most 
commonly consumed food (average 4.6 portions per day), with cereals and millets 
being the most commonly consumed food group (average 697g/day). Those with 
NAFLD consumed more animal protein, cereals and millets and fats and edible oils 
than controls (p=0.022, p=0.003, p=0.001). When comparing the macronutrient 
intake between NAFLD cases and controls, there was no difference in total calorie 
intake, but the proportion of energy intake as fat was higher in the NAFLD group 
(32.53% vs 31.51%, p<0.001), with a corresponding lower proportion of 
carbohydrate intake (53.59% vs 54.65%, p=0.002). There was an increased 
consumption of fat overall in the NAFLD group (g/day) with an increased intake of 
saturated fats in particular (58.2g/day vs. 55.6g/day, p=0.008). Saturated fats are 
consumed most commonly from animal sources (both meat and dairy), and within 
this cohort, it is likely therefore that the increased saturated fat intake in the NAFLD 
group comes from an increased consumption of animal protein and/or edible oils. 
The NAFLD group also consumed more fibre of both subtypes (48.86g/day vs 
47.09g/day, p=0.016). Interestingly, the NAFLD group were more active than the 
control group (56.28 vs 54.99 METhr/week p=0.028), spending less time sedentary 
(8.08 vs 8.32 hours/week, p=0.023). 
Through multivariate modelling, it was shown that an average daily increase of 1% in 
the proportion of diet consumed as fat is associated with an increased risk of NAFLD 
of 2%, independently of other variables (adjusted OR 1.02, 1.00-1.03, p=0.019). None 
of the other lifestyle factors appeared to influence NAFLD risk when adjusted for 
confounders. Of note, are the low log likelihood and pseudo-R2 within the 
multivariate models. The adjusted R2 (pseudo-R2) denotes the percentage of 
variation explained by the variables within the model i.e. a perfect model would 
predict 100% of the variation (log likelihood = zero, R2 = 1.0). In the final multivariate 
model presented within this chapter, the pseudo-R2 was 0.13, despite including 
variables that are known to strongly influence NAFLD risk (BMI, diabetes). This 
highlights the inherent randomness within real-world data, particularly given the 
large sample size and variation within this population in question. Cox and Wermuth 




an underlying perfect regression relationship”[213], and whilst small, an R2 value of 
0.13 can still be considered significantly different to zero. 
As demonstrated through the work of Chapters 1 and 2, people of Indian ethnicity 
are at increased risk of NAFLD due to their propensity to insulin resistance and 
predisposition to central adiposity, which, at a lower BMI compared to other 
ethnicities, has been shown to further compound metabolic risk. The data presented 
in this chapter has also demonstrated that lifestyle factors may play a role in the 
Indian NAFLD phenotype.  
This work supports the findings of Sathiaraj et al, who examined nutritional risk 
factors for NAFLD within a population with a similar disease prevalence[176]. They 
showed that increased percentage of fat intake resulted in a much more dramatic 
rise in NAFLD risk than this study found (OR 2.51, 1.99-3.31). Despite there being 
much larger differences in nutrient intake between their cases and controls, much 
like this study, fat intake remained the only nutritional variable that independently 
influenced disease risk. 
Parallels can also be drawn between this work and that of Singh et al, who 
demonstrated that those with NAFLD were more likely to consume fried food and 
follow a non-vegetarian diet[177]. Whilst they did not collect detailed macronutrient 
data, the increased consumption of fried food and animal protein are mirrored in the 
findings within this work. 
3.5.2 Strengths and weaknesses of the study 
Study cohort 
The Trivandrum NAFLD cohort, from which this data is collected, is, to the author’s 
knowledge, the largest population-based study of NAFLD prevalence and associated 
risk factors within an Indian population. The biggest strength of this work is the use 
of random, population-level sampling across the breadth of geographic and social 
regions of this district, resulting in the data collected forming an accurate 
representation of the population as a whole. The combination of demographic, 
anthropometric and lifestyle data mean the cohort is deeply characterised. This 
enables accurate assessment of overall NAFLD phenotype, allowing adjustment for 
multiple possible confounders when examining specific variables – in this case, 
lifestyle. It is also a large study. The two other studies of nutrition and NAFLD risk 
within India are significantly smaller. The larger study comprised 642 participants 
who were sampled from consecutive patients attending hospital appointments 
within a large East Indian city[177] - resulting in a bias towards the urban, higher 
socioeconomic class and resulting in a sex disparity (M:F 3:1). The other study was 
smaller still (n=200), recruiting its participants from those attending routine 
employment check-ups[176]. Again, this resulted in significant selection bias towards 
those of a socioeconomic class who have employment that included health checks, 




studies are therefore limited in their accuracy and generalisability even within the 
populations in which they were conducted. 
Dietary data 
Another strength of this study comes from the utilisation of a region-specific FFQ. 
This FFQ was designed and validated within the population in question using 
repeated food diaries, making it the ideal tool to capture detailed information about 
their precise dietary habits. In this piece of work, it has been utilised to look at the 
macronutrient composition of diet in relation to NAFLD risk, but it could also be used 
to examine the interaction between different dietary patterns and risk of disease.  
Sathiaraj et al reported using an FFQ within their study, although they do not specify 
which they used, and appeared to only include foods that were eaten daily, weekly 
or monthly[176]. They do however use the same reference for the calculation of the 
macronutrient composition of food as used in this work[212]. Singh et al used a 
different approach, combining categorical questions (e.g. predominant grain type 
consumed) with questions about frequency of intake of certain foods, which was 
limited to daily/alternate days or weekly/twice weekly[177]. The method of dietary 
data collection within their study is very vague, and although the results may be 
more useful for interventional strategies (i.e. reduction in fried food consumption), 
the lack of detail and breadth of data collected may have resulted in important 
findings being missed. 
The use of FFQs have been well validated in large, epidemiological studies[214], but 
they do have their limitations. FFQ data are vulnerable to systemic reporting/recall 
bias, comprised of both intake-related and person-specific biases[215]. Intake bias 
occurs when study groups feel pressure to follow a certain dietary pattern. In this 
case, participants were aware that they are taking part in a study related to fatty 
liver disease, so may have tended to under-report unhealthy dietary practices. 
Person-specific bias refers to the difference between a persons reported average 
intake, and the true average intake. This may be affected by socio-cultural influence 
or certain personality characteristics, and as such are difficult to quantify. If one 
were to compare this work to other studies that utilise FFQs, it is reasonable to think 
that all data would be biased to a similar degree. Despite the predisposition of FFQs 
to attenuate results between cases and controls through systemic bias, this study 
has conclusively demonstrated a difference in fat intake between cases and controls, 
an effect which therefore may even be under-reported. Alternatives to FFQ for 
dietary data collection include 24-hour dietary recall and dietary records. 24-hour 
dietary recall is time consuming, requiring interviewers to document the recalled 
dietary intake of the participant over the past 24 hours, over a number of days. 
Whilst it may be more detailed, it is subject to significant recall and interviewer bias, 
and was not appropriate for use in this study. Dietary records require participants 
themselves to document their dietary intake over a number of days. Whilst this 
generates detailed data, it has a large respondent burden, requiring both literacy 




Physical activity data 
Throughout the literature, there is a lot of conflicting evidence about the impact of 
physical activity on NAFLD risk. Within Indian populations, there is a particular lack of 
large, detailed data related to exercise in relation to disease in general. The PURE 
study compared physical activity data from high-income countries (where physical 
activity is often recreational) to low-income countries including India (where activity 
is more likely to be occupational)[216]. Similar to this work, an international physical 
activity questionnaire (IPAQ) was used and data presented in terms of MET as the 
measure of activity. It was found that, regardless of setting, exercise improves 
cardiovascular morbidity and mortality across different socioeconomic strata. The 
same could be assumed for NAFLD. Although GPAQ is broadly considered a suitable 
tool to use for large, epidemiological studies, its limitation, in this work in particular, 
relates to the way in which data on the different forms of exercise was collected. 
Participants were asked to report how many hours were spent active within an 8hr 
working day, and how many hours were spent active in an 8hr period outside the 
working day; the total number of hours spent active within 16 hours of a day (which 
is why this data is presented as MET hours, rather than minutes). This is likely to 
have resulted in overestimation of the amount of exercise done, as culturally women 
are less likely to work than men but did not report zero hours of occupation-related 
activity. The wording of the questions implied an assumption that every day 
contained both occupational and non-occupational activity. Again, this is likely to 
result in inclusion of more occupational activity than is actually done for any given 
week. This general overestimation is highlighted when comparing these results with 
those from the PURE study, where people from low-income countries did on average 
2520 METmin/week, whereas the cohort in this work did on average 3338 
METmin/week (56 METhr/week). Regardless of the inability to compare these 
findings with other works, reporting errors in this study are the same across the 
population, meaning comparison between cases and controls was still relevant.  
Finally, whilst this large quantity, high quality data has given insights into the impact 
of diet and exercise on NAFLD risk within Trivandrum, this may not be entirely 
representative of the whole of India, which is made up of many distinct and unique 
cultures.  
3.5.3 Study implications and future work 
The work of this chapter demonstrates the impact of lifestyle on risk of NAFLD within 
a population already shown to have high rates of disease compared to current global 
estimates. In particular, consumption of a diet composed of higher proportion of fat 
is independently associated with increased risk of NAFLD. This is an important finding 
and has public health implications within India, which could inform local education 
strategies and future government policy on a larger scale.  
Whilst this work adds to the evidence base that dietary fat influences NAFLD risk 
(particularly in an Indian population), attempts at interventional strategies that 




population level. Future work that utilises these data are likely to involve analysis of 
dietary patterns within the population. This will enable further understanding of the 
major dietary constituents in terms of types of fats and edible oils, and sources of 
protein consumed and their association with NAFLD risk. Findings from this and 
planned further work are likely to inform future dietary intervention studies within 




As a result of economic changes over the last 30 years, there have been significant 
alterations in dietary patterns across India. Where previously childhood malnutrition 
and unsafe water were a major health burden, diet-related non-communicable 
diseases including diabetes are now the leading cause of death within India[154]. 
This is due to a shift away from consumption of coarse grains towards consumption 
of rice and wheat[217], and more pertinently, there has also been an increase in fat 
intake across all socioeconomic groups, often in the form of highly saturated 
ghee[218]. The work of this chapter has demonstrated that this increase in dietary 
fat may be associated with an increased risk of NAFLD within India. This confirms, in 
part, the hypothesis outlined at the beginning of this chapter. This finding may help 
inform future observational and interventional studies focussing on the components 
of the Indian diet and their relationship with metabolic risk, further strengthening 
the need for education and policy change in the future. 
To understand whether a change in lifestyle results in altered NAFLD risk profile, the 
following chapter will examine whether acculturation through migration to the UK 





CHAPTER 4: The impact of socio-cultural factors on NAFLD 




Through industrialisation and urbanisation of Asia, rates of obesity, diabetes and the 
metabolic syndrome have dramatically risen[219] – matching and overtaking those 
of Western countries[7, 220]. This highlights the important role of changing lifestyle 
habits on NAFLD risk in a population who already possess an innate risk of disease 
(as outlined in Chapter 1). Westernisation of Indian culture has resulted in increasing 
consumption of fat across the country[218], which, as demonstrated in the previous 
chapter, is likely to be a contributory factor in the increased NAFLD risk in India. 
However, less is known about the impact of migration into Western countries and 
the resultant change in socio-cultural habits on the NAFLD risk profile in people of 
Indian ethnicity.  
4.1.1 Acculturation 
Acculturation is a sociological process by which a person assimilates to a different 
culture, typically the dominant culture[221]. As Indian migrants in the UK become 
more accultured, exposure to new lifestyles, diets, beliefs and environments may 
change their risk of developing chronic disease, including NAFLD. Understanding this 
accultural effect may provide further insight into the impact of different factors that 
influence NAFLD risk and may help inform the development of culturally appropriate 
interventions for disease prevention and management. In 2005 Patel et al undertook 
a study looking at the impact of migration on coronary heart disease risk, comparing 
risk profiles of Gujarati Indians living in Britain, who have higher rates of 
hypertension and hyperlipidaemia, to their contemporaries in villages of origin in 
India[222]. They demonstrated that British Gujaratis had a BMI that was 6kg/m2 (4.5-
7.4kg/m2) higher than their native counterparts. They had a greater total calorie 
intake and proportion of intake as fat despite an increased energy expenditure 
(almost 40% more Kcal per day) and with little difference in glucose tolerance. This 
implied that the adverse effect of migration on cardiovascular risk is nutritional in 
nature. Studies looking at dietary acculturation suggest that it is the “accessory 
foods”, such as sugary drinks and fat-rich snacks, which are the first to be 
exchanged[223], and that the adoption of a Western diet as opposed to maintaining 
an Eastern or mixed diet strongly correlates with presence of the metabolic 
syndrome[224]. 
Acculturation may not however be a linear process, and speed of acculturation may 
be influenced by numerous factors related both to place of origin (urban vs rural; 
socioeconomic class) and place of migration as well as duration of residence and 
generation within the UK[225]. In 2003, Harding examined the mortality of South 




residence was associated with an all-cause mortality HR of 1.07 (1.02-1.13) and 
cardiovascular disease mortality HR of 1.09 (1.03-1.16)[226]. Other studies did not 
however confirm this finding, showing no association between language preference, 
generation or duration of residence and risk of NAFLD[227].  
Based on this, people of Indian ethnicity who migrate to the UK are likely to adopt 
British lifestyle habits. This may include increased physical activity, increased total 
calorie intake and increased intake of fat and sugar. Although innately more insulin 
resistant, this diet may potentiate insulin resistance and result in altered body 
composition, (increased BMI and decreased waist-hip ratio) compared to their native 
counterparts, thus increasing the risk of metabolic disease and NAFLD through 
dietary acculturation. 
4.1.2 NAFLD risk in UK-South Asians 
There are only a few studies published in the literature relating to NAFLD risk in 
migrant South Asian groups.  
Alazawi et al. performed a large, retrospective, population-based study looking at 
the rates of abnormal LFTs and coded NAFLD diagnoses from an ethnically diverse 
region of London[228]. They analysed primary care data from over 690,000 adults 
and found that rates of NAFLD diagnoses were highest in people of Bangladeshi 
origin (1.8%), and that Bangladeshi origin was itself an independent risk factor for 
NAFLD. They compared risk factors between cases and controls and demonstrated 
that increasing BMI was the strongest risk factor for NAFLD across the whole study 
population (adjusted OR 1.63 overweight, OR 2.44 obese). However, this study does 
not include data from native Bangladeshi populations, making assessment of the 
impact of acculturation difficult. 
Neukam et al also conducted a study looking at rates of NAFLD within a UK South 
Asian cohort[229]. They analysed data from a cardiovascular screening programme 
from members of two London Hindu temples, largely formed of UK Gujarati 
migrants. This retrospective, cross-sectional study calculated NAFLD prevalence 
within this UK South Asian population using the fatty liver index (based on BMI, GGT, 
triglycerides and waist circumference). Within a sample size of 597 UK Gujarati 
Indians, the NAFLD prevalence was 31%, demonstrating higher rates of NAFLD 
compared to the global pooled average[1]. This study did not however include any 
comparator groups, making ethnic/migrant comparisons impossible. 
The only other work in the literature that directly compared a migrant South Asian 
population with their native counterparts was undertaken by Patel et al[222]. This 
group compared the cardiovascular risk profile of UK Gujarati Indians with their 
siblings living in India. Whilst not looking specifically at people with NAFLD, many of 
the parameters measured within this study form part of the general NAFLD risk 
profile, and as such is a useful comparator paper to the work of this chapter. Their 




quality demographic, anthropometric and lifestyle data including use of repeated 
food diaries and accelerometers to enable analysis of energy intake vs expenditure.  
It was shown that the UK-migrant participants had a higher BMI and waist-hip ratio, 
as well as increased rates of diabetes and obesity. Following migration to the UK, 
South Asians had an increased calorie intake and increased intake as fat. Again, lack 
of a control group made evaluation of NAFLD risk within this study impossible.  
The aim of this chapter is therefore to add to the above evidence by comparing a UK-
migrant South Asian cohort with a native Indian cohort, using a UK-Caucasian cohort 
as a comparator, examining whether acculturation may result in differences in 
NAFLD risk profile. 
 
4.2 Hypotheses, aims and objectives 
 
This chapter will address the following hypothesis, using the subsequent aims and 
objectives: 
 Migration of South Asians to the UK results in alteration of NAFLD risk profile 
through dietary acculturation 
AIM 3: To compare NAFLD risk profile of native Indians with their UK migrant 
counterparts  
Objective I)  Design and create a multi-ethnic study comprised of native Indian, 
UK-migrant Indians and Caucasians with and without NAFLD, 
collecting data regarding NAFLD risk profile  
Objective J)  Compare NAFLD phenotype between native Indian, UK-migrant Indian 
and Caucasian cohorts 
Objective K) Perform case-control analysis of NAFLD risk across the multi-ethnic 
study 





4.3.1 Study design 
This observational, cross-sectional study was designed to enable collection and 
comparison of data on both clinical and behavioural risk factors associated with 
NAFLD from three distinct self-identified ethnic cohorts, each comprised of NAFLD 




a) UK South Asian  
b) Native Indian (a sub-group of the Trivandrum NAFLD cohort – Chapter 2) 
c) UK Caucasian 
For this chapter, it should be noted that the modern definitions of South Asia include 
Afghanistan, India, Pakistan, Bangladesh, Sri Lanka, Nepal, Bhutan and Maldives. 
4.3.2 Recruitment 
Indian cohort 
Participants of the Indian cohort of this study were recruited from the Trivandrum 
NAFLD cohort (Chapter 2). As recruitment and data collection for the original cohort 
was completed in 2016, risk profiles and lifestyle habits of its participants may have 
changed. For this reason, those participants randomly selected for this study 
underwent the same study regime as the UK cohorts (including re-collection of 
anthropometric, pathological and lifestyle data), enabling accurate comparison at 
the same time point. As the Trivandrum NAFLD cohort participants were managed 
locally, their site team recruited participants for this study.  
UK cohort 
Originally, the intention was to recruit all participants of the UK cohorts of this study 
(UK South Asian and UK-Caucasian) from a previous study which identified patients 
with NAFLD within the community[206]. Participants of this previous study who had 
consented to be contacted about future research were allocated a number, and 
through use of a random number generator were invited to participate. The aim was 
to recruit a random sample of the local population, whilst ensuring an adequate 
number of participants with NAFLD were identified. During recruitment, the NAFLD 
sub-groups became over-subscribed (as NAFLD was only identified on the study day), 
and there was difficulty in recruiting participants to the South Asian cohort. 
Therefore, a more pragmatic approach was adopted. Additional participants were 
recruited through distribution of promotional material and Participant Information 
Sheets within the community, and by identifying potential participants more likely to 
be controls based on age, medical history and/or FibroScan® result. 
4.3.3 NAFLD risk factor data 
To compare NAFLD risk profiles between ethnic cohorts, data was collected from the 
following domains: 
Body composition 
There are strong links between BMI, the metabolic syndrome and NAFLD. This is 
particularly evident in South Asian populations where every increase in BMI of 
1kg/m2 results in an increased risk of diabetes and hypertension of 15%, compared 
to 11% in Caucasians[158]. Evidence also shows that rates of NAFLD are higher with 
increasing BMI even within the “normal” range (18.5-22.9kg/m2) in Indian 
populations[142]. In addition to BMI, increased visceral adiposity has also been 




shows that Indian populations tend to central adiposity with increased visceral 
fat[167, 168].  
Therefore, in this study, BMI, waist-to-hip ratio, presence of obesity and total body 
fat percentage (via bioimpedance) were selected as appropriate measures of body 
composition. 
Insulin resistance 
The concept of lipid-induced insulin resistance is key to the pathogenesis of NAFLD, 
where excess energy intake saturates cutaneous and visceral adipose tissue lipid 
stores, leading to spill-over of free fatty acids which are deposited in skeletal muscle 
(worsening whole-body insulin resistance) and the liver – an early step in the 
development of NAFLD[50].  Whilst glycaemic clamping remains the gold standard 
for measuring insulin resistance, its cost and complexity limits its use in 
observational studies like this. An alternative technique that is often used in both 
clinical practice and epidemiological studies is HOMA-IR[230]. HOMA-IR shows 
significant correlation with glycaemic clamps in non-diabetic patients and has been 
used in a number of studies relating to NAFLD[231, 232]. 
For the purposes of this study, HOMA-IR was calculated from fasting glucose 
(mmol/l) and fasting insulin (mU/l) levels in non-diabetic patients ((fasting 
insulin*fasting glucose)/405), whilst presence of diabetes (formal diagnosis, 
treatment or fasting blood glucose >7.0mmol/l) was dichotomous. 
Dietary data 
There are numerous methods of dietary data collection including single or multiple 
24-hour dietary recalls, weighed diet records, self-reports of diet history and food 
frequency questionnaires (FFQ). In terms of habitual diet, all of these methods are 
subject to measurement errors from random misreporting or systemic reporting 
bias, thus limiting their accuracy[233]. FFQs have however long been used over other 
dietary methods in epidemiological studies. They are easy to deliver and have a 
lower responder burden when capturing long-term habitual intakes, rather than 
collecting diary data, which, whilst accurate, only include data on foods eaten over 
the last few days.  
The EPIC FFQ, which has been validated against biomarkers and repeated 24-hour 
dietary recalls[234], was utilised for collection of dietary data for the UK groups in 
this study (i.e. for participants who are either UK South Asian or UK-Caucasian). As 
outlined in Chapter 3, a locally devised and validated FFQ was used to collect dietary 
data from the native Indian cohort[211].  
Physical activity data 
Physical activity or inactivity can be measured in a number of different ways. Direct 
methods, such as use of accelerometers or multi-sensor array, offer optimal accuracy 
for a given time frame but may not give a representative result when looking at 
physical activity over longer periods or habitual levels, plus they require use of 




methods include logbooks and questionnaires. Logbooks may provide a detailed 
assessment of activity over a relatively short period of time, but have a high 
administrative burden. Self-reported questionnaires are used more commonly, are 
easy and quick to deliver and give a global view of an individual’s activity but are 
subject to recall bias[236].  Different physical activity questionnaires report different 
outputs, and are therefore chosen depending on the activity domain of interest 
(work/leisure), time within each of these domains, or physical activity as continuous 
data expressed in metabolic equivalents (MET) of energy expenditure. This method 
assigns MET values to different levels of exercise e.g. moderate (4 METs) or vigorous 
(8 METs).  
This study utilised the Global Physical Activity questionnaire[237] for the collection 
of physical activity data within the UK cohorts (UK South Asian and Caucasian), which 
has been well validated across different populations[238]. It provides MET data that 
could be compared to the physical activity data collected using the local 
questionnaire for the Indian cohort (Chapter 3).  
4.3.4 Sample size calculation 
When designing this study, a sample size calculation was undertaken to ensure 
ability to identify statistically significant differences for these variables between 
groups. As there is a paucity of data on NAFLD risk in relation to acculturation, 
sample size was calculated using a number of different studies that compared risk 
profiles between cases and controls within Indian populations[176], compared 
baseline profiles between Caucasians and Indians in America[173] and compared 
cardiovascular risk between UK migrant Indians and their native counterparts[222]. 
To be able to detect a difference of 250kcal in daily total calorie intake between 
groups (10% of the recommended daily total calorie intake of 2500kcal for 
men[239]), using standard assumptions of 80% power and a significance level of 5% 
and taking data on diet from a case-control study on risk factors for NAFLD in 
India[176], a difference between means calculation gave a sample size of 21 per 
group. Similarly, to detect a 6g difference in daily total fat (6% of the daily 
recommended intake of 97g of fat), a sample size of 18 participants per group was 
required. Finally, to detect a difference of 50g in daily total carbohydrate intake (15% 
of the daily recommended intake of 333g, a sample size of 22 participants per group 
was needed. 
Under the same conditions (80% power and significance level of 5%), a sample size 
of 14 participants per group would enable detection of a 1.35 mass units difference 
in HOMA-IR, a difference that was statistically significant when comparing insulin 
resistance between Caucasians and Indians[173], and in a case control study of 
native Indians[177] 
Powering the study to look for differences in physical activity was more difficult, as 
there is conflicting evidence in the literature about whether reduced levels of activity 




difference between NAFLD/control groups, neither did a comparable study done by 
Singh et al[177]. A study done looking at levels of physical activity in UK South Asians 
and Caucasians did however show a difference between ethnicities. Using this data, 
a sample size of 22 would enable detection with 80% power a 3METhr/day 
difference between ethnicities – the difference detected when comparing Asian and 
Caucasian groups of similar sample size in the United States[137]. 
Based on these calculations, each ethnic cohort was comprised of 20 NAFLD and 20 
controls (Figure 4-1).  
 
Figure 4-1. Ethnic cohort study design 
 
4.3.5 Eligibility criteria 
Inclusion: 
- Adult participants aged 18 years or over 
- Male 
- Able to give informed consent 
- UK cohorts: Self-identify as either “White” or “South Asian” 
- For NAFLD groups: Fatty/echo-bright liver on ultrasound 
This study also forms the basis of work in Chapter 5, which examines BAT activity in 
relation to ethnicity and NAFLD risk. Due to a number of gender-specific confounders 
(menstrual cycle, age) which were likely to affect results from small study groups, 
recruitment was limited to men.  
Due to the conflicting evidence on the impact of duration of residence of migrant 
populations on acculturation, no restriction was imposed on length of time in the UK. 
Exclusion: 
- Female 
- Known or suspected cirrhosis on clinical/histological/radiological grounds 
- Current or recent significant history of self-reported alcohol consumption 
(>14units per week) 
- Other documented causes of chronic liver disease including: 




 Drug-induced liver disease 
 Alcohol-related liver disease 
 Autoimmune hepatitis 
 Wilson’s disease or Haemochromatosis 
 Primary biliary cholangitis or primary sclerosing cholangitis 
- Currently taking medication that can induce steatosis (corticosteroids, 
Amiodarone, Tamoxifen, Methotrexate) 
- Evidence of any other unstable or untreated clinically significant 
immunological, endocrine, haematological, gastrointestinal, neurological, 
neoplastic or psychiatric disease 
- Presence of hair within the region of interest (neck) that cannot be removed 
prior to the study visit (this relates to the work in Chapter 5) 
4.3.6 Ethical approval 
Indian cohort 
This study and all relevant local documentation received approval from the Sree 
Gokulam Medical College Institutional Ethics Committee (04/36/01/2013, 18/05/17), 
Trivandrum, India.  
UK cohorts 
This study and all relevant documentation received approval from the University of 
Nottingham, Faculty of Medicine and Health Sciences Research Ethics Committee 
(REC: 26/299/05/2017, 14/06/17) and the Nottingham University Hospitals NHS 
Trust Research and Development department. It also received Health Research 
Authority approval for the site (28/06/17: 17/HRA/3356). Amendments to the 
protocol and participant information sheet to include recruitment from the 
community were subsequently approved through the local REC (18/04/18). As 
participants were not NHS patients, NHS ethical approval was not needed and was 
thus not sought. 
4.3.7 Consent 
All participants provided written informed consent on the day of the study regime, 
having received a detailed Participant Information Sheet and having had sufficient 
time to consider participating or not. Participants had the opportunity to ask 
questions prior to signing consent and before undergoing any investigations related 
to the study. If needed, translator services were available to assist with discussion of 
the study as well as during the study visit. 
Indian participants received the information sheet and consent form in Malayalam, 
which had undergone forward and backward translation for verification of 
information. Local staff were available to answer questions. 
4.3.8 Study regime 
Participants attended a single morning study visit lasting approximately 3 hours, 




preceding 24 hours. On arrival, eligibility was checked against the inclusion/exclusion 
criteria which included a brief medical, alcohol and drug history, after which 
informed consent was given. They then underwent the following investigations and 
were offered refreshments on regime completion: 
To determine body composition: 
i. Height: measured to the nearest 0.5cm using a stadiometer (Marsden, 
Rotherham, UK) placed against a wall 
ii. Weight: measured to the nearest 0.1kg using electronic standing scales (Seca, 
Hamburg, Germany) 
iii. Body mass index: kg/m2  
(BMI cut-offs for: Caucasians; <18.5 underweight, 18.5-25 normal, 25-29.9 
overweight, ≥30 obese, Asians; <18.5 underweight, 18.5-23 normal, 23-27.5 
overweight, ≥27.5 obese)[240] 
iv. Waist circumference: measured to the nearest cm using a non-expanding 
tape at the midpoint between the lower rib margin and the iliac crest  
Central obesity defined as South Asians ≥90cm, Caucasians ≥102cm as per Indian 
consensus statement and IDF metabolic syndrome definition[194, 241].  
v. Hip circumference: measured to the nearest cm using a non-expanding tape 
at the largest point around the buttocks 
vi. Waist-hip ratio: waist(cm)/hip(cm) 
vii. Body fat percentage (%) measured using bi-frequency terapolar 
bioimpedance analyser (Bioelectric Impedance Analyser – Analisi 
Composizione Corporea; Biotekna S.R.I®, Italy)  
To determine baseline liver function (including markers of non-specific liver injury) 
and metabolic profile, 8ml of whole blood was taken by a healthcare professional 
trained in venepuncture for: 
i. Full blood count 
ii. Urea, creatinine and electrolytes 
iii. Liver function tests (LFTs - ALT, AST, ALP, Albumin, Bilirubin) 
iv. Lipid profile (Cholesterol, HDL, LDL, Triglycerides) 
v. HOMA-IR (Fasting Glucose and Insulin) 
To collect lifestyle data: 
i. Average dietary intake of macronutrients over the past year: Assessed 
through completion of an EPIC FFQ [234], or using a locally validated Indian 
FFQ[211] presented as intake of macronutrients as grams per day (g/day) 
ii. Average physical activity as MET-minutes per week as measured by a 
GPAQ[237], or using the local Indian physical activity questionnaire. 
To identify presence of NAFLD through ultrasound of the abdomen, imaging was 




of the Queens Medical Centre, Nottingham, or within the Sree Gokulam Medical 
College, Trivandrum. Presence or absence of NAFLD was binary and was assessed 
using the hepatic/renal echo-intensity ratio (>0.5) [242]. Due to logistical constraints, 
a specific ultrasonographer was not used at each site, and the ultrasound scans were 
not crosschecked. 
4.3.9 Data collection and management 
Study participants were assigned a participant study code (UK = SA-XXX, India = IN-
XXX) for use on case report forms, other study documents and electronic database. A 
separate confidential record of participants’ name, date of birth, local hospital 
number, address and participant study number was created to enable identification 
of all participants enrolled into the study. This confidential record was password 
protected and held on an NHS server for a year after the study ended. 
Participants were informed of the local General Data Protection Regulation policies 
within the Participant Information Sheet and agreed to these by signing the consent 
form. Data collected during the study regime were documented on paper CRFs using 
individual participant study code as the identifier. These paper records were stored 
in secured filing cabinets within a locked office on NHS premises to which only 
authorised members of staff have access – all of whom have a duty of confidentiality 
to the participants. Data from paper CRFs were directly inputted into a master 
spreadsheet and were held and backed up on a University server requiring both 
electronic permission to access the storage drive and password access to the 
database. Under UK Data Protection laws, the University was the Data Controller 
(was legally responsible for the data security) and the Chief Investigator of this study 
was the Data Custodian (managed access to the data). Laboratory data were entered 
manually using local NHS clinical software. All research data has been and will be 
kept securely for seven years after which time it will be disposed of securely. 
4.3.10 Data analysis  
Baseline data from each group (NAFLD and control) within each ethnic cohort were 
initially presented as follows (Table 4-1): Categorical data were presented as 
numbers (percentage) and continuous data were presented as mean (SD) for 
Normally distributed data and median (IQR) for non-normal data. The reported 
variables within this work would usually be Normally distributed within the 
populations sampled (except for HOMA-IR which is only measured in non-diabetics, 
making it positively skewed) and study numbers within groups were too small to 
make statistical testing for Normality (such as the Shapiro-Wilks test) meaningful. 
Central limit theorem suggests that when testing for differences between groups 
(NAFLD cases and controls), these differences are also expected to be Normally 
distributed[198]. In addition, it can be assumed that the data had homogeneity of 
variance and that data points were independent and were derived from an equal-
interval scale. For these reasons, the majority of continuous data (except HOMA-IR) 




collinearity using Pearson’s correlation coefficient, using a correlation coefficient of 
r≥0.4 as evidence of a moderate correlation and r≥0.7 as strong correlation[243].   
Comparison was then made between the UK Indian cohort and the Trivandrum 
NAFLD cohort (from which they were recruited) to ensure adequate sampling, using 
pertinent variables from anthropometric, medical and lifestyle domains (age, BMI, 
presence of diabetes, physical activity and calorie intake). As the UK Indian cohort 
was comprised solely of male participants, the comparison was made between the 
UK cohort and male members of the Trivandrum NAFLD cohort. Inter-cohort 
comparisons were then made (comparing ethnic cohorts as a whole).  Statistical 
significance was set at p<0.05. 
When comparing continuous data between two groups (i.e. between UK-Indian and 
Trivandrum cohorts and between NAFLD and Control groups), unpaired, two-tailed 
Students t test of equal variance was used for parametric data, and Mann-Whitney U 
test for non-parametric data (HOMA-IR). Chi squared and two-sample test of 
proportion were used for categorical data. For comparison between more than two 
groups (i.e. between the three ethnic cohorts), analyses are done using ANOVA (with 
Bonferroni correction where differences were identified) for parametric data or 
Kruskal-Wallis test for non-parametric data.  
Intra-cohort comparisons (comparing NAFLD and control groups within each ethnic 
cohort) were initially presented as the difference in mean/median for continuous 
data and difference in proportion for categorical data, along with 95% confidence 
intervals (95% CI) (Table 4-3). This helped identify which variables were significantly 
different (both statistically and clinically) between NAFLD and control groups across 
the ethnic cohorts. Further to this, unadjusted odds ratios for NAFLD (95% CI) were 
calculated for the selected variables within each ethnic cohort (Table 4-4). NAFLD 
odds ratio for waist-hip ratio was calculated for an increase in ratio of 0.01 as a log 
reduction for ease of data handling.  
In order to understand the confounding effect of different variables on NAFLD risk, 
an adjusted logistic regression model was created. To begin with, this was done 
using the entire dataset (n=130) to give the most power to detect differences 
between the NAFLD and control groups overall. An initial model was created through 
the forward, stepwise addition of variables. This included variables identified a priori 
from this work (Chapter 4) and the literature (e.g. age and diabetes). It also included 
variables that showed the strongest univariate difference between NAFLD and 
control groups across the ethnic cohorts of this study (e.g. presence of obesity, 
diabetes and central obesity) as well as variables that appeared to have a modest 
impact on NAFLD risk (p value <0.20, e.g. dyslipidaemia). Finally, variables that were 
of specific interest to this body of work were included to see whether they improved 
the model (METmin/wk and total calorie intake). For each sequential variable added, 
likelihood testing was applied to compare the explanatory power (Pseudo-R2) of the 
subsequent iteration to its previous iteration. The p value for the likelihood test 




likelihood ratio from the previous iteration (i.e. the variable should be kept in). Those 
variables that did not improve the model were removed.  
To understand the impact of ethnicity on the final model, further analyses were 
undertaken using likelihood ratio testing. Ethnicity could not be included as an 
independent variable within the final model, as the numbers within each ethnic 
group were fixed. Therefore, comparator models were created to examine whether 
there was an additional effect of ethnicity on each of the variables included within 
the null model (except age, which is not influenced by ethnicity). South Asian and 
Indian ethnicity were compared to Caucasian ethnicity as the base category. 




4.4.1 Participant characteristics 
A total of 130 participants were recruited to the study (UK Caucasian 44, UK South 
Asian 45, Indian 41). As presence of NAFLD was identified on the day of the study 
visit, and because recruitment of participants from both countries were from cohorts 
of people at risk of NAFLD, the NAFLD groups were oversubscribed. The baseline 























49 (10) 45 (12) 60 (13) 49 (16) 49 (12) 48 (12) 
BMI (kg/m2) 
Mean (SD) 
- Underweight n (%) 
- Normal n (%) 
- Overweight n (%) 
- Obese n (%) 
28.32 (3.51) 
 
0   (0) 
1   (4) 




0   (0) 
5   (25) 




0   (0) 
9   (37.5) 




0   (0) 
17 (85) 
1   (5) 
2   (10) 
26.46 (3.43) 
 
0   (0) 
3   (15) 




4   (19.05) 
10 (47.62) 
3   (14.28) 
4   (19.05) 
Waist-hip ratio 
Mean (SD) 



















Body fat (%) 
Mean (SD) 




11 (44) 3 (15) 20 (83.33) 6 (30) 6 (30) 5 (23.81) 
Hypertension 
n (%) 
7 (28) 4 (20) 16 (66.7) 4 (20) 6 (30) 4 (19.1) 
Dyslipidaemia 
n (%) 






















12 (48) 6 (30) 21 (87.5) 5 (25) 7 (35) 5 (23.8) 
Lifestyle 
Total calories kcal/day 
Mean (SD) 
2015 (904) 1809 (718) 1849 (871) 1786 (550) 2658 (424) 2754 (548) 
Protein g/day 
Mean (SD) 
81.9 (37.4) 70.4 (27.4) 88.9 (36.2) 82.6 (24.4) 88.1 (27.2) 81.3 (19.4) 
Carbohydrate g/day 
Mean (SD) 
259.1 (119.7) 233.9 (101.3) 209.6 (116.8) 198.3  (68.3) 385.5 (68.5) 411.6 (103.9) 
Fat g/day 
Mean (SD) 
78.4 (39.4) 70.5 (31.5) 76.0 (39.4) 71.9 (25.7) 85.3 (24.5) 86.9 (19.6) 
MET min/week 
Mean (SD) 
2952 (4114) 3101 (3323) 1840 (2007) 3962 (3744) 2886 (1148) 2693 (815) 
LFTs 
ALT U/l  
Mean (SD) 
33.8 (23.7) 23.9 (10.9) 32.8 (20.7) 26.3 (11.6) 52.2 (27.4) 47.0 (34.3) 
ALP U/l  
Mean (SD) 
83.2 (22.2) 76.4 (21.6) 88.7 (30.3) 66.3 (22.7) 84 (32.7) 76.8 (30.0) 
Platelets       
Platelets 10^9/l  
Mean (SD) 





















Cholesterol mmol/l  
Mean (SD) 
4.6 (1.0) 4.7 (0.7) 4.2 (1.5) 4.7 (1.2) 5.6 (1.2) 5.9 (1.3) 
Triglycerides mmol/l 
Mean (SD) 
0.7 (0.5) 0.4 (0.5) 0.9 (0.3) 0.3 (0.5) 0.4 (0.5) 0.5 (0.5)  
HDL mmol/l  
Mean (SD) 
0.5 (0.5) 0.3 (0.5) 0.9 (0.3) 0.3 (0.5) 0.4 (0.5) 0.2 (0.4) 
LDL mmol/l  
Mean (SD) 
2.6 (1.0) 2.7 (0.6) 2.1 (1.1) 2.6 (1.1) 3.7 (1.0) 3.9 (1.0) 
LDL-C mmol/l  
Mean (SD) 
3.0 (0.9) 3.1 (0.7) 2.6 (1.3) 2.9 (1.1) 4.0 (1.1) 4.2 (1.2) 
Metabolic  
Glucose mmol/l  
Mean (SD) 
7.7 (4.3) 5.7 (1.6) 9.4 (6.1) 5.9 (1.9) 5.3 (2.1) 5.1 (2.5) 
Insulin mU/l  
Mean (SD) 
11.5 (7.8) 7.7 (5.2) 24.7 (39.9) 5.9 (5.0) 25.8 (50.6) 14.1 (15.4) 
HOMA-IR 
Median (IQR) 
0.13 (0.07) 0.06 (0.04) 0.16 (0.2) 0.02 (0.07 0.11 (0.09) 0.06 (0.09) 






Abbreviations: BMI = body mass index, MET = Metabolic equivalents, ALT = alanine transferase, ALP = alkaline phosphatase, HDL = high-density 
lipoproteins, LDL = low-density lipoproteins, LDL-C = low-density lipoprotein cholesterol, HOMA-IR = homeostatic model assessment of insulin 
resistance 
BMI cut-offs for: Caucasians; <18.5 underweight, 18.5-25 normal, 25-29.9 overweight, ≥30 obese, Asians; <18.5 underweight, 18.5-23 normal, 
23-27.5 overweight, ≥27.5 obese, central obesity = ≥90cm for Asian cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 
glucose>7.0mg/dl. HOMA-IR calculated if not on diabetic treatment. Hypertension = diagnosis or treatment. Dyslipidaemia = TG>1.7mg/dl, 
HDL<1.03mg/dl or on treatment. Metabolic syndrome = central obesity + two of (raised triglycerides, reduced HDL, presence of hypertension, 
presence of diabetes or glucose ≥5.6mg/dl), HOMA-IR ((fasting insulin*fasting glucose)/405) calculated for those not on treatment for diabetes. 




Correlation between BMI and body fat % across the whole study population was 
strongly positive (r=0.91, p<0.001) (Figure 4-2) suggesting collinearity of variables, 
and as such BMI alone was used for further analyses. BMI had a weak but significant 
positive correlation with waist-hip ratio (r=0.42, p<0.001) and as such waist-hip ratio 








Figure 4-2. Correlation between BMI and a) body fat % (r=0.91, p<0.001) b) waist-hip ratio (r=0.42, p<0.001) across all ethnic cohorts 




Indian cohort comparison 
Prior to analysing differences between the ethnic cohorts, comparison was made 
between the Indian cohort and male participants of the Trivandrum NAFLD cohort to 
ensure adequate sampling. These data are presented in Table 4-2. 
 









48.3 (11.7) 47.91 (11.97) 0.839 
BMI (kgm2) 
Mean (SD) 
24.28 (4.12) 24.95 (3.83) 0.277 
Diabetes 
n (%) 
10 (24.39) 486 (60.60) <0.001 
MET (min/week) 
Mean (SD) 
2787.32 (983.50) 2991.02 (1009.83) 0.208 
Total calories (kcal/day) 
Mean (SD) 
2707.21 (487.52) 2901.08 (863.49) 0.154 
Table 4-2 Comparison of UK-Indian and Trivandrum NAFLD cohort 
Abbreviations: BMI = Body mass index, MET = Metabolic equivalent 
Diabetic = diagnosis or fasting glucose>7.0mg/dl 
The UK-Indian cohort is representative of the Trivandrum NAFLD cohort in terms of 
age, BMI, amount of physical activity undertaken and total calories consumed per 
day. However, there were significantly fewer participants with diabetes in this study 
cohort, although rates of diabetes within the Trivandrum NAFLD cohort overall (both 
men and women) were comparable – 26.33%.  
Ethnic comparison 
Table 4-1 shows that the UK Caucasian cohort was significantly older than both the 
UK South Asian (p=0.005) and Indian cohorts (p=0.024), who were of similar age 
(p=0.585). The Indian cohort had a significantly lower BMI and body fat % than both 
UK Caucasians (p<0.001, p=0.001) and UK South Asians (p=0.001, p=0.002), who had 
similar body composition. Rates of being overweight or obese (as per ethnic cut-offs) 
were highest in the UK South Asian cohort (n= 39, 86.7%) compared to Indian (n=24, 
58.5%) and UK Caucasian (n=18, 40.9%) cohorts. There was no difference in waist-hip 
ratio between cohorts (p=0.30).  
Rates of diabetes were highest in the UK Caucasian cohort (59.1%), with lower rates 
in the UK South Asian (31.1%) and Indian (26.8%) cohorts. There was no difference in 
HOMA-IR between ethnic groups (p=0.15). There were no differences in rates of 




rates of metabolic syndrome overall were highest in the UK Caucasian cohort (59.1%) 
compared to UK South Asian (40%) and Indian cohorts (29%).  
The Indian cohort consumed significantly more total calories per day compared to 
the two UK cohorts (p<0.001), who consumed similar amounts (p=1.00). There was 
no difference in protein or fat intake between cohorts (p=0.071, p=0.150), but the 
Indian cohort consumed significantly more carbohydrate per day compared to the 
two UK cohorts (p<0.001), who consumed similar amounts (p=0.125). There was no 
difference in METmin/wk between groups (p=0.920).  
The Indian cohort had higher levels of total cholesterol, LDL-C and ALT than the UK 
cohorts (p<0.001). The low levels of glucose in the Indian cohort compared to the UK 
Caucasians is likely to be a result of the low rates of diabetes. There were no other 
differences in blood parameters that were of clinical note. 
Case-control comparison 
Next, the differences between NAFLD cases and controls within each cohort were 







 UK South Asian 
NAFLD vs Control 
Difference in mean/median/%  
(95% CI) n=45 
UK Caucasian 
NAFLD vs Control 
Difference in mean/median/%  
(95% CI) n=44 
Indian 
NAFLD vs Control 
Difference in mean/median/%  









2.86  (0.95, 4.78) 
 




6.09 (3.36, 8.80)  
 




4.25  (2.00, 6.50) 
 








0.044 (-0.007, 0.095) 
 




0.123 (0.076, 0.170) 
 




0.044 (0.011, 0.078) 
 







0.29 (0.04, 0.54) p=0.041 0.53 (0.28, 0.78) p<0.001 0.06 (-0.21, 0.33) p=0.650 
Hypertension 
(%) 
0.08 (-0.17, 0.33) p=0.532 0.47  (0.21, 0.72) p=0.002 0.11 (-0.15, 0.37) p=0.411 
Dyslipidaemia 
(%)  
0.31 (0.04, 0.58) p=0.033 0.62 (0.39, 0.85) p<0.001 -0.07 (-0.38, 0.23) p=0.653 
Metabolic syndrome 
(%)  







 UK South Asian 
NAFLD vs Control 
Difference in mean/median/%  
(95% CI) n=45 
UK Caucasian 
NAFLD vs Control 
Difference in mean/median/%  
(95% CI) n=44 
Indian 
NAFLD vs Control 
Difference in mean/median/%  
(95% CI) n=41 
Lifestyle 
Total Calories (kcal) 
(Mean)  
205.15 (-295.16, 05.45) p=0.413 63.13  (-390.73, 16.99) p=0.780 -95.44  (-405.93, 215.04) p=0.538 
Protein (g/day) 
(Mean)  
11.50 (8.7, 31.7) p=0.257 6.28 (-12.94, 25.49) p=0.513 6.75 (-8.10, 21.59) p=0.363 
Carbohydrate (g/day) 
(Mean)  
25.19 (-42.54, 92.92) p=0.457 11.25 (-48.54, 71.05) p=0.706 -26.10 (-81.98, 29.77) p=0.351 
Fat (g/day) 
(Mean) 
7.93 (-13.93, 29.80) p=0.468 4.14 (-16.55, 24.83) p=0.688 -1.63 (-15.63, 12.37) p=0.815 
METmin/wk 
(Mean) 




9.9 (-1.7, 21.5) p=0.091 6.5 (-3.9, 17.0) p=0.215 5.2  (-14.5, 24.9) p=0.060 
ALP (U/l) 
(Mean) 












 UK South Asian 
NAFLD vs Control 
Difference in mean/median/%  
(95% CI) n=45 
UK Caucasian 
NAFLD vs Control 
Difference in mean/median/%  
(95% CI) n=44 
Indian 
NAFLD vs Control 
Difference in mean/median/%  




-0.1 (-0.6, 0.4) p=0.719 -0.6 (-1.4, 0.3) p=0.181 -0.3 (-1.1, 0.5) p=0.408 
Triglycerides (mmol/l) 
(Mean) 
0.3 (-0.01, 0.6) p=0.063 0.6 (0.3, 0.8) p=0.001 -0.1 (-0.4, 0.2) p=0.857 
HDL (mmol/l) 
(Mean) 
0.2 (-0.1, 0.5) p=0.144 0.6 (0.3, 0.8) p=0.001 0.2 (-0.1, 0.4) p=0.143 
LDL (mmol/l) 
(Mean) 
0.1 (-0.4, 0.6) p=0.700 -0.6 (-1.2, 0.1) p=0.140 0.2 (-0.5, 0.9) p=0.530 
LDL-C (mmol/l) 
(Mean) 




2.0 (-0.05, 4.0) p=0.055 3.5 (0.6, 6.4) p=0.019 0.2 (-1.3, 1.6) p=0.797 
Insulin (mU/l) 
(Mean) 
3.8 (-0.3, 7.9) p=0.071 18.8 (0.6, 37.0) p=0.041 11.6 (-11.7, 35.0) p=0.321 
HOMA-IR  
(Median) 






Table 4-3. Intra-cohort differences between NAFLD cases and controls 
Abbreviations: BMI = body mass index, MET = Metabolic equivalents, ALT = alanine transferase, ALP = alkaline phosphatase, HDL = high-density 
lipoproteins, LDL = low-density lipoproteins, LDL-C = low-density lipoprotein cholesterol, HOMA-IR = homeostatic model assessment of insulin 
resistance 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis 
or fasting glucose>7.0mg/dl. HOMA-IR calculated if not on diabetic treatment. Hypertension = diagnosis or treatment. Dyslipidaemia = 
TG>1.7mg/dl, HDL<1.03mg/dl or on treatment. Metabolic syndrome = central obesity + two of (raised triglycerides, reduced HDL, presence of 
hypertension, presence of diabetes or glucose ≥5.6mg/dl), HOMA-IR ((fasting insulin*fasting glucose)/405) calculated for those not on 




NAFLD and control groups were matched for age in the South Asian cohorts 
(UK South Asian and Indian), but NAFLD cases were significantly older than 
controls in the Caucasian cohort. Across all ethnic cohorts, BMI and 
proportion of those who were obese were higher in the NAFLD group, as was 
central adiposity, except for the UK South Asian group. Of note, the 
differences between cases and controls were much larger within the 
Caucasian cohort compared to the South Asian and Indian cohorts. For 
example, the difference in BMI between cases and controls within the 
Caucasian cohort was 6kg/m2 compared to 4kg/m2 in Indian and 3kg/m2 in UK 
South Asian cohorts.  
Diabetes rates were higher in the NAFLD groups of both UK-based cohorts 
(UK South Asian and UK Caucasian), but were similar between groups in the 
Indian cohort. All components of the metabolic syndrome were more 
prevalent in the Caucasian NAFLD group compared to controls, with only 
diabetes and dyslipidaemia being more prevalent in the UK South Asian 
NAFLD group (vs. controls). 
There was no difference in total calorie intake, or intake of individual 
macronutrients between NAFLD cases and controls in any of the ethnic 
cohorts. UK Caucasians with NAFLD were significantly less physically active 
than their control counterparts (p=0.021), although the confidence interval 
was wide (-335.8,-3908.2). This difference was not seen in either of the South 
Asian cohorts. 
There was minimal difference in blood-based parameters between cases and 
controls within cohorts, except for marginally increased Triglyceride, HDL and 
ALP levels (a difference that is statistically but not clinically significant) and 
raised measures of glucose and insulin sensitivity within the Caucasian NAFLD 
group. This difference in insulin sensitivity is accounted for by differences in 
rates of diabetes.  
As planned, variables known a priori to impact NAFLD risk, along with those 
that were significantly different between cases and controls across these 
ethnic cohorts, as well as those of particular interest to this body of work 
(e.g. lifestyle factors) were included for calculation of univariate NAFLD odds 
ratios. This included; age, BMI, presence of obesity (including central obesity 
as a separate variable), components of the metabolic syndrome, METmin/wk 






 UK South Asian 
n=45 
unadjusted OR (95% CI) 
UK Caucasian 
n=44 
unadjusted OR (95% CI) 
Indian 
n=41 
unadjusted OR (95% CI) 
Age (years) 1.03 (0.98, 1.09) p=0.274 1.05 (1.01, 1.10) p=0.023 1.01 (0.96, 1.06) p=0.784 
BMI (kg/m2) 
Obesity 
1.39 (1.08, 1.79) 
11.00 (0.90, 134.06) 
p=0.012 
p=0.021 
1.42 (1.15, 1.76) 
14.17 (1.91, 105.10) 
p=0.001 
p<0.001 
1.41 (1.12, 1.77)  
10.83 (1.39, 84.17) 
p=0.003  
p=0.004 
Central obesity 1.75 (0.40, 7.63) p=0.456 * * 8.18 (1.50, 44.49) p=0.015 
Diabetes 4.45 (0.94, 21.04) p=0.045 11.67 (2.07, 65.68) p<0.001 1.37 (0.34, 5.60) p=0.655 
Hypertension 1.56 (0.37, 6.45) p=0.536 8.00 (1.64, 39.04) p=0.002 1.82 (0.41, 8.00) p=0.417 
Dyslipidaemia 3.87 (1.00, 15.03) p=0.037 25.67 (2.63, 250.90) p<0.001 0.75 (0.21, 2.61) p=0.647 
Metabolic syndrome 2.15 (0.60, 7.69) p=0.224 21.00 (2.67, 164.91) p<0.001 1.72 (0.43, 6.91) p=0.433 
Total calories (kcal/day) 1.00 (0.99, 1.00) p=0.407 1.00 (0.99, 1.00) p=0.775 1.00 (0.99, 1.00) p=0.528 
METmin/wk 1.00 (0.99, 1.00) p=0.893 0.99 (0.98, 0.99) p=0.012 1.00 (0.99, 1.00) p=0.529 





Abbreviations: BMI = Body mass index, MET = Metabolic equivalent 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 
cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 
glucose>7.0mg/dl. Hypertension = diagnosis or treatment. Dyslipidaemia = 
TG>1.7mg/dl, HDL<1.03mg/dl or on treatment, Metabolic syndrome = central obesity 
+ 2 of (raised triglycerides, reduced HDL, presence of hypertension, presence of 
diabetes or glucose ≥5.6mg/dl) 
*Central obesity predicted NAFLD perfectly in the Caucasian group and as such, 
these data were omitted. 
Age was associated with increased odds of NAFLD within the Caucasian group only. 
As previously noted, the Indian and UK South Asian cohorts were comprised of 
participants of similar age across both NAFLD and control groups, which may be why 
this effect was not seen within these cohorts.  
Measures of body composition were associated with increased NAFLD risk across the 
whole study population, with the largest effect from presence of obesity (unadjusted 
OR 10.83-11.00). The confidence intervals for these variables were however 
extremely large. Presence of diabetes also appeared to increase NAFLD risk although 
not significantly so in the Indian cohort – which may be related to the low rates of 
diabetes. There was variation in impact of the individual components of the 
metabolic syndrome on NAFLD risk between cohorts. Again, within the UK Caucasian 
cohort, presence of the metabolic syndrome was strongly associated with NAFLD 
(unadjusted OR 21.00, 2.67-164.91, p<0.001). This variable also appeared to be 
strongly related to NAFLD within the other cohorts, but not significantly so. Total 
calorie intake did not influence NAFLD risk across the cohorts, and increased physical 
activity appeared to reduce risk of NAFLD marginally in the Caucasian cohort only. 
Overall, the impact of individual variables on NAFLD risk showed larger odds ratios 
for the UK Caucasian cohort compared to the other cohorts (e.g. presence of the 
diabetes appeared to increase NAFLD risk 11-fold in Caucasians, but only 4-fold in UK 
South Asians and not at all in native Indians).  
4.4.2 Logistic regression 
A logistic regression model was created using the whole dataset initially (n=130), 
including the variables identified as having an impact on NAFLD risk a priori, from the 
literature (i.e. age, diabetes) or through calculation of unadjusted odds ratios 
(obesity, central obesity, dyslipidaemia). Variables of specific interest to this body of 
work (METmin/wk, total calorie intake) were added subsequently to see whether 
they improved the final model. The development of the final model is outlined 
through the tables below which demonstrate the sequential addition (and removal if 
no improvement) of variables and the resultant likelihood ratios, R2 values and a p 
value. This p value demonstrates whether the subsequent iteration results in a 





 Adjusted OR (95% CI) 
n=130 
Constant 1.13 (0.80, 1.60) 
Table 4-5. Iteration 0 (R2=0.00, log likelihood=-89.86) 
 
 Adjusted OR (95% CI) 
n=130 
Age (years) 1.03 (1.00, 1.06) 




 Adjusted OR (95% CI) 
n=130 
Age (years) 1.01 (0.98, 1.05) 
Obesity 6.91 (3.15, 15.16) 
Table 4-7. Iteration 2, addition of obesity to the model (R2=0.17, log likelihood=-
74.29, p<0.001) 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5 
 
 Adjusted OR (95% CI) 
n=130 
Age (years) 1.02 (0.99, 1.05) 
Obesity 5.10 (2.21, 11.76) 
Central obesity 2.89 (0.96, 8.68) 
Table 4-8. Iteration 3, addition of central obesity to the model (R2=0.19, log 
likelihood=-72.42, p=0.053) 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 





 Adjusted OR (95% CI) 
n=130 
P value 
Age (years) 0.99 (0.96, 1.04) 0.811 
Obesity 4.50 (1.92, 10.56) 0.001 
Central obesity 2.76 (0.91, 8.39) 0.074 
Diabetes 2.83 (0.98, 8.23) 0.055 
Table 4-9. Iteration 4, addition of diabetes to the model (R2=0.22, log likelihood=-
70.51, p=0.050) 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 
cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 
glucose>7.0mg/d, 
 
 Adjusted OR (95% CI) 
n=130 
Age (years) 1.00 (0.96, 1.04) 
Obesity 6.00 (2.69, 13.39) 
Diabetes 2.895 (1.03, 8.48) 
Table 4-10. Iteration 5, removal of central obesity from the model (R2=0.20, log 
likelihood=-72.18, p=0.067) 
 




 Adjusted OR (95% CI) 
n=130 
Age (years) 0.99 (0.96, 1.03) 
Obesity 4.31 (1.81, 10.23) 
Central obesity 2.54 (0.81, 7.97) 
Diabetes 2.56 (0.83, 7.82) 
Dyslipidaemia 1.35 (0.52, 3.48) 
Table 4-11. Iteration 5, addition of dyslipidaemia to the model (R2=0.22, log 
likelihood=-70.32, p=0.541) 
 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 
cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 




 Adjusted OR (95% CI) 
n=130 
Age (years) 0.99 (0.96, 1.04) 
Obesity 4.55 (1.93, 10.72) 
Central obesity 2.93 (0.96, 8.95) 
Diabetes 3.09 (1.03, 9.30) 
Total calories (kcal/day) 1.00 (0.99, 1.00) 
Table 4-12. Iteration 6, addition of total calories to the final model (R2=0.22, log 
likelihood=-69.81, p=0.240) 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 
cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 
glucose>7.0mg/d 
 
 Adjusted OR (95% CI) 
n=130 
Age (years) 0.99 (0.95, 1.03) 
Obesity 4.57 (1.92, 10.86) 
Central obesity 2.76 (0.90, 8.50) 
Diabetes 3.09 (1.05, 9.10) 
METmin/wk 1.00 (0.99, 1.00) 
Table 4-13. Iteration 7, addition of METmin/wk to the final model (R2=0.23, log 
likelihood=-69.51, p=0.163) 
Abbreviations: MET = Metabolic equivalent 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 
cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 
glucose>7.0mg/d 
Whilst the inclusion of age and diabetes did not increase the proportion of variation 
explained, they are well documented as strong risk factors for NAFLD and were 
therefore included. Presence of obesity had a strong influence on NAFLD risk 
(adjusted OR 4.50, 1.92-10.56). Presence of central adiposity also appeared to 
increase NAFLD risk (adjusted OR 2.76, 0.91-8.39), but not statistically so (p=0.074). 
Subsequent removal of the central obesity variable did not improve the model (Table 
4-10), so it was kept in. Diabetes, as a risk factor alone, improved the strength of the 
model compared to components of, or presence of, the metabolic syndrome. The 
inclusion of this variable alone also improved the power of the model. Subsequent 
addition of dyslipidaemia, calorie intake and METmin/wk did not improve the model 




4.4.3. Impact of ethnicity 
So far the data have been used in their entirety (n=130) to give the strongest model 
for NAFLD risk prediction (Table 4-9). To understand the impact of ethnicity on this 
model, further analyses were undertaken through likelihood ratio testing, comparing 
the null model (Table 4-9) with models including ethnicity as an interaction effect for 
each variable (except age – which is not influenced by ethnicity). Again, each 
iteration includes the resultant likelihood ratios, R2 values and a p value. This p value 
demonstrates whether the subsequent iteration results in a significant change in 
likelihood ratio from the null model (Table 4-9): 
 
 Adjusted OR (95% CI) 
n=130 
Age 0.99 (0.95, 1.03) 
Obesity 6.00 (0.89, 40.36) 
Obesity 
- South Asian 
- Indian 
 
0.50 (0.09, 2.90) 
0.63 (0.09, 4.35) 
Central obesity 2.78 (0.91, 8.48) 
Diabetes 2.74 (0.90, 8.31) 
Table 4-14. Comparator model examining the interaction effect of ethnicity on 
obesity (R2=0.22, log likelihood -69.97, p=0.900) 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 
cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 
glucose>7.0mg/d 
 
 Adjusted OR (95% CI) 
n=121** 
Age 0.99 (0.95, 1.03) 
Obesity 5.53 (2.05, 14.92) 
Central obesity 3.05 (0.50 18.78) 
Central obesity 
- South Asian 
- Indian 
 
0.50 (0.16, 1.61) 
¥Omitted 
Diabetes 2.49 (0.82, 7.53) 
Table 4-15. Comparator model examining the interaction effect of ethnicity on 
central obesity (R2=0.19, log likelihood -67.01) 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 





**When examining the impact of ethnicity on NAFLD risk in relation to central 
obesity, nine observations were dropped from the Caucasian group as they predicted 
NAFLD perfectly. This resulted in unequal numbers between the null model (Table 4-
9) and this model (Table 4-15) so they could not be directly compared (i.e. no p value 
presented). 
 
 Adjusted OR (95% CI) 
n=130 
Age 0.99 (0.95, 1.03) 
Obesity 6.03 (2.18, 16.68) 
Central obesity 2.64 (0.83, 8.28) 
Diabetes 1.54 (0.20, 11.66) 
Diabetes 
- South Asian 
- Indian 
 
2.73 (0.37, 20.23) 
¥Omitted 
Table 4-16. Comparator model examining the interaction effect of ethnicity on 
presence of diabetes (R2=0.27, log likelihood -66.80, p=0.290) 
Obesity = Caucasians; BMI≥30, Asians; BMI≥27.5, central obesity = ≥90cm for Asian 
cohorts, ≥102cm for Caucasian cohort. Diabetic = diagnosis or fasting 
glucose>7.0mg/d¥ When examining the impact of ethnicity on NAFLD risk in relation 
to central obesity and diabetes, data from the Indian group were omitted due to 
collinearity between these risk factors and Indian ethnicity i.e. the characteristics of 
the Indian NAFLD participants with central obesity or diabetes perfectly predicted 
NAFLD.  
Through likelihood ratio testing, it was shown that none of these comparator models 
improved the null model - which did not include ethnicity (p=0.901, p=0.290). This 
means that the results of the original model stand even when testing the individual 
ethnic cohorts (i.e. there is no need for a stratified model). 
Therefore, regardless of ethnicity and despite apparent differences in baseline data 
between groups, obesity is associated with a 4-fold increase in NAFLD risk across the 
study population as a whole. Presence of diabetes and central obesity appear to also 
have an impact on NAFLD risk, although the results are not statistically significant 
based on the predefined criteria on multivariate analysis. Increasing age does not 







4.5.1 Principal findings 
The baseline characteristics of the ethnic cohorts within this study were different. 
The Indian cohort had a lower BMI, whilst the UK Caucasian group were older, with a 
higher prevalence of diabetes. The Indian cohort appeared to consume more 
carbohydrate and more calories overall compared to the UK cohorts. When 
comparing NAFLD cases and controls within each ethnic cohort, BMI and rates of 
obesity were higher in all NAFLD groups, whilst rates of diabetes were only higher in 
the UK-based cohorts. Of note, all differences seen between cases and controls were 
much more dramatic in the UK-Caucasian cohort, with the difference in BMI 
between cases and controls within the Caucasian cohort being 6kg/m2 compared to 
4kg/m2 in Indian and 3kg/m2 in UK South Asian cohorts. There was no difference in 
difference in dietary intake or physical activity between any case-control groups, 
except that UK-Caucasians with NAFLD did significantly less exercise than controls. 
Through univariate analysis, increasing BMI and presence of obesity had a strong 
association with NAFLD across all cohorts (obesity unadjusted OR 10.83-14.17). 
Through multivariate logistic regression modelling, presence of obesity was strongly 
and independently associated with increased NAFLD risk across the whole study 
population (adjusted OR 4.50, 1.92-10.56, p=0.001). Central adiposity and presence 
of diabetes also appeared to be associated with NAFLD, but not statistically so 
(central obesity adjusted OR 2.76 (p=0.074), diabetes adjusted OR 2.83 (p=0.055)). 
Through likelihood ratio testing, it was demonstrated that the inclusion of ethnicity 
as an interaction effect did not alter the final regression model (Table 4-9); although 
it did highlight collinearity of factors within certain ethnic groups (e.g. rates of 
central obesity and diabetes in the Indian cohort). This may reflect the limitations of 
the study sample size and presence of sampling error. 
The principal finding of this chapter is, therefore, that there is commonality of risk 
factors for NAFLD across the ethnic cohorts within this study – namely presence of 
obesity and diabetes. Despite this commonality of risk, conclusions can be drawn 
about the difference in NAFLD risk profile between the native Indian and UK-migrant 
South Asian cohorts. South Asians that live in the UK had a higher BMI than their 
native Indian counterparts (27.1kg/m2 vs 24.3kg/m2) and had the highest rates of 
obesity compared to the other ethnic cohorts (87% vs 59% vs 41%). Rates of diabetes 
were higher in the UK South Asian group (31.1%) than the Indian group (26.8%), 
whose rates of diabetes appeared significantly lower than the male participants of 
the large NAFLD cohort from which they were sampled (60.60%), although rates of 
diabetes within that cohort overall were comparable (26.33%)[244]. There does 
appear to be an element of dietary acculturation in the UK South Asian group, who 
have total calorie and carbohydrate intakes similar to the UK Caucasian group, which 




This work adds to the work of Alazawi et al, who noted that increasing BMI was the 
strongest risk factor for NAFLD within an ethnically diverse population in London (OR 
1.63 overweight, OR 2.44 obese)[228]. Whilst their study sample size was 
significantly larger, the baseline characteristics of their South Asian contingent were 
similar to the cohort used in this work (rates of overweight or obese 73% vs. 71%), 
suggesting the results are broadly comparable. Alazawi et al. demonstrated an 
increased risk of NAFLD diagnosis in people of Bangladeshi origin living in London 
compared to their Caucasian neighbours. Their study however was unable to analyse 
the cause for this increased risk or assess whether this risk has changed through 
migration to the UK. 
Similarly, this work draws parallels with the findings of Patel et al, who 
demonstrated an increase in BMI and rates of obesity in UK-migrant Gujarati 
Indians[222]. Contrary to the findings of the work of this chapter, they found an 
increased intake of calories and fat in their UK-migrant group. Whilst a larger sample 
size, a more robust sampling technique and lifestyle measures with better accuracy 
mean that the data from Patel et al. is probably more reliable, the lack of a control 
group make evaluation of NAFLD risk impossible. Whilst it could be thought that the 
heterogeneity in ethnic origin within the UK South Asian cohort used in this chapter 
may have “diluted” the results, the use of such a specific community in a Gujarati 
town in India in their study mean their results may not be generalisable to the South 
Asian or Indian community as a whole. 
4.5.2 Strengths and weaknesses of the study 
This is the first prospective study to examine the differences in NAFLD phenotype 
between native Indians and UK-migrant groups, utilising UK Caucasians as 
comparators. It also included data from both NAFLD and controls, enabling case-
control analysis of risk within each ethnic group. This study incorporated a large 
breadth of data, including demographic, anthropometric, physiological and lifestyle 
components, resulting in deeply phenotyped groups. Other studies that have looked 
at NAFLD risk in South Asians living in the UK have been limited by the diagnostic 
tools used to identify NAFLD, a lack of comparator groups, or by the breadth of data 
collected (as above).  
Whilst being the only study of its kind, confirming findings that are consistent with 
the available literature, and demonstrating that although the NAFLD phenotype is 
different in migrant populations, overall risk factors for NAFLD are similar to those in 
India, this study does have weaknesses – most notably related to its power. The 
sample size calculations performed prior to commencing the study used the 
available evidence from NAFLD case control studies in people of South Asian 
ethnicity[176, 177].  Whilst powering the study adequately for each individual 
variable, the combination of multiple variables is likely to have reduced the power of 
the study overall. This means that where there appeared to be important differences 
between groups, the confidence intervals were too large to give any certainty to 




differences in diet may have influenced differences in NAFLD risk profile, but were 
not conclusively demonstrated. Another limitation is the use of different FFQs for 
different cohorts. Whilst this was a considered decision to enable accurate, culture-
specific collection of macronutrient data, this does mean that comparison of dietary 
data between groups may not be entirely accurate. In addition, whilst the original 
sampling framework for the UK cohorts of this study utilised random sampling 
techniques, the oversubscription of the NAFLD groups meant that the sampling 
technique had to become more pragmatic, which may have led to sampling bias. 
Whilst the Indian cohort within this work was broadly representative of the large 
NAFLD cohort from which they were sampled (Table 4-2), the resultant NAFLD group 
had certain characteristics (presence of central obesity or diabetes) that perfectly 
predicted NAFLD, making detailed logistic regression analysis difficult. This is 
demonstrated through the low log likelihood and pseudo R2 of the final model (Table 
4-13). Whilst a pseudo-R2 value of 0.23 suggests that only 23% of the variation is 
explained by the variables within the model, as discussed in the last chapter (section 
3.5.1), models with a binary outcome tend to have a low R2 value, even in the 
presence of a perfect underlying regression relationship[213]. 
4.5.3 Study implications and future work 
Although those factors that influence NAFLD risk are the same in both UK-migrant 
South Asian and native Indian groups, this work does also demonstrate some 
differences in body composition and dietary intake that could be attributable to a 
degree of acculturation. Further work is needed to analyse the impact of changes in 
macronutrient intake and adaptation of dietary habits (potentially through 
longitudinal data collection), including types of protein consumed, the ways in which 
food are cooked and choice of available snacks. More detailed analysis could also 
include data on the micronutrient composition of diet and include data on caffeine 
intake, which has also been linked to NAFLD risk[245]. 
True rates of NAFLD amongst people of South Asian ethnicity living here in the UK 
are unknown, and therefore there is a need for larger epidemiological studies 
looking at rates of disease across ethnicities. It is already known that people of South 
Asian heritage have higher rates of diabetes[5], and data presented within this thesis 
and within the literature support the suggestion that they have higher risk of NAFLD 
compared to Caucasians[228]. This is particularly pertinent as people of South Asian 
ethnicity form approximately 5.3% of the UK population[246], meaning there are a 
large number of people at risk of NAFLD, or with undiagnosed disease within the 
community. It may therefore be important to target NAFLD screening programmes 
within areas with a high prevalence of people of South Asian heritage.  
Little is known about the interaction of genes and lifestyle on NAFLD risk. Whilst 
multiple genome-wide association studies have shown which variants may 
predispose to NAFLD risk within European cohorts, to date there has not been a 
study looking at people of South Asian ethnicity. Future work may include a GWAS of 




habits and NAFLD genotype, and promote a deeper understanding of the change in 




Despite a commonality of risk for NAFLD across ethnic groups, South Asians who 
have migrated to the UK may have a different NAFLD risk phenotype compared to 
their native counterparts, particularly in relation to measures of body composition. 
These differences could be related to acculturation to a Western lifestyle, although 
this study was not designed to demonstrate causality. Whilst the work of Chapter 2 
(Trivandrum NAFLD cohort) showed that people of Indian ethnicity were at increased 
risk of NAFLD compared to global estimates, further work is required to see whether 
differences in phenotype of UK-based South Asian groups results in increased NAFLD 
risk (compared to their native counterparts), and whether interaction between diet 
and genetics impacts this further. 
Finally, in addition to changes in lifestyle factors in migrant South Asians, there may 
be other factors that alter NAFLD risk through migration. One such hypothesis is that 
change in BAT activity following relative cold adaptation of people whose heritage 
are from hotter climates may alter NAFLD risk. Further work looking at this 





CHAPTER 5: The association of brown adipose tissue activity 




5.1.1 Brown adipose tissue   
As described in Chapter 1, brown adipose tissue was first identified in the 16th 
century[96]. It is a highly metabolically active organ, which is able to release energy 
as heat through uncoupling of mitochondrial respiration and is a major effector of 
adaptive thermogenesis. Having previously been thought to disappear with age, it 
has now been shown to persist into adulthood[98], and as such has recently become 
a focus for research as a possible target for anti-obesity treatment.  
Numerous studies have demonstrated decreased BAT activity with increasing 
BMI[113, 247, 248], in the presence of diabetes[114, 249] and as such may influence 
NAFLD risk and ethnic variation in disease prevalence. 
5.1.2 BAT activity and non-alcoholic fatty liver disease (NAFLD) 
The links between obesity, diabetes and NAFLD have been described in detail in 
Chapter 1. Briefly, excess lipid is deposited in skeletal muscle and the liver, resulting 
in organ-specific insulin resistance, which in turn drives further lipid accumulation 
within the liver through de novo lipogenesis from carbohydrate which is not utilised 
by insulin resistant muscle[50]. Reduced BAT activity has also been shown to play an 
important role in insulin resistance[114], whole body energy expenditure[249], 
obesity[113] and lipid metabolism[115], suggesting a possible role in the 
development of NAFLD. 
When activated, BAT utilises fat and glucose as substrates for thermogenesis. This 
includes the use of intracellular triglyceride droplets, and the uptake of lipids and 
glucose from the circulation[250]. This was initially demonstrated in mouse models, 
where cold-induction or transplantation of BAT resulted in improved insulin 
sensitivity, lipid profiles and decreased body weight[115, 251]. Further studies in 
man showed that increasing BAT activity through cold activation could improve 
measures of insulin sensitivity[116, 117] and, on retrospective review of PET-CT 
scans done for clinical purposes, that those with NAFLD were less likely to have 
active BAT[121, 122]. 
5.1.3 BAT activity and ethnicity 
Through Chapters 1, 2 and 4 it has been consistently shown that people of South 
Asian ethnicity have a more unfavourable metabolic profile compared to Caucasians, 
and that this results in increased risk of NAFLD. BAT activity has also been shown to 




reduced BAT activity may underpin the disadvantageous metabolic phenotype within 
this group. 
At present, there are limited data in the literature about the influence of ethnicity on 
BAT activity. The large, early retrospective studies of clinical PET-CT scans did not 
include data on patient ethnicity[252, 253]. Cronin et al. reported a large 
retrospective cohort of 6867 patients who underwent PET-CT, demonstrating again 
that sex, age and BMI are associated with presence of BAT, but that there were no 
differences between ethnic groups[254]. However, this cohort was mainly comprised 
of Caucasians, with small numbers of Black, Hispanic and Asian patients. More 
recently, a Dutch group prospectively examined the differences in BAT activity 
between healthy, lean Caucasians and South-Asians.  Hindustani-Surinamese 
participants – people of South Asian ancestry who migrated to the Netherlands from 
Surinam (a former Dutch colony) – were recruited for both studies undertaken by 
this group. These South Asian participants were born in the Netherlands but had 
Hindustani-Surinamese parents. Their initial study of 10 Caucasian, 10 South Asian 
men showed no difference in cold-induced BAT activity as measured by PET-CT or 
BAT volume between the groups[178]. A further study undertaken a year later 
repeated this work, comparing BAT activity between 12 Caucasians and 12 South 
Asians, including measures of energy expenditure[179]. At baseline, the South Asian 
group had a lower energy expenditure and a lower BAT volume. Glucose uptake on 
cold activation did not differ between groups, but energy expenditure did seem to 
increase to a lesser degree in the South Asian group (20% vs 13% p=0.09) – a 
difference that may have been more pronounced if a larger sample size had been 
used. Of note, the reduced BAT volume in the South Asian group may influence the 
detection of small changes in glucose uptake via PET-CT. If the foci of tracer uptake 
are small, the radioactivity concentration can be underestimated due to resolution 
losses[255].  
These are the only two studies to directly compare BAT activity between South 
Asians and Caucasians, and are limited by their small sample size, and by the fact 
that, although their South Asian groups are genetically South Asian, they are likely to 
be culturally and environmentally European, which may impact their metabolic 
profile and BAT activity. 
5.1.4 BAT activity and genetics 
BAT activity is influenced by environment, with evidence demonstrating changes in 
activity according to season and outdoor temperature, despite imaging being 
undertaken in a temperature-controlled environment[249, 252, 256]. Early studies 
showed that prolonged cold exposure reduced presence of shivering but did not 
change metabolic rate, indicating an increase in non-shivering thermogenesis from 
BAT[257]. More recent studies confirm this finding, and that cold acclimation can 
accentuate acute cold-induced BAT activity, but whether long-term cold acclimation 
can result in long-term changes to basal metabolic rate remain to be seen[258]. In 




activity between ethnicities. It has been theorised that the ancestral exposure to 
cold necessitated the enhancement of thermogenesis through the activity of BAT, 
and that the reverse may be true for the descendants of heat-adapted 
populations[259]. Therefore, it may be that evolutionary climate exposure plays a 
part in the ethnic variation in obesity and diabetes. In addition to these proposed 
“thrifty” genotypes, presence of genetic variants that directly influence BAT activity 
through UCP1 or beta-adrenergic receptors have also been shown to impact rates of 
obesity and diabetes and may influence ethnic differences in BAT activity[260-262]. 
Variants within the FTO haplotype (the strongest genetic association with 
obesity[263]) have recently been mechanistically linked to BAT activity, so may be of 
interest when examining differences between populations[264].  
Another SNP that has been linked to perception and adaptation to cold is the 
Transient Receptor Potential (TRP) cation channel subfamily member 8 gene 
(TRPM8), whose allele frequency varies significantly with latitude[265]. It has been 
postulated that positive selection raised its frequency in the Eurasian population 
during the last 25,000 years making it an interesting focus for future studies of its 
role in determining BAT activity.  
 
5.2 Hypothesis, aims and objectives 
 
This chapter will address the following hypotheses, using the subsequent aims and 
objectives: 
 Indians have lower brown adipose tissue activity than Caucasians 
 Reduced brown adipose tissue activity increases NAFLD risk 
AIM 4: To investigate the ethnic differences in BAT activity and its impact on NAFLD 
risk  
Objective M)  Assess the BAT activity across the multi-ethnic study 
Objective N)  Compare BAT activity between native Indian, UK-migrant Indian and 
Caucasian cohorts 
Objective O) Perform case-control analysis of NAFLD risk with regard to BAT 
activity across the multi-ethnic study 
Objective P) Analyse the impact of ethnicity on BAT activity and NAFLD risk within 
the multi-ethnic study 









Methods of assessing BAT function 
BAT activity can be measured in several ways, which can be broadly divided into 
direct and indirect measures. 
Direct measures of activity require tissue samples through biopsy – usually taken 
from the supraclavicular depot under imaging guidance. Activity can be assessed by 
measuring gene expression markers (UCP1 mRNA[266], lipoprotein lipase 
mRNA[267]), gene products (UCP1 or BAT lipid content), or from measures of 
mitochondrial respiration[268, 269]. These measurements are usually limited to 
animal models or small human studies due to their invasive nature. 
Indirect measures of BAT activity are more commonly used in research. The principal 
output from activated BAT is heat, so calorimetry may be the most suitable tool. 
Indirect calorimetry measures oxygen consumption and carbon dioxide production, 
enabling calculation of energy expenditure using the Weir equation (EE(J) = 
15.818VO2(l/min) + 5.176VCO2(l/min)). It can therefore be used to measure the 
increase in energy expenditure in response to cold-activation of BAT[249, 270]. The 
limitation of this method, however, is that a rise in metabolic rate in response to cold 
may not be entirely attributable to increased BAT activity. Studies have shown that 
UCP1 knockout mice maintain the ability to increase their metabolic rate in response 
to cold[271, 272]. This means that the use of calorimetry alone may not be a 
sufficient method to measure BAT activity. 
PET-CT 
As previously described, it was the symmetrical glucose uptake in the supraclavicular 
fossae on PET-CT that led to the resurgence of interest in BAT physiology[273]. This 
uptake was subsequently proven to be due to BAT, through direct measures of 
activity via biopsy[274-278]. Since then, PET-CT (specifically 18F-FDG PET-CT) has 
been considered the gold standard for measuring BAT activity in humans, where PET 
measures the uptake of glucose (the substrate utilised by active BAT) and CT 
measures the density of the tissue of interest (distinguishing it from WAT). Often the 
detection of active BAT on PET-CT is reported in a binary fashion as “BAT positive” or 
“BAT negative” rather than as a continuous measure. This is because multiple factors 
may influence the reporting of small changes in glucose uptake (BAT activity) 
between participants or studies, including variability in scanner model, system 
calibration, resolution, 18F-FDG dose, scan duration and the region of interest (ROI) 
selected. 
PET-CT has other limitations. It requires exposure to relatively high levels of radiation 
(8mSv), costs around $450 per scan and requires around 1.5hours of time from 




activation. This means that studies of healthy individuals are limited to small 
numbers, particularly if repeated imaging is required, reducing confidence in results. 
Measurement of BAT volume and activity can also vary according to PET resolution, 
the ROI and PET threshold criteria chosen. This means that studies may not be 
comparable. Larger studies can be undertaken by retrospectively looking at imaging 
done for clinical reasons, but conditions and protocols are optimised to minimise 
BAT activity, resulting in much lower prevalence of BAT activity detected [277, 279] 
than in those studies that activate BAT [276, 278]. Data from these studies may not 
necessarily be extrapolated to healthy individuals. 
In addition to the practical constraints, there are also methodological limitations. PET 
measures the uptake of glucose (18F-FDG) within tissues, and, because BAT utilises 
glucose as a substrate for oxidation, the amount of glucose uptake within BAT could 
be used as a measure of the tissue’s activity. However, there are studies that show 
that glucose (18F-FDG) uptake is unaffected in UCP1 knockout mice where 
thermogenesis from BAT activity is diminished[280]. It is also noted that BAT uses 
fatty acids as its main substrate[249]. It is the process of lipolysis of triglycerides to 
produce fatty acids for BAT substrate that requires glucose, rather than the 
utilisation of glucose itself as a substrate[281]. This means that PET-CT may not 
always detect metabolically active BAT. 
Due to the multiple limitations to the current “gold-standard” for measurement of 
BAT activity, a number of other indirect measures of activity are being used in clinical 
research. 
Magnetic resonance imaging 
MRI has properties that make it an alternative to PET-CT for the measurement of 
BAT activity. MRI (whether MRI or MRS) can differentiate between BAT and WAT 
through differences in lipid/water fractions. White adipocytes contain a single lipid 
vacuole[282] and minimal water, whereas brown adipocytes contain multiple 
vacuoles[250] and significantly higher amounts of water. Studies using either MRI or 
MRS have demonstrated the ability to detect BAT under both cold-stimulated and 
thermoneutral conditions, even in the supposed absence of BAT on PET-CT[283, 
284]. The triglyceride content of BAT has also been linked to insulin sensitivity in 
healthy volunteers[285] and has led to further studies comparing BAT fat fraction in 
patients with different levels of insulin resistance[114]. This clinical utility, along with 
absence of ionising radiation make MRI an attractive modality for the assessment of 
BAT activity, particularly in larger, longitudinal studies. The main restrictions of this 
method are its cost and limited availability.  
Infrared thermography (IRT) 
IRT is a process by which the infra-red radiation emitted from an object is measured, 
converted to radiometric data and finally presented as temperature data (often in 





IRT is non-invasive and does not require ionising radiation and therefore offers an 
attractive alternate method for the indirect measurement of BAT activity. IRT 
requires very little equipment and can give good quality data through repeated or 
serial measurements of large numbers of individuals. Contrary to PET-CT, IRT 
measures heat as the key outcome of thermogenesis, rather than an upstream 
substrate. As the largest depot of BAT in adults is found within the supraclavicular 
fossae,  this region is usually imaged, often comparing basal to stimulated 
thermogenesis, and, at times, in relation to a reference point. 
IRT has been used  to study BAT since the 1970’s[287]. Over time, animal models 
confirmed that BAT activity as measured by IRT correlated with other methods such 
as PET-CT[288] or calorimetry[289]. More recently, IRT has been used to assess cold-
induced BAT activity in humans[290, 291]. When comparing IRT to PET-CT, it was 
initially shown that those individuals who were “BAT-positive” on PET-CT had an 
increased temperature of the BAT hotspot, relative to a reference point in response 
to cooling, but there was no response in “BAT-negative” individuals[292, 293]. 
Subsequent work has confirmed that the BAT hotspot as measured by IRT closely 
corresponds to the area of maximal uptake on PET-CT in repeated imaging of healthy 
volunteers, demonstrating that IRT may be a suitable alternative to PET-CT for the 
measurement of BAT activity. 
A major limitation of IRT is the fact that the measurement of BAT activity relies on 
the radiation of the heat it produces through adipose and subcutaneous tissues. 
Adipose tissue is highly insulating[294] and increased adiposity reduces skin 
temperature[295], which can make detection of BAT through thick adipose tissue of 
the neck difficult. It is also well documented that BMI is inversely associated with 
BAT activity[296-298], making detection of reduced activity through an area of 
decreased conduction potentially more difficult[279]. At present, there is a paucity 
of studies that examine the use of IRT in overweight/obese individuals. One study 
comparing lean and obese men showed no increase in energy expenditure or 
supraclavicular temperature via IRT in the obese group in response to cold. The 
limitations of this work are that the imaging protocol was not outlined, suggesting 
that IRT was done at a single time-point, thus losing data on the dynamic nature of 
BAT activity. In addition, the cooling protocol involved immersion of both hands into 
ice water, which is likely to have elicited a pain response, rather than pure cold-
activation of BAT. This study was also limited by a small sample size (obese n=16). 
Contrary to this finding, Hartwig et al. examined the use of IRT in assessing BAT 
activity in response to glucose load and cold in 5 healthy and 5 overweight 
women[299]. In this study, a thermogenic response as measured by IRT was noted in 
all participants, both lean and obese. Again, the imaging protocol was not clear, 
highlighting the need for further detailed studies of this nature. 
Methods of activating BAT 
In addition to differences in methods of measuring BAT activity, it is also important 




number of ways: through cooling[248, 258], use of pharmacological agents[300], 
diet[301] or even stress[302]. As the core function of BAT is thermogenesis, cooling 
is the most common method of stimulation used. This can be done acutely, using 
short cooling protocols[303], or through cold acclimation over a period of time[258]. 
Cooling can be achieved through lowering of ambient air temperature[292], through 
immersion in cold water[290] or through use of cooling blankets[293]. Whichever 
modality is used, the temperature selected must not be so low as to cause shivering, 
thus switching off non-shivering thermogenesis, or pain, which activates the 
sympathetic nervous system and may influence BAT activity. Cooling protocols that 
utilise water or blankets can be standardised for a given study or personalised to the 
individual participant, which involves reducing the temperature to a point below 
which shivering is induced, and then bringing the temperature up until shivering 
stops. With such variability in methods and protocols, comparison of data between 
studies can be difficult, as highlighted by a Dutch group who demonstrated different 
outcomes when comparing BAT activity between South Asians and Caucasians when 
using different techniques[304].  
When cooling is used as the method of activation, it is also pertinent to consider its 
duration. Initial response to cold stimulus is rapid; 5 minutes of cooling is enough to 
detect a change in temperature via IRT[290]. Longer periods of cooling have however 
shown further increases in temperature, with studies using durations of 30 minutes, 
1 hour or even 2 hours[291, 292, 303]. The comfort of participants must also be 
considered, as well as how pragmatic it is to conduct long imaging protocols in 
studies of reasonable sample size. 
5.3.2 Study design 
This study used data collected from the multi-ethnic study outlined in Chapter 4. As 
previously described, this cohort was created to enable collection and analysis of 
data on risk factors associated with NAFLD, and to enable comparison of both clinical 
and environmental risk profiles between ethnic groups. Data from different variables 
known to impact NAFLD risk and/or BAT activity were collected in a cross-sectional 
manner, at a single time point. This included age, measures of body composition 
(including subclavicular skinfold thickness as a measure of neck adiposity) and 
presence of diabetes – variables that are known to impact BAT activity.  
The eligibility criteria and recruitment method for this study are outlined in Chapter 
4 (4.3). This part of the study regime was outlined within the participant information 
sheet, was included within the consent form and was covered by the same ethical 
approvals (both in India and in the UK). 
Through the work of this chapter, the aim is to investigate whether ethnic 
differences in BAT activity may contribute to the increased metabolic/NAFLD risk in 
people of Indian ethnicity. BAT activity was measured using IRT in both NAFLD cases 
and controls, comparing native Indian, UK Indian and UK Caucasian populations using 
the study outlined in Chapter 4. Although evidence for the use of IRT in participants 




activity within a large sample size (n=120), using tools that are portable and practical 
for a study that involves assessment of people within a lower-middle income 
environment. In addition, the inclusion of metabolic variables (obesity, presence of 
diabetes) in final logistic regression analysis will reduce any impact of confounding.  
A cooling protocol that utilised a water blanket wrapped around the right arm and 
set to 14˚C was chosen. Cooling occurred after 20 minutes of acclimation to a room 
temperature of 22˚C and continued for 20 minutes to enable dynamic assessment of 
BAT activity. An individualised cooling protocol was not suitable for this study, as the 
induction of shivering to identify an appropriate cooling temperature would 
invalidate further assessment of non-shivering thermogenesis during the single study 
visit. Whilst preferable, electromyography to assess for presence of shivering was 
unavailable, so participants were closely monitored and asked at regular intervals 
about presence of shivering. This protocol has been utilised in other studies of this 
nature within this study group and has shown to provide adequate activation of 
BAT[293]. 
5.3.3 Study regime 
As outlined in Chapter 4, participants attended a single morning study visit lasting 
approximately 3 hours, having fasted from midnight and avoided caffeine and 
strenuous exercise in the preceding 24 hours. These specifics were outlined in the 
participant information sheet as caffeine may increase sympathetic activation of BAT 
and strenuous exercise can increase skin temperature, both of which may influence 
BAT activity as measured by IRT.  On arrival, participant eligibility was checked 
against the inclusion/exclusion criteria, which included a brief medical, alcohol and 
drug history. Participants then underwent measures of body composition and 
venepuncture for assessment of basic blood parameters. UK-Caucasian and UK-
South Asian participants had skinfold thickness measured to the nearest 0.1cm in the 
midline below the right clavicle using Harpenden callipers (HaB direct, Warwickshire, 
UK). This was used as a surrogate marker of neck adiposity and enabled analysis of 
its correlation with other measures of body composition. Participants then 
completed questionnaires on lifestyle habits and underwent an abdominal 
ultrasound for assessment of liver fat.  
For the assessment of BAT activity, IRT was undertaken in line with the Delphi 
consensus on the measurement of human skin temperature[305], and through 
modification of existing protocols used within the local study group (Early Life 
Research Group, Division of Child Health, University of Nottingham).  Imaging was 
done in a room under closely monitored conditions. The ambient temperature was 
set to 22°C (thermoneutral zone 22-24°C), with documentation of the external air 
temperature being noted from the Meteorological Office (www.metoffice.gov.uk). If 
air conditioning was required to maintain a thermoneutral ambient temperature, a 
partition was used to ensure no direct airflow across the ROI. Participants were 
positioned away from sources of infrared radiation (e.g. electronic devices or 




psychrometer to the nearest 0.01°C (M0297 Extech). Thermal imaging was 
undertaken using a FLIR E60 60Hz infrared camera to the nearest 0.01°C (FLIR 
systems, Wilsonville, Oregon, USA), which was calibrated before each participant 
using atmospheric temperature and humidity, reflective temperature and with 
emissivity set at 0.98. The camera was positioned one metre from and perpendicular 
to the ROI. The ROI is the supraclavicular fossa, as outlined by the outline of the neck 
laterally, using the point where the sternocleidomastoids reach the lateral part of 
the neck superiorly, the clavicle inferiorly, with the sternal notch as the central point 
(Figure 5-1.). Foil tabs were attached to each of these anatomical landmarks, 
enabling analysis of subsequent thermal data.  
 
Figure 5-1. Anatomical landmarks of the region of interest (ROI) 
Participants wore standardised clothing provided by the investigator – including 
shorts and T-shirt with an open neck away from the ROI. Participants were asked to 
sit upright, with their head in a neutral position for the entirety of the protocol. A 
cooling blanket (Balnketrol II, Cincinnati subzero) was attached to the participants’ 
right arm, and an oxygen saturation probe (V100, Dinamap technology) was attached 
to a finger on the left hand. Participants’ temperature was taken using an ear 
thermometer (Thermoscan pro 6000, Braun) and blood pressure was measured 
(V100, Dinamap technology) from the left arm. Ibuttons (Maxim, San Jose, USA) 
were secured at seven anatomical positions (Figure 5-2.), having been programmed 
to take measurements every minute, enabling calculation of mean skin temperature 








Figure 5-2. Anatomical locations of ibuttons 
Imaging was recorded through thermal video of the participant’s ROI using FLIR+ 
software (FLIR systems, Wilsonville, Oregon, USA). The first 20 minutes of imaging 
was completed at the thermoneutral temperature of the room (22°C). Pulse rate was 
documented every minute (V100, Dinamap technology) to show if sympathetic 
activation had occurred during cooling, and at regular intervals, the participant was 
asked if there was presence of shivering. After 20 minutes of acclimatisation, the 
cooling blanket was activated at a temperature of 14°C. Imaging and monitoring 
continued for a further 20 minutes of cooling. On completion of the imaging 
protocol, measurement of blood pressure was repeated, as were measurements of 
ambient temperature and humidity. Participants were then given a packed lunch and 
allowed to leave. 
5.3.4 Data collection and management 
Data collection and management strategies for the study overall were outlined in 
Chapter 4 (4.3). Below is information pertaining to data used specifically in this 
chapter. 
Data management 
Thermal imaging data files were saved in duplicate using the same study number 
format as outlined previously (SA-XXX) – one on an external hard drive kept within a 
locked drawer within a locked office on NHS premises, and one on a University of 





Thermal imaging data were configured utilising code written using MATLAB software 
(MathWorks, Massachusetts, USA). This code was designed and written by Dr James 
Law. Still images were identified for every 5 seconds of video, with re-selection of an 
image within a 2.5 second range if the ROI was not clearly presented (i.e. if 
participant had turned their head). For each image, the ROI as demarcated by the foil 
markers was outlined, where the medial and inferior borders were defined by 
straight lines between the appropriate apices (Figure 5-3.).  
 
Figure 5-3. a) Direct thermal image captured using FLIR E60 60Hz infrared camera b) 
MATLAB output outlining region of interest bilaterally (blue lines), reference point 
(turquoise circle) and hottest 10% of pixels (red)  
 
The contour of the neck was defined programmatically by identifying the 
temperature gradient between the participant and the background. The hottest 10% 
of pixels within the ROI were identified and the median of these points were 
calculated (equivalent to the 95th percentile). Corresponding graphical outputs were 
created to visualise this “hotspot”. A reference region consisting of a circle of 10-
pixel diameter was selected just below the left acromioclavicular apex for 
comparison. This area was identified as the closest comparator to the mean skin 
temperature from the ibutton data as opposed to a reference point just below the 
sternal notch apex as used in other studies (Figure 5-4.)[303]. This thermal imaging 
reference was used in analysis of change of ROI temperature in response to cold, as 
opposed to using mean skin temperature, as it enabled calculation of change in 
relative temperature using a single modality (IRT) rather than using different 






Figure 5-4. a) Thermal data from infrared thermography reference point (rolling average over 1 minute) b) Average skin temperature from 




As with other imaging modalities, radiometric data are subject to an error term, 
through physiological rhythms, inherent “noise” within the measurement, or a 
combination of the two. “Noise” can be limited through averaging out data over a 
time period. Therefore, a rolling average (10 time-points, 50 seconds) was applied to 
the thermal data created. Thermal data was collected and presented as per example 
data in Figure 5-5. 
Figure 5-5. Example thermal imaging data output a) Trel = Tscv-Tref b) baseTscv c) 
peakTscv d) ΔTrel = peakTrel-baseTrel 
 
baseTscv = baseline temperature of the supraclavicular ROI in the minute prior to 
cooling, baseTref = baseline temperature of the reference point in the minute prior to 
cooling, baseTrel = baseline relative temperature (baseTscv-baseTref), peakTscv = 
maximal temperature of the supraclavicular ROI during cooling, peakTref = 
temperature of the reference point at peak Tscv, peakTrel = maximal relative 
temperature, ΔTrel = Change in relative temperature (peak relative temperature – 




Whilst there were numerous measures of BAT activity reported in response to cold, 
ΔTrel has been shown to correlate closely to BAT activity as measured via PET-
CT[303], and as such was the primary endpoint for analysis. 
5.3.5 Data analysis 
Baseline data from each group (NAFLD and control), within each ethnic cohort were 
initially presented as follows (Table 5-1): Categorical data were presented as 
numbers (percentage) and continuous data as mean (SD). As described previously, 
the reported variables within this work would usually be considered Normally 
distributed within the populations sampled and study numbers within groups were 
too small to make statistical testing for Normality (such as the Shapiro-Wilks test) 
meaningful. Central limit theorem suggests that, when testing for differences 
between groups (NAFLD cases and controls), these differences are also expected to 
be Normally distributed[198]. In addition, it can be assumed that the data had 
homogeneity of variance and that data points were independent and were derived 
from an equal-interval scale. For these reasons, all continuous data were considered 
parametric. Pearson’s correlation coefficient was used to examine for collinearity 
between BMI and subclavicular skinfold thickness, with a correlation coefficient of 
r≥0.4 considered moderate correlation and r≥0.7 strong correlation[243]. Correlation 
between subclavicular skinfold thickness and BAT activity (ΔTrel) was also assessed. 
Differences were analysed between baseline characteristics of the ethnic cohorts as 
a whole and between NAFLD cases and controls (data as presented in Chapter 4). 
Comparisons were then made in environment (temperature/humidity) and measures 
of sympathetic activity pre- and post-cooling, in BAT activity between ethnic cohorts, 
between the control groups of each ethnic cohort and in BAT activity between 
NAFLD cases and controls overall. These were done using unpaired, two-tailed 
Students t-test of equal variance for continuous data (parametric), and chi squared 
and two-sample test of proportion for categorical data. For comparisons between 
more than two groups (i.e. between the three ethnic cohorts), analyses were done 
using ANOVA with Bonferroni correction where differences were identified for 
continuous data. Statistical significance was set at p<0.05. 
To understand the confounding effect of different variables on BAT activity and 
subsequent NAFLD risk, an adjusted logistic regression model was created. This was 
initially done using the entire dataset (n=126) to give the most power to detect 
differences between NAFLD and control groups overall. A regression model was 
created through the addition of sequential variables known to impact BAT activity 
and NAFLD risk, including those identified a priori from the literature and the work of 
the preceding chapters i.e. age, BMI and presence of diabetes.  
To understand the impact of incorporating the effect of ethnicity within this model, 
further analysis was undertaken through likelihood ratio testing, using ethnicity as an 
interaction term for each variable (as demonstrated previously in Chapter 4 – 4.4.3). 
Ethnicity could not be included as an independent variable within the final model, as 




created to examine whether there was an additional effect of ethnicity on BAT 
activity and BMI (not age - which is not influenced by ethnicity). South Asian and 
Indian ethnicity were compared to Caucasian ethnicity as the base category. 




A total of 130 participants were recruited to the study (UK Caucasian 44, UK South 
Asian 45, Indian 41). Thermal imaging data were corrupted in three participants and 
one did not undergo IRT. These participants were therefore excluded from analysis 
leaving a study size of n=126. The baseline demographics of the study group are 
presented in Table 5-1. More detailed participant characteristics were presented in 
























50 (10) 45 (12) 60 (13) 50 (16) 49 (12) 48 (12) 
BMI (kg/m2) 
Mean (SD) 
27.64 (2.84) 25.46 (2.67) 31.57 (4.98) 25.31 (3.73) 26.46 (3.43) 22.20 (3.69) 
Central obesity 
n (%) 
18 (81.82) 15 (75.00) 24 (100.00) 10 (52.63) 18 (90.00) 11 (52.38) 
Subclavicular skinfold thickness (cm) 
Mean (SD) 
7.54 (1.95) 5.74 (1.84) 8.69 (3.00) 5.31 (1.98) N/A N/A 
Diabetes 
n (%) 
10 (45.5) 3 (15) 20 (83.3) 6 (30) 6 (30) 5 (23.8) 
Table 5-1. Brown adipose tissue study participant characteristics  
Abbreviations: BMI = Body mass index 




5.4.1 Participant characteristics 
Ethnic comparison 
UK Caucasian participants were older than both UK South Asian (p=0.013) and Indian 
participants (p=0.033) – who were of similar age (p=1.000). The Indian group had a 
lower BMI than both the UK Caucasian (p<0.001) and UK South Asian participants 
(p=0.045) – whose BMI was lower, but not statistically so than their Caucasian 
counterparts (p=0.060). There were no differences in rates of central obesity 
between ethnic cohorts. Rates of diabetes were higher in the UK Caucasian cohort 
compared to the UK South Asian (p=0.006) and Indian cohorts (p=0.002). There was 
no difference in diabetes rates between UK South Asians and Indians (p=0.679). 
Body composition comparison 
There was no difference in subclavicular skinfold thickness between UK Caucasians 
and UK South Asians (p=0.398). There was a strong positive correlation between 
subclavicular skinfold thickness and BMI (r=0.73 p<0.001) meaning BMI as a measure 
could be used to adjust for differences in neck adiposity. There was a moderate, 
negative correlation between subclavicular skinfold thickness and BAT activity (ΔTrel) 
(r=-0.49 p<0.001), but, because there were no data for the Indian cohort, this 





Figure 5-6. Scatterplot demonstrating correlation between subclavicular skinfold thickness (cm) and a) BMI (kg/m2) (r=0.73, p<0.001) b) ΔTrel 
(°C) (r=-0.49, p<0.001)  
Abbreviations: BMI = Body mass index 





Comparing NAFLD cases to controls overall (n=126), those with NAFLD were older 
(p=0.016) and had a higher BMI (p<0.001). Rates of central obesity and diabetes 
were significantly higher in the NAFLD group (p<0.001). 
5.4.2 Environment 
During study visits, measures were taken to ensure that the environment remained 
controlled for both ambient temperature and humidity, and that BAT activation was 
the result of cooling alone and not through activation of the sympathetic nervous 
system (either through anxiety or pain). 
Room temperature and humidity were measured at the start and end of the imaging 
protocol. Mean start temperature overall was 22.21°C (0.98) and end temperature 
was 22.51°C (1.31), showing a statistically significant difference of 0.30°C (p=0.004). 
Although statistically different, this is unlikely to make a significant clinical 
difference, given that cold activation requires a much larger change in temperature 
(22˚C to 14°C). Mean overall start humidity was 49.85% (14.06) and end humidity 
was 49.83% (13.52), showing no significant difference through the imaging protocol 
(p=0.742). 
Mean pulse rates for the acclimatisation period and cooling period were calculated 
for each participant, and the differences between these means across the whole 
study population were not significant (p=0.261). Blood pressure was taken before 
and after the imaging protocol. Systolic BP decreased overall following cooling (-
3.4mmHg p=0.002) which is clinically appropriate given that participants were sitting 
still and were being actively cooled. It is also unlikely therefore, that sympathetic 
drive had increased. There was no difference in diastolic BP following cooling 
(p=0.277). 
IRT for the Indian cohort was undertaken in Trivandrum, India between 20/05/17 
and 30/05/17. The average external temperature during this time was 30˚C. IRT for 
the UK cohorts was undertaken in Nottingham, UK between October 2017 and 
March 2019, across different seasons and external temperatures. The annual 
average temperature in Nottingham is significantly lower at 10˚C (p<0.001).  
5.4.3 BAT activity and ethnicity 













Absolute Base Tscv (°C) 
Mean (SD) 
34.09 (0.48) 34.12 (0.64) 33.61 (0.70) 
Peak Tscv (°C) 
Mean (SD) 
34.28 (0.50) 34.29 (0.68) 33.87 (0.68) 
Δ Tscv (°C) 
Mean (SD) 
0.20 (0.14) 0.22 (0.15) 0.28 (0.26) 
Relative Base Trel (°C) 
Mean (SD) 
2.13 (0.54) 2.24 (0.56) 2.68 (0.64) 
Peak Trel (°C) 
Mean (SD) 
2.70 (0.60) 2.74 (0.62) 3.04 (0.61) 
Δ Trel (°C) 
Mean (SD) 
0.57 (0.21) 0.50 0.20) 0.36 (0.21) 
Table 5-2. Measures of brown adipose tissue activity for each cohort 
baseTscv = baseline temperature of the supraclavicular ROI in the minute prior to 
cooling, baseTrel = baseline relative temperature (baseTscv-baseTref), peakTscv = 
maximal temperature of the supraclavicular ROI during cooling, peakTrel = maximal 
relative temperature, ΔTscv = peakTscv – baseTscv), ΔTrel = Change in relative 
temperature (peak relative temperature – base relative temperature (Tscv-Tref) 
At baseline, Tscv was significantly lower in the Indian group compared to UK 
Caucasians (p=0.001) and UK South Asians (p=0.002). The same is seen for peak Tscv 
(Caucasians p=0.009, South Asians p=0.011 Figure 5-7). There were no differences in 
ΔTscv between ethnic groups (p=0.132). There was no difference in supraclavicular 








Figure 5-7. Boxplots depicting a) baseline and b) peak Tscv for each ethnicity 





Relative temperature at baseline was higher in Indians compared to UK Caucasians 
(p=0.003) and UK South Asians (p<0.001), with no difference between the UK 
cohorts (p=1.000). At peak, relative temperature was higher in Indians than UK South 
Asians (p=0.038) but not significantly so compared to UK Caucasians (p=0.078 Figure 
5-8). Again, there was no difference between the UK cohorts (p=1.000). The change 
in relative temperature from baseline to peak (ΔTrel) was significantly lower in 
Indians compared to UK Caucasians (p=0.010) and UK South Asians (p<0.001), with 








Figure 5-8. a) Mean baseline and peak Tscv b) Mean baseline and peak Trel. UK-South Asian (blue), UK-Caucasian (yellow), Indian (green) 






Despite having a lower BMI (known to correlate with higher BAT activity), ΔTrel was 
significantly lower in the Indian cohort compared to the UK Caucasian (-0.134 
p=0.010), and UK South Asian (-0.210 p<0.001) cohorts. There was no difference in 
BAT activity between the UK cohorts (p=0.286). 
To understand the impact of external environment better, BAT activity was 
compared between the control groups within each cohort (Table 5-3). 
 









Δ Trel (°C) 
Mean (SD) 
0.617 (0.256) 0.567 (0.184) 0.363 (0.193) 
Table 5-3. Brown adipose tissue activity in control groups 
ΔTrel = Change in relative temperature within supraclavicular region of interest 
Again, a significant difference was seen between the Indian and both UK Caucasian (-
0.204 p=0.012) and UK South Asian control groups (-0.254 p=0.001) with no 
difference between the UK cohorts (0.050 p=1.000). 
5.4.4 BAT activity and NAFLD 
Initial, unadjusted analysis of differences in BAT activity between NAFLD cases and 
controls overall (n=126) showed that baseline Tscv was lower in participants with 
NAFLD (p=0.020), as was peak Tscv, although not significantly (p=0.058). There was 
no difference in ΔTscv between groups (p=0.893). Baseline Trel was again lower in 
the NAFLD group (p=0.028), as was peak Trel (p=0.004) but overall, although ΔTrel 
was lower in the NAFLD group, it was not significantly so (p=0.086). These 










Absolute Base Tscr (°C) 
Mean (SD) 
33.81 (0.65) 34.08 (0.63) 0.020 
Peak Tscr (°C) 
Mean (SD) 
34.04 (0.64) 34.26 (0.64) 0.058 
Δ Tscr (°C) 
Mean (SD) 
0.23 (0.21) 0.23 (0.17) 0.893 
Relative Base Trel (°C) 
Mean (SD) 
2.23 (0.52) 2.47 (0.71) 0.028 
Peak Trel (°C) 
Mean (SD) 
2.67 (0.53) 2.99 (0.67) 0.004 
Δ Trel (°C) 
Mean (SD) 
0.44 (0.20) 0.51 (0.24) 0.086 
Table 5-4. Measures of brown adipose tissue activity in NAFLD and Control groups 
baseTscv = baseline temperature of the supraclavicular ROI in the minute prior to 
cooling, baseTrel = baseline relative temperature (baseTscv-baseTref), peakTscv = 
maximal temperature of the supraclavicular ROI during cooling, peakTrel = maximal 
relative temperature, ΔTscv = peakTscv – baseTscv), ΔTrel = Change in relative 
temperature (peak relative temperature – base relative temperature (Tscv-Tref) 
5.4.5 Logistic regression 
To understand the confounding effect of different variables on BAT activity and 
subsequent NAFLD risk, an adjusted logistic regression model was created. This was 
initially done using the entire dataset (n=126) to give the most power to detect 
differences between NAFLD and control groups overall. This model was created 
through the addition of sequential variables known to impact BAT activity, including 
age, BMI and diabetes.  
The development of the final model is outlined through the tables below, which 
demonstrate the sequential addition of variables and the resultant likelihood ratios, 
R2 values and a p value. This p value demonstrates whether the subsequent iteration 
results in a significant change in likelihood ratio from the previous iteration. 
 
 Adjusted OR (95% CI) 
n=126 
Constant 1.10 (0.78, 1.56) 





 Adjusted OR (95% CI) 
n=126 
BAT activity (ΔTrel (°C)) 0.24 (0.05, 1.24) 
Table 5-6. Iteration 1, addition of BAT activity to the model (R2=0.02, log likelihood=-
85.69, p=0.083) 
Abbreviations: BAT = brown adipose tissue 
ΔTrel = change in relative temperature within the supraclavicular region of interest 
 
 Adjusted OR (95% CI) 
n=126 
BAT activity (ΔTrel (°C)) 0.35 (0.06, 1.89) 
Age (years) 1.03 (1.00, 1.06) 
Table 5-7. Iteration 2, addition of age to the model (R2=0.04, log likelihood=-83.51, 
p=0.037) 
Abbreviations: BAT = brown adipose tissue 
ΔTrel = change in relative temperature within the supraclavicular region of interest 
 
 Adjusted OR (95% CI) 
n=126 
BAT activity (ΔTrel (°C)) 0.42 (0.06, 1.89) 
Age (years) 1.01 (0.97, 1.04) 
BMI (kg/m2) 1.33 (1.17, 1.51) 
Table 5-8. Iteration 3, addition of BMI to the model (R2=0.21, log likelihood=-69.21, 
p<0.001) 
Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular region of interest 
 
 Adjusted OR (95% CI) 
n=126 
P value 
BAT activity (ΔTrel (°C)) 0.47 (0.07, 3.20) 0.444 
Age (years) 0.99 (0.96, 1.03) 0.769 
BMI (kg/m2) 1.31 (1.15, 1.50) <0.001 
Diabetes 1.99 (0.70, 5.66) 0.199 





Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular region of interest, 
diabetes = formal diagnosis or fasting glucose>7.0mg/dl 
Whilst the inclusion of age and diabetes did not increase the proportion of variation 
explained within the model, the evidence presented in the introduction to this 
chapter highlights their documented impact on BAT activity and were therefore 
included. Table 5-9 outlines the final logistic regression model and demonstrates 
that BAT activity is not associated with NAFLD risk (adjusted OR 0.47 0.07-3.20 
p=0.444), and that the biggest impact on NAFLD risk appears to come from BMI (OR 
1.31 1.15-1.50 p<0.001).  
5.4.6 Impact of ethnicity 
To understand the impact of incorporating the different ethnic groups within this 
model, further analysis was undertaken through likelihood ratio testing, using 
ethnicity as an interaction term for each variable (as demonstrated previously in 
Chapter 4 – 4.4.3). Ethnicity cannot be included as an independent variable within 
the final model, as the number within each ethnic group was fixed. Therefore, 
comparator models were created to examine whether there is an additional effect of 
ethnicity on BAT activity, BMI and presence of diabetes (not age - which is not 
influenced by ethnicity). South Asian and Indian ethnicity were compared to 
Caucasian ethnicity as the base category. 
 Adjusted OR (95% CI) 
n=126 
BAT activity (ΔTrel (°C)) 0.30 (0.03, 2.73) 
BAT activity (ΔTrel (°C)) 
- South Asian 
- Indian 
 
2.42 (0.39, 14.82) 
6.97 (0.65, 74.62) 
Age (years) 0.99 (0.96, 1.04) 
BMI (kg/m2) 1.35 (1.17, 1.54) 
Diabetes 2.21 (0.76, 6.46) 
Table 5-10. Comparator model examining the interaction effect of ethnicity on BAT 
activity (R2=0.23, log likelihood=-67.00, p=0.252) 
Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular region of interest, 





 Adjusted OR (95% CI) 
n=126 
BAT activity (ΔTrel (°C)) 1.01 (0.12, 8.74) 
Age (years) 1.00 (0.96, 1.04) 
BMI (kg/m2) 1.34 (1.17, 1.53) 
BMI (kg/m2) 
- South Asian 
- Indian 
 
1.02 (0.98, 1.06) 
1.04 (0.99, 1.09 
Diabetes 2.33 (0.78, 6.93) 
Table 5-11. Comparator model examining the interaction effect of ethnicity on BMI 
(R2=0.24, log likelihood=-66.62, p=0.172) 
Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular region of interest, 
diabetes = formal diagnosis or fasting glucose>7.0mg/dl 
 
 Adjusted OR (95% CI) 
n=126 
BAT activity (ΔTrel (°C)) 1.78 (0.19, 17.00) 
Age (years) 0.99 (0.95, 1.04) 
BMI (kg/m2) 1.43 (1.22, 1.67) 
Diabetes 4.75 (0.64, 35.02) 
Diabetes 
- South Asian 
- Indian 
 
2.99 (0.44, 20.35) 
¥Omitted 
Table 5-12. Comparator model examining the interaction effect of ethnicity on 
presence of diabetes (R2=0.28, log likelihood=-63.19) 
Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular region of interest, 
diabetes = formal diagnosis or fasting glucose>7.0mg/dl 
¥ As seen in Chapter 4 (4.4.3), when examining the impact of ethnicity on NAFLD risk 
in relation to diabetes, data from the Indian group were omitted due to collinearity 
between these risk factors and Indian ethnicity i.e. the characteristics of the Indian 
NAFLD participants with diabetes perfectly predicted NAFLD.  
These models were then compared to the null model (Table 5-9) using likelihood 
ratio testing. This shows that none of the above comparator models improve the null 
model, which did not include ethnicity (p=0.252, p=0.172). This means that there 
was no impact of ethnicity on the null model, despite apparent differences in BAT 




5.4.7 BAT activity and diabetes 
These data show that BAT activity is not directly associated with NAFLD. However, 
given the links between BAT activity and insulin sensitivity, analysis was undertaken 
to examine whether reduced BAT activity may be associated with presence of 
diabetes (as a metabolic precursor to NAFLD). Using the same logistic regression 
model (without the inclusion of diabetes as a variable), the influence of BAT activity 
on presence of diabetes was assessed. These data are presented in Table 5-13. 
 Adjusted Odds Ratio 
(95% CI) 
P value 
BAT activity (ΔTrel (°C)) 0.29 (0.03 – 3.03) 0.301 
Age (years) 1.12 (1.07 – 1.18) <0.001 
BMI (kg/m2) 1.22 (1.08 – 1.38) 0.001 
Table 5-13. Adjusted logistic regression for diabetes risk 
Abbreviations: BAT = brown adipose tissue, BMI = Body mass index 
ΔTrel = change in relative temperature within the supraclavicular region of interest 
This shows that BAT activity is not associated with diabetes risk. Risk of diabetes 
within these cohorts is influenced mainly by BMI and age. Again, through likelihood 
ratio testing, the inclusion of ethnicity as an interaction term did not alter the 




5.5.1 Principal findings 
BAT activity was lower in native Indians compared to UK South Asians and UK 
Caucasians. This difference was significant even in the presence of a lower BMI, 
which has been shown to correlate with higher BAT activity. This difference 
appeared to be environmental rather than genetic, as there was no difference in BAT 
activity between control groups of different ethnicities who live in the same country 
(UK Caucasian and UK South Asian).  
BAT activity was not directly associated with NAFLD risk. Any differences in BAT 
activity were related to increasing BMI (even within the native Indian population 
who have a lower BMI), which itself is known to increase NAFLD risk. The same can 
be concluded for BAT activity in relation to diabetes risk. Again, this highlights the 
Asian-paradox, whereby small changes in BMI within this ethnic group result in 
significantly higher risk of disease, whether cardiovascular or in relation to 
components of the metabolic syndrome[158].  
There is paucity of studies that examine the difference in BAT activity between 




findings of this work to the current literature. When examining differences in BAT 
activity between ethnicities, this study is similar to the work done by the Dutch 
group who looked at differences in BAT activity between South Asians and 
Caucasians[179]. Their study utilised a group of participants whose heritage was 
South Asian, but who were born in Europe. Although they found that BAT volume 
was lower in those of South Asian descent, BAT activity did not differ between 
groups. Their finding is echoed in this work, with no difference seen in BAT activity 
between Caucasians and South Asians living within the UK. Where the Dutch group 
had a pool of participants of a particular heritage, of the same generation, this study 
recruited South Asian participants from different South Asian countries, with 
different cultures, of different generations and of different lengths of residence in 
the UK. Whilst this may result in heterogeneity in diet, lifestyle and genetics within 
the group, it is still important to have demonstrated that living in the UK appears to 
result in adaptation of BAT activity to levels similar to UK Caucasians. 
The only other studies that examined BAT activity in relation to NAFLD were 
conducted through retrospective review of PET-CTs performed for clinical 
purposes[121, 122]. This makes it impossible to compare the findings of this work to 
those. They were not designed to examine active BAT, were undertaken in patients 
within the diseased state, and did not include pertinent data about other potential 
metabolic confounders such as presence of diabetes. It is however interesting that 
both such studies noted increased odds of NAFLD in those without active BAT. Whilst 
clinical PET-CT as a modality may under-report BAT activity, the CT component may 
be more accurate at identifying NAFLD. This means that the use of ultrasound in this 
work may in fact under-report NAFLD within the study group, reducing the power of 
its results. 
5.5.2 Strengths and weaknesses of the study 
This cross-sectional, multi-cohort case control study is, to the author’s knowledge, 
the largest study of BAT activity utilising IRT as a technique – with other studies of 
this kind having sample sizes of between 8-58 participants[292, 299, 303, 307]. It 
may also be the largest clinical, prospective study of BAT activity in the literature 
overall, with studies that use PET-CT as an imaging modality being limited by cost 
and exposure to radiation [119, 120, 178, 179]. Whilst there have been numerous 
retrospective studies, methodological studies and studies of BAT activity and 
function in healthy volunteers, there is a paucity of data on the impact of BAT 
activity in the disease state. This is particularly pertinent when the majority of work 
done in the field of BAT focusses on its physiological links to whole body energy 
expenditure and potential role in obesity, with only a minority of observational or 
interventional studies involving patients[114, 116, 120]. This study allowed 
comparison of real-world BAT activity between different ethnicities, in different 





This pragmatic approach was enabled by using IRT as an imaging modality. Thermal 
imaging – in this case, video imaging – provided an enormous amount of data from a 
large number of participants, who did not require invasive procedures, or exposure 
to radiation. Its portable nature meant imaging could be undertaken wherever a 
climate-controlled room could be created. Within this study, individual images, 
selected at 5-second intervals, were used to create a detailed outline of the dynamic 
temperature changes that occur through activation of BAT. Many previous studies 
that used IRT for the assessment of BAT activity took single images at different time 
points[279, 291, 292], or at much longer intervals[293, 308]. The use of larger 
numbers of time points is becoming more prevalent[303], but with the ability of 
modern thermal cameras to capture images at 300 frames per second, there is scope 
to further improve the accuracy of data captured. IRT has now been validated 
against PET-CT, with ΔTrel being the measure that most closely correlated with BAT 
activity measured as 18FDG uptake. The use of relative temperature changes in 
response to cold enables participants to become their own controls, standardising 
results and allowing direct comparison of individuals. Thus, through utilisation of a 
validated tool, under standardised conditions (as outlined by the Delphi Statement 
on thermal imaging[305]), capturing large amounts of data in different countries, this 
study has been able to demonstrate accurately the differences in BAT activity 
between ethnicities. 
There is a wealth of evidence on the recruitment and increase in activity of BAT in 
response to prolonged cold acclimation, with some studies involving days or weeks 
of acclimation to lower temperatures[257, 258, 309]. It can therefore be surmised 
that any period of time living within a colder climate (Nottingham average annual 
temperature 10°C vs Trivandrum average annual temperature 30°C), is likely to 
result in higher BAT activity, as demonstrated by this work. These differences in BAT 
activity remain apparent, even when the internal study environment is maintained 
between cohorts, regardless of country. A potential concern about this work could 
be that the study environment, although consistent across cohorts, may be felt as 
cold to the native Indian participants, resulting in pre-activation of BAT at baseline. 
The comparable work from the Dutch group found that South Asians had a higher 
shiver temperature (temperature at which an individual starts shivering), despite 
living in the same country. They did however note that the temperature at which 
shivering ceased (at which BAT activity/non-shivering thermogenesis could be 
measured) was the same between groups[179]. Within this study, the relative 
temperature was higher in the Indian cohort, even at baseline, which could be 
thought to represent pre-activation of BAT in response to a “cold” acclimation 
environment. It is however more likely to be a result of reduced skin perfusion in 
response to the perceived “cold” rather than BAT activation, as the temperature of 
both the supraclavicular fossa and reference point were significantly lower in this 
group compared to the UK cohorts. If BAT had been active from the outset, the 
supraclavicular temperature would be expected to be higher. If anything, this 




exposed to a perceived cold environment, the temperature of their supraclavicular 
fossa was lower than the UK cohorts. In addition, the fact that the native Indians 
were “warmer” from the outset may mean that they were cooled by the same 
stimulus to a lesser extent. One way this could have been identified would have been 
to use IRT to measure the arm temperature after the protocol was completed, 
comparing the degree to which it was cooled between cohorts.   
Whilst pragmatic in its approach, with a study design focussed specifically on the 
differences between populations with components and sequelae of the metabolic 
syndrome, this study did involve a very heterogeneous group of participants, many 
of whom were on lipid-lowering or anti-hypertensive medications, even within the 
control groups (data presented in Chapter 4). Whilst those with conditions or who 
are on treatments that may influence BAT activity (e.g. thyroid dysfunction, beta-
blockers etc.) were excluded, little is known about the impact of, for example, 
diabetic medications on BAT activity – particularly as BAT utilises glucose as a 
substrate.  
Within this study, participants were sampled from similar places. The UK participants 
were recruited from a study designed to identify NAFLD within the community, and 
the Indian participants from a large NAFLD cohort. This was done with the aim to 
reduce variability between groups, resulting in similar rates of metabolic factors 
between cohorts. This was not entirely successful, as the UK Caucasian cohort was 
significantly older, were of higher BMI and had higher rates of diabetes. These 
confounding factors were however adjusted for within the logistic regression 
models, and despite these differences, the Indian cohort were shown to have lower 
rates of BAT activity. 
5.5.3 Study implications and future work 
This study showed that BAT activity is influenced principally by environment, not just 
by ethnicity. Living in a colder environment is likely to increase BAT activity, as 
supported by this work and published literature. Whilst BAT activity does not directly 
influence NAFLD or diabetes risk, the physiological role it plays suggests that it does 
have an impact on metabolic factors, such as insulin resistance, which in turn affect 
NAFLD risk. Further work is required to analyse the relationship between BAT activity 
and individual components of the metabolic syndrome (and their treatment), and to 
identify whether there is any potential for an intervention that increases BAT 
activity. This will require larger studies of patients of specific phenotypes, using more 
detailed measures of insulin resistance and lipid physiology, but in which IRT may 
prove a useful tool. 
Whilst IRT has been validated against the current gold standard as a tool to measure 
BAT activity, this validation work was done using healthy, lean volunteers; and 
therefore its use is an important limitation to this study, which focussed on 
participants with complications of obesity. Whilst these data showed that 
subclavicular skinfold thickness (as a surrogate measure of neck adiposity) correlates 




thermal data were not adjusted to incorporate factors such as anatomical 
differences in neck shape and size, tissue depth and skin perfusion. Further 
methodological studies are therefore required, to compare IRT to PET-CT in this 
group, and to refine the IRT technique for use with patients of different phenotypes. 
Finally, further work is also required to understand the role of genetics on BAT 
activity. Whilst these findings indicate that lower BAT activity among Indians in India 
is related to their environment, genetic factors may determine cold perception and 
hence, thermoregulation through BAT function. As previously described, allele 
frequency of an SNP in the Transient Receptor Potential (TRP) cation channel 
subfamily member 8 gene with a central role in cold sensation varies significantly 
with the latitude[265], and through positive selection its frequency in the Eurasian 
population during the last 25,000 years may have increased. Further work using data 
from this study to explore whether TRPM8 alleles have a key role in determining BAT 
activity is underway (preliminary work has been accepted for poster presentation – 




In reference to the hypotheses addressed within this chapter, this study 
demonstrated that NAFLD risk is not associated with decreased BAT activity directly. 
Although BAT activity was lower in native Indians, it was due to environment rather 
than ethnicity, as BAT activity was higher in South Asians who live in the UK. Whilst 
there is overwhelming evidence in the literature, as well as presented within this 
thesis (Chapter 2.) that people of Indian ethnicity are at increased risk of diabetes 
and NAFLD, this study has suggested that reduced BAT activity is not a key 
determinant. Further work is required to analyse the role of BAT activity on 
individual components of the metabolic syndrome and to understand the genetic 





CHAPTER 6: Conclusion 
 
The purpose of this thesis was to add to the current evidence base regarding NAFLD 
risk in people of Indian origin, to estimate accurately the NAFLD prevalence across a 
large Indian district and confirm which factors influence disease risk. This chapter will 
summarise the main findings of this work, the extent to which the work confirmed or 
refuted the original hypotheses (Section 1.5), its research implications and potential 
future studies.  
 
6.1 Principal findings 
 
6.1.1 Increased prevalence of NAFLD within India 
The prevalence of NAFLD is rising on a global scale, with a worldwide pooled 
prevalence estimated at 25.24%[1]. Data from large population-based studies in 
India are however lacking, with quoted rates of disease at a population level varying 
from 8.7-32% depending on study sample, setting and diagnostic tool used (Table 1-
2). Through the work of Chapter 2, it was demonstrated that the prevalence of 
NAFLD within a large South Indian population is significantly higher than global 
estimates (49.8%), confirming the first hypothesis.  Despite having higher 
prevalence, the severity of disease appeared to be comparable to the West[206], 
with 4.5% of those with NAFLD having evidence of advanced chronic liver disease. 
Those with evidence of fibrosis were more likely to be male, of higher BMI and have 
diabetes. 
6.1.2 Commonality of NAFLD risk 
In addition to establishing the increased prevalence of NAFLD within India, this work 
also demonstrated the commonality of NAFLD risk between India and the Western 
world, in line with the second hypothesis.  
Obesity has long been an established risk factor for NAFLD, with a global pooled 
obesity prevalence amongst NAFLD patients of 51.34%[1]. Within Asian populations, 
obesity has been identified as the strongest risk factor for disease due to the so-
called Asian Paradox – where small increases in BMI equate to much larger increases 
in disease risk among populations who are in general of lower BMI overall. This has 
resulted in the reclassification of BMI cut-offs for Asian populations[4]. The work of 
Chapter 2 confirms this link, with 64.9% of those with NAFLD being categorised as 
obese, and presence of obesity being the strongest risk factor for NAFLD within an 
Indian population (adjusted OR 2.81 2.15-3.68, p<0.001). The impact of obesity on 
NAFLD risk appears to be the same for both native and migrant Indian populations, 
as shown by the data from Chapter 4. Here it was demonstrated that, regardless of 
ethnicity, presence of obesity increased NAFLD risk 4-fold (adjusted OR 4.50, 1.92-




In addition to obesity, insulin resistance and diabetes are also closely linked to 
NAFLD. The global pooled prevalence of diabetes in those with NAFLD is 22.5%[1], 
which is lower than the rates within the Indian population sampled in Chapter 3 
(34.1%). Prevalence of diabetes within India is much higher than the Western world 
(>2 million vs. 31,000 mean annual increment[5]) and as such is another strong 
contributing factor to the increased NAFLD prevalence within this population. 
Interestingly, diabetes did not appear to impact NAFLD risk within the work of 
Chapter 4, which may be due to sampling error within the native Indian group, who 
had equal numbers of diabetics in case and control groups.  
6.1.3 Dietary habits may influence NAFLD risk in India 
Changing dietary habits and physical activity levels over the last century are also 
thought to be contributing to the rising burden of NAFLD worldwide. Within India, 
there has been a shift away from consumption of coarse grains towards 
consumption of rice and wheat[217]. More pertinently, there has also been an 
increase in fat intake, often in the form of highly saturated ghee[218]. Within 
Chapter 3, it was demonstrated that, in addition to the traditional clinical risk factors 
outlined above, increased dietary fat (in particular saturated fat) is independently 
associated with increased NAFLD risk within this Indian population (adjusted OR 1.02 
1.00-1.03, p=0.019). This confirmed in part, the hypothesis relating to dietary 
composition and NAFLD risk. Contrary to evidence in the literature however, dietary 
carbohydrate intake does not appear to influence NAFLD risk within this Indian 
population   
In relation to the hypothesis that acculturation can alter NAFLD risk profile, the work 
presented in Chapter 4 suggested a degree of dietary acculturation in UK-migrant 
South Asians, who consumed a diet of similar total calorie and macronutrient 
composition as UK-Caucasians, and who appeared to eat less total calories and 
carbohydrate than native Indians. Dietary habits did not however appear to be 
associated with NAFLD risk in either native or migrant Indian groups, with the 
strongest association being with presence of obesity regardless of ethnicity.  
6.1.4 BAT activity does not influence NAFLD risk 
There has been increasing interest in BAT activity and its link to obesity and 
metabolic disease including NAFLD. The hypothesis that reduced BAT activity in 
people of Indian ethnicity may contribute to their adverse metabolic profile and 
increased NAFLD riskwas examined through the work of Chapter 5. It was shown 
that, whilst BAT activity was lower in native Indian compared to UK-migrant South 
Asian and UK Caucasian cohorts, the difference appeared to be due to environment.  
Reduced BAT activity was not directly associated with increased NAFLD risk, and that 
any differences in BAT activity were related to increasing BMI, which is itself a risk 





6.2 Implications and future work 
 
6.2.1 Screening programmes 
This body of work demonstrates that NAFLD prevalence is significantly higher in India 
than both national and global estimates. It is already well documented that people of 
Indian ethnicity have much higher rates of diabetes, have a predisposition to central 
adiposity and are at increased risk of obesity-related morbidity and mortality at a 
lower BMI than other ethnic groups. NAFLD screening programmes could therefore 
focus the limited resources on those populations who are at highest risk – in 
particular the urban, Southern districts who have the highest documented rates of 
obesity[201]. The Wilson-Junger criteria for a valid screening programme include the 
need for the condition to be an important health problem, with a natural history that 
is known, that has an acceptable and suitable test that can detect disease early and 
can enable early intervention that is more beneficial than management of late 
disease[310]. Through population-level sampling, this work has proven that large-
scale screening for NAFLD can be achieved using ultrasound. Consideration does 
however need to be taken to ensure accurate reproducibility of NAFLD diagnosis 
using this modality. Inter/intra-observer variability could have been improved 
throughout this work if scans were performed by a single operator, with findings 
confirmed by a second reviewer. FibroScan®, with the ability to measure controlled 
attenuated parameter score (a measure of steatosis), may be an even better 
alternative. Its portable nature, ability to identify and stratify disease and provide 
opportunity for point-of-care intervention/education within the community make it 
particularly suitable, as a large proportion of the Indian population resides within the 
rural regions where access to healthcare is limited. Future work should ensure 
validity of FibroScan® data, through collection of 10 valid readings, aiming for an IQR 
that is less than 30% of the median reading[207]. This was not achieved within the 
work of Chapter 2, reducing confidence in data relating to severity of disease within 
this population.  
In addition to screening for NAFLD within at-risk populations in India, it may also be 
worthwhile including Indian (or South Asian) ethnicity as a factor when considering 
risk of NAFLD within the UK. This is particularly pertinent as use of Asia-specific BMI 
cut-offs within the UK is not always widespread and may result in UK-Asians being 
incorrectly categorised as normal BMI and thus low risk for disease. Again, suitable 
screening programmes may best be instigated within areas of high ethnic diversity, 
where it has already been shown that particular South Asian populations have higher 
rates of NAFLD than their Caucasian neighbours[228]. 
6.2.2 Dietary intervention  
Having identified that increased intake of fat is independently associated with 
increased NAFLD risk within India (particularly saturated fat), this could become a 
focus for interventional strategies for both disease prevention and treatment. 




pragmatic at a population level. Basic food group analysis appeared to show that the 
higher fat intake came from increased intake of edible oils and animal protein; 
however further work is required to identify which dietary patterns are linked to 
NAFLD risk in this population. Alterations in the types of grains eaten, cooking oils 
used and consumption of meat are more realistic alternatives for future 
interventional strategies. Indeed, pilot studies of this kind are already appearing in 
the literature (canola oil vs ghee[311], red rice vs white rice ClinicalTrials.gov 
NCT03844165).   
6.2.3 Indian NAFLD genome-wide association study 
The work of this thesis has focussed mainly on the impact of lifestyle on the 
increased susceptibility to NAFLD in people of Indian ethnicity. In addition to these 
“environmental” factors, genetics are also well known to play a role. Through GWAS 
and candidate gene studies, multiple genetic variants have been shown to influence 
NAFLD risk, some of which have also been shown to impact NAFLD risk in Indian 
populations. To date however, there has not been a NAFLD GWAS performed in an 
Indian population. During the creation of the Trivandrum NAFLD cohort, whole blood 
aliquots were taken from each participant, from which DNA was extracted. Future 
work within this cohort will therefore include a GWAS to confirm/identify variants 
that affect NAFLD risk within this group, and will enable examination of the 




In conclusion, prevalence of NAFLD is significantly higher in India than current global 
estimates. There is a commonality of risk between India and the West – namely 
presence of obesity and diabetes. Whilst there may be a degree of acculturation to a 
Western lifestyle with UK-migration, NAFLD risk factors are unchanged across ethnic 
groups. Through detailed dietary analysis, it was shown that an increased intake of 
saturated fat as cooking oil and animal protein might be a contributory factor to 
increased NAFLD risk in India, which could be the focus for further research and 
future interventional studies. Finally, having shown that BAT activity is lower in 
native Indians, this is due to differences in environment, and that reduced BAT 
activity is not directly linked to NAFLD risk, but is associated with increased BMI, 
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Appendix 1. Indian FFQ item list and average item portion intake per day (n=2047) 
FFQ 
Item 
Food Recipe Average portion 
per day 
(n=2047) 
1 Coffee with milk with sugar 0.203 
2 Coffee without milk with sugar 0.208 
3 Coffee without sugar with milk 1.423 
4 Coffee without milk without sugar  0.168 
5 Milk with sugar 0.576 
6 Milk without sugar 0.894 
7 Tea with milk with sugar 2.557 
8 Tea without milk with sugar 1.802 
9 Tea without sugar with milk  2.323 
10 Tea without sugar without milk  1.482 
11 Ada (Jaggery and Coconut) 0.024 
12 Ada (Sugar and coconut) 0.074 
13 Ada (Coconut) 0.037 
14 Appam (with coconut) 0.496 
15 Appam (without coconut) 0.475 
16 Bread Toast  0.127 
17 Chappathi 0.781 
18 Dosai (Maida) 0.072 
19 Dosai (P.R.+B.G) 0.847 
20 Dosai (R.R.+B.G) 0.824 
21 Dosai (R.R.+Coconut) 0.355 







Food Recipe Average portion 
per day 
(n=2047) 
23 Dosai (Wheat flour) 0.317 
24 Dosai (Raw rice) 0.434 
25 Iddli (P.B. + R.R. + B.G.) 0.464 
26 Iddli (R.R.+B.G.) 0.892 
27 Idiappam 0.321 
28 Kozhukatta (Coconut+jaggery) 0.075 
29 Kozhukatta (Coconut+sugar) 0.069 
30 Kozhukatta (Coconut) 0.097 
31 Oothappam 0.088 
32 Oratti 0.104 
33 Poori (Maida) 0.170 
34 Poori (Wheat flour) 0.138 
35 Porotta 0.065 
36 Puttu (Raw rice) 0.243 
37 Puttu (Wheat flour) 0.174 
38 Puttu (Semolina) 0.040 
39 Sandwitch 0.094 
40 Uppuma(rice) 0.211 
41 Uppuma (Semolina) 0.056 
42 Uppuma (Wheat) 0.156 
43 Biriyani ( chicken) 0.103 
44 Biriyani (Beef) 0.047 
45 Biriyani(Egg) 0.029 
46 Biriyani (mutton) 0.045 







Food Recipe Average portion 
per day 
(n=2047) 
48 Curd Rice  0.040 
49 Fried rice  0.046 
50 Fried rice (Beef) 0.055 
51 Fried rice(Chicken) 0.058 
52 Fried rice(Egg) 0.107 
53 Fried rice (fish) 0.028 
54 Fried rice(mutton) 0.030 
55 Lemon rice 0.423 
56 Pazhamkanji 4.567 
57 Rice (P.B.) 2.013 
58 Rice(Raw) 0.142 
59 Rice gruel 0.100 
60 Tomato rice 0.143 
61 Wheat gruel 0.066 
62 Amaranth (red) curry 0.092 
63 Amaranth (green) curry 0.221 
64 Amaranth (red) curry with dhal 0.106 
65 Amaranth (green) curry with dhal 0.022 
66 Ash gourd curry 0.217 
67 Aviyal with curd 0.324 
68 Aviyal without curd 0.030 
69 Beet root Pachadi 0.109 
70 Bengal gram dhal 0.031 
71 Bitter gourd kichadi 0.035 







Food Recipe Average portion 
per day 
(n=2047) 
73 Butter milk curry with coconut 0.048 
74 Butter milk curry without coconut 0.138 
75 Buttermilk 0.117 
76 Cabbage Aviyal 0.057 
77 Cauliflower curry 0.076 
78 Chammanthi podi 0.082 
79 Cherkkurmani's curry 0.212 
80 Coconut Chutney (dry) 0.390 
81 Coconut Chutney (wet) 0.110 
82 Coconut ozhichucurry 0.040 
83 Cow pea curry 0.070 
84 Cucumber kichadi 0.035 
85 Cucumber pachadi 0.116 
86 Curd 0.054 
87 Drum stick curry 0.089 
88 Drum stick curry with dhal 0.046 
89 Drum stick leaves curry 0.041 
90 Erisseri with pulses 0.028 
91 Erisseri without pulses 0.036 
92 Garlic chutney 0.116 
93 Green gram curry 0.042 
94 Green gram dhal curry 0.020 
95 Jack Aviyal 0.020 
96 Jack fruit curry 0.064 







Food Recipe Average portion 
per day 
(n=2047) 
98 Ladies finger kichadi 0.171 
99 Mixed vegetable Kuruma 0.141 
100 Mulaku chutney 0.020 
101 Olan 0.099 
102 Onion curry 0.058 
103 Palak Curry 0.029 
104 Papaya curry 0.087 
105 Peas curry 0.040 
106 Plantain stem pachady 0.148 
107 Potato curry 0.132 
108 Pulissery 0.091 
109 Pulin curry 0.178 
110 Rasam with dhal 0.242 
111 Rasam without dhal 0.051 
112 Raw banana curry 0.640 
113 Red gram dhal curry 0.305 
114 Sambar ( with dhal) 0.159 
115 Sambar (without dhal) 0.029 
116 Soya chunks curry 0.033 
117 Stew 0.036 
118 Tapioca Aviyal 0.109 
119 Tapioca curry with coconut 0.182 
120 Tapioca curry without coconut 0.066 
121 Thiyyal 0.190 







Food Recipe Average portion 
per day 
(n=2047) 
123 Tomato curry 0.065 
124 Tomato Kichadi 0.091 
125 Tomato Onion curry 0.045 
126 Tomato Pachadi 0.016 
127 Agathi Thoran 0.101 
128 Amaranth (green) thoran 0.073 
129 Amaranth (red) thoran with dhal jack 
seed 
0.030 
130 Amaranth  thoran (red) 0.046 
131 Banana peel thoran 0.052 
132 Banana peel thoran (dhal) 0.109 
133 Beans thoran 0.219 
134 Beet root thoran 0.156 
135 Bengal gram dhal thoran 0.059 
136 Bitter gourd thoran 0.135 
137 Black gram dhal thoran  0.065 
138 Brinjal thoran 0.097 
139 Cabbage thoran 0.097 
140 Carrot thoran 0.060 
141 Cauliflower thoran 0.032 
142 Chekkurumanis thoran 0.108 
143 Cluster beans thoran 0.064 
144 Cow pea pod thoran 0.075 
145 Cow pea thoran 0.038 







Food Recipe Average portion 
per day 
(n=2047) 
147 Drumstick thoran 0.037 
148 Drumstick jack seed thoran 0.058 
149 Green gram thoran 0.085 
150 Horse gram 0.021 
151 Jack seed thoran 0.018 
152 Jack tender thoran 0.051 
153 Kovai thoran 0.164 
154 Ladies finger thoran 0.062 
155 Onion thoran 0.034 
156 Onion stalk thoran 0.030 
157 Papaya thoran 0.025 
158 Plantain flower thoran 0.024 
159 Plantain flower thoran(dhal) 0.022 
160 Plantain stem thoran 0.019 
161 Plantain stem thoran with dhal 0.069 
162 Potato thoran 0.033 
163 Pappad thoran  0.045 
164 Raw banana Thoran 0.040 
165 Snake gourd thoran 0.030 
166 Tapioca thoran 0.089 
167 Thakara leaf thoran 0.026 
168 Yam thoran 0.107 
169 Yam leaf thoran 0.022 
170 Amaranth green (sauté) 0.072 







Food Recipe Average portion 
per day 
(n=2047) 
172 Beans sauté 0.054 
173 Beet root sauté 0.036 
174 Bengal gram chundal 0.077 
175 Bitter gourd sauté 0.061 
176 Brinjal sauté 0.075 
177 Cabbage sauté 0.051 
178 Carrot sauté 0.049 
179 Chekkurmanis sauté 0.028 
180 Cluster beans sauté 0.020 
181 Cow pea pod sauté 0.084 
182 Cow pea sauté 0.031 
183 Drumstick leaves sauté 0.043 
184 Green gram sauté 0.017 
185 Jack fruit seed sauté 0.016 
186 Koorka sauté 0.045 
187 Kovai sauté 0.112 
188 Ladies finger sauté 0.028 
189 Papaya sauté 0.057 
190 Potato sauté 0.038 
191 Raw banana sauté 0.036 
192 Snake gourd sauté 0.030 
193 Tapioca sauté 0.035 
194 Yam Sauté 0.035 
195 Brinjal fry 0.138 







Food Recipe Average portion 
per day 
(n=2047) 
197 Potato fry 0.019 
198 Yam fry 0.071 
199 Boild egg 0.031 
200 Boiled egg thoran 0.072 
201 Bull's eye 0.034 
202 Egg Aviyal  0.052 
203 Egg curry (duck) 0.056 
204 Egg curry (hen) 0.105 
205 Egg omlette 0.111 
206 Egg roast (hen) 0.034 
207 Egg thoran 0.023 
208 Crab thiyyal 0.021 
209 Crab thoran 0.068 
210 Dry fish curry 0.045 
211 Dry fish fry 1.622 
212 Fish curry (with coconut) 0.778 
213 Fish curry (without coconut) 0.584 
214 Fish fry 0.030 
215 Fish peera 0.038 
216 Fish (Tuna) thiyyal 0.028 
217 Fish Thoran 0.020 
218 Prawn curry 0.021 
219 Prawn fry 0.020 
220 Prawn thiyyal 0.023 







Food Recipe Average portion 
per day 
(n=2047) 
222 Beef curry (Buffalo) 0.060 
223 Beef curry (cow) 0.038 
224 Beef fry (Buffalo) 0.027 
225 Beef fry (cow) 0.067 
226 Chicken curry  (2 small pieces) 0.056 
227 Chicken fry 0.039 
228 Mutton curry 0.077 
229 Mutton fry 0.120 
230 Tomato onion salad 0.085 
231 Tomato onion raita 0.032 
232 Carrot cucumber salad 0.025 
233 Carrot raita 0.037 
234 Cucumber raita 0.069 
235 Onion salad 0.014 
236 Sprouted Green Gram Salad 0.019 
237 Bilimbi pickle 0.021 
238 Garlic pickle 0.027 
239 Ginger curry 0.054 
240 Ginger pickle 0.022 
241 Goose berry pickle 0.105 
242 Lime pickle 0.061 
243 Mango pickle 0.173 
244 Pappad 0.031 
245 Achappam 0.019 







Food Recipe Average portion 
per day 
(n=2047) 
247 Baji-Capsicum 0.051 
248 Banana Baji (raw plantain) 0.051 
249 Banana fry 0.056 
250 Bengal gram vada 0.253 
251 Biscuit 0.119 
252 Biscuit (Cream) 0.016 
253 Boli 0.033 
254 Bonda 0.070 
255 Bread  0.063 
256 Bread with jam 0.028 
257 Bun 0.034 
258 Cake 0.025 
259 Chakka Appam 0.044 
260 Chicken roll 0.068 
261 Chips (banana) 0.023 
262 Chips (Jack) 0.114 
263 Chips (potato) 0.036 
264 Chips (Tapioca) 0.028 
265 Cutlet (Veg) 0.029 
266 Cutlet (non veg.) 0.029 
267 Diamond Cut 0.025 
268 Dilkush 0.022 
269 Fruit Salad 0.055 
270 Fruity bread 0.134 







Food Recipe Average portion 
per day 
(n=2047) 
272 Ground nut candy 0.016 
273 Halwa 0.022 
274 Ice cream 0.019 
275 Jilebi 0.058 
276 Karachavu 0.034 
277 Kuzhalappam 0.018 
278 Laddu 0.018 
279 Madhura Seva 0.021 
280 Maladdoo 0.120 
281 Masala Biscuits 0.022 
282 Masala Dosai 0.018 
283 Meat roll 0.029 
284 Milk shake 0.105 
285 Mixture 0.036 
286 Modhakam 0.036 
287 Munthirikothu 0.052 
288 Murukku 0.015 
289 Mysore pak 0.045 
290 Nancut 0.018 
291 Neyyappam 0.017 
292 Noodles 0.291 
293 Oats 0.036 
294 Omappodi 0.046 
295 Onion vada 0.050 







Food Recipe Average portion 
per day 
(n=2047) 
297 Pastry 0.018 
298 Payasam 0.091 
299 Peas fry 0.015 
300 Peda 0.039 
301 Pudding 0.022 
302 Puffs (Egg) 0.048 
303 Puffs (non - veg.) 0.222 
304 Puffs (Veg.) 0.017 
305 Rava laddoo 0.057 
306 Rice flakes with jaggery 0.144 
307 Rice balls 0.056 
308 Rusk 0.025 
309 Samosa – Veg. 0.087 
310 Samosa – (non-Veg) 0.025 
311 Tea – Rusk 0.037 
312 Thirali 0.121 
313 Till balls (small) 0.042 
314 Unniappam 0.015 
315 Urad Vadai 0.015 
316 Vatta Appam 0.017 
317 Beef soup 0.155 
318 Corn soup 0.590 
319 Mutton soup 0.111 
320 Chicken soup 0.103 







Food Recipe Average portion 
per day 
(n=2047) 
322 Tomato soup  0.020 
323 Vegetable soup 0.027 
324 Apple juice 0.059 
325 Carrot juice 0.109 
326 Grape juice 0.030 
327 Lime ginger Juice  0.048 
328 Lime juice 0.030 
329 Mango juice 0.022 
330 Mussambi 0.017 
331 Orange juice 0.016 
332 Pineapple juice  0.023 
333 Tender coconut water 0.244 
334 Water melon juice 0.030 
335 Apple 0.039 
336 Banana 0.016 
337 Dates 0.036 
338 Grapes 0.033 
339 Guava 0.019 
340 Jack fruit 0.041 
341 Jamboo 0.019 
342 Mango  0.024 
343 Orange 0.665 
344 Papaya 0.018 
345 Pineapple 0.039 







Food Recipe Average portion 
per day 
(n=2047) 
347 Plum 0.020 
348 Robesta 0.033 
349 Seethafal 0.015 
350 Water melon 0.026 
351 Ghee rice 0.020 
352 Kalan 0.021 
353 Amaranth with moru curry 0.015 
354 Bilimbi with dhal curry 0.015 
355 Bread fruit curry 0.020 
356 Boiled Kachil 0.011 
357 Cluster beans juice  0.014 
358 Soaked fenugreek 0.015 
359 Pomegranate 0.077 
360 Cashew nuts 0.140 
361 Green mango 0.042 
362 Noodles soup 0.015 
363 Curd chilli 0.020 
364 Gooseberry juice 0.014 
365 Cucumber salad 0.015 
366 Bullock's heart 0.210 
367 Ghee roast 0.016 
368 Drumstick leaves juice 0.867 
369 Semolina gruel 0.064 
370 Sugar 0.020 







Food Recipe Average portion 
per day 
(n=2047) 
372 Green chille 0.016 
373 Rasavada 0.015 
374 Boiled Colocasia 0.016 
375 Carrot salad 0.025 
376 Peas onion sauté 0.022 
377 Bread fruit thoran 0.019 
378 Butter 0.035 
379 Brinjal Kichadi 0.012 
380 Coconut milk with sugar 0.017 
381 Mulakoshum curry 0.038 
382 Coffee with jaggery  0.015 
383 Almond 0.034 
384 Bread fruit thiyyal 0.059 
385 Rice gruel with green gram 0.047 
386 Colocasia leaf thoran 0.203 
387 Dry fish chutney 0.208 
388 Jack Fruit 1.423 
389 Jack Pappad 0.168 
 
Appendix 2. Modified Global Physical Activity Questionnaire (GPAQ) 
Section A: Occupational Physical Activity 
For every 8 hours spent at work, on a typical day how many hours do you spend on: 
- Activities involving mainly sitting or standing with only a little walking  
- Activities that require the same effort as heavy walking, cleaning etc. 
- Activities that require the same effort as heavy lifting or heavy construction 
work 




For every 8 hours spent not at work, on a typical day how many hours do you spend 
on: 
- Activities involving mainly sitting or standing with only a little walking  
- Activities that require the same effort as heavy walking, cleaning etc. 
- Activities that require the same effort as heavy lifting or heavy construction 
work 
Section C: Transportation Physical Activity 
On an average day, how much time do you spend on: 
- Getting around in a car, bus or a motorcycle 
- Getting around by walking or cycling 
 
